Engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
Engineered meganucleases targeting the HBV 27-28 recognition sequence in the HBsAg and pol genes enhance therapeutic efficacy against HBV by inactivating key viral genes, addressing the limitations of current treatments and genetic variability.
Patent Information
- Application Number
- PCT/IB2026/054497
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Current anti-HBV drugs have limitations such as severe adverse reactions and require long-term administration, and the HBV genome's genetic variability leads to challenges in developing effective therapies.
Engineered meganucleases are developed to target the HBV 27-28 recognition sequence within the HBsAg and pol genes, enhancing on-target specificity while minimizing off-target cutting, using a first and second subunit with hypervariable regions to bind and cleave the recognition sequence.
The engineered meganucleases effectively inactivate both the HBsAg and pol genes, providing a targeted therapeutic approach to HBV infection and related hepatocellular carcinoma, with improved specificity and reduced off-target effects.
Smart Images

Figure IB2026054497_12112026_PF_FP_ABST
Abstract
Description
[0001] ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME
[0002] FIELD OF THE INVENTION
[0003] The disclosure relates to the field of virology, molecular biology, and recombinant nucleic acid technology. In particular, the disclosure relates to optimized engineered meganucleases having specificity for a recognition sequence within the genome of the hepatitis B virus. Such engineered meganucleases are useful in methods for treating hepatitis B virus infections and diseases caused by hepatitis B virus.
[0004] REFERENCE TO A SEQUENCE LISTING SUBMITTED ELECTRONICALLY AS AN XML FILE
[0005] The instant application contains a Sequence Listing which has been submitted in XML format via USPTO Patent Center and is hereby incorporated by reference in its entirety. Said XML copy, created on May 6, 2026, is named “P89339-2090WO.xml” and is 90,276 bytes in size.
[0006] BACKGROUND OF THE INVENTION
[0007] The hepatitis B virus (HBV) is a major health problem worldwide and more than 350 million people are chronic carriers. HBV infection is a serious and common infectious disease of the liver. Chronic infection is associated with an increased risk to develop severe liver diseases, including liver cirrhosis and hepatocellular carcinoma (HCC), one of the most common forms of human cancer. The estimated risk of HCC in chronic HBV carriers is approximately 100 times greater than in uninfected individuals. About a third of the world population has been infected at one point in their lives, including 240 million to 350 million who have chronic infections. Over 750,000 people die of hepatitis B each year. About 300,000 of these are due to liver cancer.
[0008] Currently available anti-HBV drugs have limitations. For example, interferon alpha administration is associated with severe adverse reactions. Nucleoside analogues are virostatic and require longterm administration.
[0009] The HBV genome exhibits genetic variability with an estimated rate of 1.4-3.2xl0'5nucleotide substitutions per site per year. A large number of virus variants arise during replication as a result of nucleotide misincorporations in the absence of any proof reading capacity by the viral polymerase. This variability has resulted in well-recognized subtypes of the virus. HBV has been classified into well-defined genotypes on the basis of an inter-group divergence of 8% or more in the complete genomic sequence, each having a distinct geographical distribution. For example, Genotype A is widespread in sub-Saharan Africa, Northern Europe, and Western Africa; genotypes 1 Atty Docket No. P893392090WO (01344)B and C are common in Asia; genotype C is primarily observed in Southeast Asia; genotype D is dominant in Africa, Europe, Mediterranean countries, and India; genotype G is reported in France, Germany, and the United States; and genotype H is commonly encountered in Central and South America. Genotype I has recently been reported in Vietnam and Laos. The newest HBV genotype, genotype J, has been identified in the Ryukyu Islands in Japan.
[0010] HBV is an enveloped DNA virus that belongs to the Hepadnaviridae family. It contains a small, partially double-stranded (DS), relaxed-circular DNA (rcDNA) genome that replicates by reverse transcription of an RNA intermediate, the pregenomic RNA (pgRNA). The circular DNA genome of HBV is unusual because the DNA is not fully double-stranded. One end of the full length strand is linked to the viral DNA polymerase. The genome is approximately 3020-3320 nucleotides long (for the full-length strand) and 1700-2800 nucleotides long (for the short lengthstrand). The negative-sense (non-coding) is complementary to the viral mRNA.
[0011] There are four known genes encoded by the genome, referred to as C, X, P, and S. The core protein is coded for by gene C (HBcAg), and its start codon is preceded by an upstream in-frame AUG start codon from which the pre-core protein is produced. The HBeAg is produced by proteolytic processing of the pre-core protein. The DNA polymerase is encoded by gene P. Gene S codes for the surface antigen (HBsAg). The HBsAg gene is one long open reading frame but contains three in frame “start” (ATG) codons that divide the gene into three sections: pre-Sl, pre-S2, and S. Because of the multiple start codons, polypeptides of three different sizes called Large (the order from surface to the inside: pre-Sl / pre-S2 / S), Middle (pre-S2 / S), and Small (S) are produced. The function of the protein coded for by gene X is not fully understood but it is associated with the development of liver cancer. It stimulates genes that promote cell growth and inactivates growth regulating molecules.
[0012] The viral DNA is found in the nucleus soon after infection of the cell. The partially doublestranded DNA is rendered fully double-stranded by completion of the (+) sense strand and removal of a protein molecule from the (-) sense strand and a short sequence of RNA from the (+) sense strand. Non-coding bases are removed from the ends of the (-) sense strand and the ends are rejoined.
[0013] The HBV life cycle begins when the virus attaches to the host cell and is internalized.
[0014] Recent studies have demonstrated that sodium-taurocholate co-transporting polypeptide (NTCP) is a functional receptor in HBV infection. The virion relaxed circular DNA (rcDNA) is delivered to the nucleus, where it is repaired to form a covalently closed-circular DNA (cccDNA). The episomal cccDNA serves as the template for the transcription of the pregenomic RNA (pgRNA) and the other viral mRNAs by the host RNA polymerase II. The transcripts are then exported to the
[0015] 2 Atty Docket No. P893392090WO (01344)cytoplasm, where translation of the viral proteins occurs. Reverse transcriptase (RT) binds to pgRNA and triggers assembly of the core proteins into immature, RNA-containing nucleocapsids. The immature nucleocapsids then undergo a process of maturation whereby pgRNA is reversed transcribed by RT to make the mature rcDNA. A unique feature of hepadnavirus reverse transcription is the RT primed initiation of minus-strand DNA synthesis, which leads to the covalent linkage of RT to the 5’ end of the minus-strand DNA.
[0016] The mature, rcDNA-containing nucleocapsids are then enveloped by the viral surface proteins and secreted as virions (secretion pathway) or, alternatively, are recycled back to the nucleus to further amplify the pool of cccDNA (recycling pathway). Persistence of cccDNA in hepatocytes plays a key role in viral persistence, reactivation of viral replication after cessation of antiviral therapy, and resistance to therapy.
[0017] Homing endonucleases are a group of naturally-occurring nucleases which recognize 15-40 base-pair cleavage sites commonly found in the genomes of plants and fungi. They are frequently associated with parasitic DNA elements, such as group 1 self-splicing introns and inteins. They naturally promote homologous recombination or gene insertion at specific locations in the host genome by producing a double-stranded break in the chromosome, which recruits the cellular DNA-repair machinery (Stoddard (2006), Q. Rev. Biophys. 38: 49-95). Homing endonucleases are commonly grouped into four families: the LAGLID ADG (SEQ ID NO: 2) family, the GIY-YIG family, the His-Cys box family and the HNH family. These families are characterized by structural motifs, which affect catalytic activity and recognition sequence. For instance, members of the LAGLID ADG (SEQ ID NO: 2) family are characterized by having either one or two copies of the conserved LAGLID ADG motif (see Chevalier et al. (2001), Nucleic Acids Res. 29(18): 3757-3774). The LAGLID ADG homing endonucleases with a single copy of the LAGLID ADG motif form homodimers, whereas members with two copies of the LAGLID ADG motif are found as monomers. Methods for producing homing endonucleases are known in the art.
[0018] LCrel (SEQ ID NO: 1) is a member of the LAGLID ADG family of homing endonucleases which recognizes and cuts a 22 basepair recognition sequence in the chloroplast chromosome of the algae Chlamydomonas reinhardtii. Genetic selection techniques have been used to modify the wildtype LCrel cleavage site preference (Sussman et al. (2004), J. Mol. Biol. 342: 31-41; Chames et al. (2005), Nucleic Acids Res. 33: el78; Seligman et al. (2002), Nucleic Acids Res. 30: 3870-9, Arnould et al. (2006), J. Mol. Biol. 355: 443-58). Methods for rationally-designing mono-LAGLIDADG homing endonucleases were described which are capable of comprehensively redesigning I-Crel and other homing endonucleases to target widely-divergent DNA sites,
[0019] 3 Atty Docket No. P893392090WO (01344)including sites in mammalian, yeast, plant, bacterial, and viral genomes (see, e.g.,
[0020] WO 2007 / 047859).
[0021] As first described in WO 2009 / 059195, 1-Crel and its engineered derivatives are normally dimeric but can be fused into a single polypeptide using a short peptide linker that joins the C-terminus of a first subunit to the N-terminus of a second subunit (see also Li et al. (2009), Nucleic Acids Res. 37:1650-62; Grizot et al. (2009), Nucleic Acids Res. 37:5405-19). Thus, a functional “single-chain” meganuclease can be expressed from a single transcript.
[0022] The use of engineered meganucleases for treatment of HBV infections has been suggested. For example, WO 2010 / 136841 suggests the use of engineered meganucleases for cleaving the genome of non-genomically integrating viruses. Such meganucleases include variants of I-Crel targeting 22 base pair meganuclease recognition sequences which differ from those described herein, and which are only present in a few HBV genotypes.
[0023] Applicants previously disclosed in PCT / US2017 / 56638, PCT / US2019 / 27203, and PCT / US2020 / 063479 a number of engineered meganucleases having specificity for recognition sequences present in the HBV genome, including the HBV 11-12 recognition sequence which is present in the HBV polymerase (pol) gene of at least HBV genotypes A-G.
[0024] SUMMARY OF THE INVENTION
[0025] The present disclosure improves upon the engineered meganucleases previously described in the art in a number of aspects. When generating an endonuclease for therapeutic administration to a patient, it is important that on-target specificity is enhanced (i.e., increased) while reducing or eliminating off-target cutting within the target cell genome. Here, Applicants have developed engineered meganucleases that target the HBV 27-28 recognition sequence. The HBV 27-28 recognition sequence is located within the hepatitis B virus surface antigen (HBsAg) gene encoding the HBsAg protein, which plays an important role in HBV infection (e.g., chronic HBV infection) by suppressing the immune system. In addition to being located within the HBsAg gene, the HBV 27-28 recognition sequence is also positioned within the HBV polymerase (pol) gene (Figure 2); thus, cleavage at this site allows for inactivation of both the HBsAg and pol genes.
[0026] The meganucleases of the present disclosure have novel and unique sequences which were generated through extensive experimentation. The meganucleases of the disclosure advance the art in a number of ways that are necessary for development of a clinical product targeting HBV infection and HBV-related hepatocellular carcinoma.
[0027] In one aspect, the present disclosure provides an engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within a hepatitis B virus (HBV)
[0028] 4 Atty Docket No. P893392090WO (01344)genome, wherein the engineered meganuclease comprises a first subunit and a second subunit, wherein the first subunit binds to a first recognition half-site of the recognition sequence and comprises a first hypervariable (HVR1) region, and wherein the second subunit binds to a second recognition half-site of the recognition sequence and comprises a second hypervariable (HVR2) region.
[0029] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 24-79 of any one of SEQ ID NOs: 5-8.
[0030] In some embodiments, in the engineered meganuclease, the HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 5-8. In some embodiments, the HVR1 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 5-8.
[0031] In some embodiments, the HVR1 region comprises a residue corresponding to residue 50 of any one of SEQ ID NOs: 5-8.
[0032] In some embodiments, the HVR1 region comprises a residue corresponding to residue 71 of SEQ ID NO: 5 or SEQ ID NO: 6.
[0033] In some embodiments, the HVR1 region comprises a residue corresponding to residue 72 of any one of SEQ ID NOs: 5, 7, or 8.
[0034] In some embodiments, the HVR1 region comprises Y, R, K, or D at a residue corresponding to residue 66 of any one of SEQ ID NOs: 5-8.
[0035] In some embodiments, the HVR1 region comprises residues 24-79 of any one of SEQ ID NOs: 5-8.
[0036] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 7-153 of any one of SEQ ID NOs: 5-8.
[0037] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-153 of any one of SEQ ID NOs: 5-8.
[0038] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%,
[0039] 5 Atty Docket No. P893392090WO (01344)at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-153 of any one of SEQ ID NOs: 5-8.
[0040] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-153 of any one of SEQ ID NOs: 5-8.
[0041] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-153 of any one of SEQ ID NOs: 5-8.
[0042] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-153 of any one of SEQ ID NOs: 5-8.
[0043] In some embodiments, the residue at position 1 of any one of SEQ ID NOs: 5-8 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A.
[0044] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 1-153 of any one of SEQ ID NOs: 5-8.
[0045] In some embodiments, the first subunit comprises a residue corresponding to residue 19 of any one of SEQ ID NOs: 5-8.
[0046] In some embodiments, the first subunit comprises a residue corresponding to residue 96 of any one of SEQ ID NOs: 5-8.
[0047] In some embodiments, the first subunit comprises a residue corresponding to residue 99 of any one of SEQ ID NOs: 5-8.
[0048] In some embodiments, the first subunit comprises a residue corresponding to residue 100 of any one of SEQ ID NOs: 5-8.
[0049] In some embodiments, the first subunit comprises a residue corresponding to residue 139 of any one of SEQ ID NOs: 5-7.
[0050] In some embodiments, the first subunit comprises G, S, or A at a residue corresponding to residue 19 of any one of SEQ ID NOs: 5-8.
[0051] 6 Atty Docket No. P893392090WO (01344)In some embodiments, the first subunit comprises E, Q, or K at a residue corresponding to residue 80 of any one of SEQ ID NOs: 5-8.
[0052] In some embodiments, the first subunit comprises residues 7-153 of any one of SEQ ID NOs: 5-8.
[0053] In some embodiments, the first subunit comprises residues 6-153 of any one of SEQ ID NOs: 5-8.
[0054] In some embodiments, the first subunit comprises residues 5-153 of any one of SEQ ID NOs: 5-8.
[0055] In some embodiments, the first subunit comprises residues 4-153 of any one of SEQ ID NOs: 5-8.
[0056] In some embodiments, the first subunit comprises residues 3-153 of any one of SEQ ID NOs: 5-8.
[0057] In some embodiments, the first subunit comprises residues 2-153 of any one of SEQ ID NOs: 5-8.
[0058] In some embodiments, the first subunit comprises residues 1-153 of any one of SEQ ID NOs: 5-8.
[0059] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 204-259 of any one of SEQ ID NOs: 5-8.
[0060] In some embodiments, the HVR2 region comprises one or more residues corresponding to residues 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of any one of SEQ ID NOs: 5-8.
[0061] In some embodiments, the HVR2 region comprises residues corresponding to residues 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of any one of SEQ ID NOs: 5-8.
[0062] In some embodiments, the HVR2 region comprises a residue corresponding to residue 237 of any one of SEQ ID NOs: 5-8.
[0063] In some embodiments, the HVR2 region comprises a residue corresponding to residue 241 of any one of SEQ ID NOs: 5-8.
[0064] In some embodiments, the HVR2 region comprises Y, R, K, or D at a residue corresponding to residue 246 of any one of SEQ ID NOs: 5-8.
[0065] In some embodiments, the HVR2 region comprises residues 204-259 of any one of SEQ ID NOs: 5-8.
[0066] 7 Atty Docket No. P893392090WO (01344)In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 187-333 of any one of SEQ ID NOs: 5-8.
[0067] In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 185-343 of any one of SEQ ID NOs: 5-8.
[0068] In some embodiments, the second subunit comprises a residue corresponding to residue 319 of any one of SEQ ID NOs: 5-7.
[0069] In some embodiments, the second subunit comprises G, S, or A at a residue corresponding to residue 199 of any one of SEQ ID NOs: 5-8.
[0070] In some embodiments, the second subunit comprises E, Q, or K at a residue corresponding to residue 260 of any one of SEQ ID NOs: 5-8.
[0071] In some embodiments, the second subunit comprises residues 187-333 of any one of SEQ ID NOs: 5-8.
[0072] In some embodiments, the second subunit comprises residues 185-343 of any one of SEQ ID NOs: 5-8.
[0073] In some embodiments, the engineered meganuclease is a single-chain meganuclease comprising a polypeptide linker, wherein the polypeptide linker covalently joins the first subunit and the second subunit.
[0074] In some embodiments, the polypeptide linker comprises an amino acid sequence of SEQ ID NO: 50.
[0075] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to any one of SEQ ID NOs: 5-8.
[0076] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-343 of any one of SEQ ID NOs: 5-8.
[0077] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least
[0078] 8 Atty Docket No. P893392090WO (01344)91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-343 of any one of SEQ ID NOs: 5-8.
[0079] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-343 of any one of SEQ ID NOs: 5-8.
[0080] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-343 of any one of SEQ ID NOs: 5-8.
[0081] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-343 of any one of SEQ ID NOs: 5-8.
[0082] In some embodiments, the engineered meganuclease comprises an amino acid sequence of any one of SEQ ID NOs: 5-8.
[0083] In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 6-343 of any one of SEQ ID NOs: 5-8.
[0084] In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 5-343 of any one of SEQ ID NOs: 5-8.
[0085] In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 4-343 of any one of SEQ ID NOs: 5-8.
[0086] In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 3-343 of any one of SEQ ID NOs: 5-8.
[0087] In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 2-343 of any one of SEQ ID NOs: 5-8.
[0088] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to a nucleic acid sequence of any one of SEQ ID NOs: 17-20.
[0089] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence of any one of SEQ ID NOs: 17-20.
[0090] 9 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% or at least 99% sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6.
[0091] In some embodiments, the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6.
[0092] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% or at least 99% sequence identity to residues 2-343 of SEQ ID NO: 5 or SEQ ID NO: 6.
[0093] In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 2-343 of SEQ ID NO: 5 or SEQ ID NO: 6.
[0094] In one aspect, the present disclosure provides an engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 5.
[0095] In one aspect, the present disclosure provides an engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein the engineered meganuclease comprises an amino acid sequence comprising residues 2-343 of SEQ ID NO: 5.
[0096] In one aspect, the present disclosure provides an engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 6.
[0097] In one aspect, the present disclosure provides an engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein the engineered meganuclease comprises an amino acid sequence comprising residues 2-343 of SEQ ID NO: 6.
[0098] In one aspect, the present disclosure provides an engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within a hepatitis B virus (HBV) genome, wherein the engineered meganuclease comprises a first subunit and a second subunit, wherein the first subunit binds to a first recognition half-site of the recognition sequence and comprises a first hypervariable (HVR1) region, and wherein the second subunit binds to a second recognition half-site of the recognition sequence and comprises a second hypervariable (HVR2) region.
[0099] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 24-79 of any one of SEQ ID NOs: 21-27.
[0100] 10 Atty Docket No. P893392090WO (01344)In some embodiments, the HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 21-27.
[0101] In some embodiments, the HVR1 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 21-27.
[0102] In some embodiments, the HVR1 region comprises a residue corresponding to residue 48 of any one of SEQ ID NOs: 23, 24, or 25.
[0103] In some embodiments, the HVR1 region comprises a residue corresponding to residue 50 of any one of SEQ ID NOs: 21-27.
[0104] In some embodiments, the HVR1 region comprises a residue corresponding to residue 71 of SEQ ID NO: 21 or SEQ ID NO: 22.
[0105] In some embodiments, the HVR1 region comprises a residue corresponding to residue 72 of any one of SEQ ID NOs: 21, 26, and 27.
[0106] In some embodiments, the HVR1 region comprises Y, R, K, or D at a residue corresponding to residue 66 of any one of SEQ ID NOs: 21-27.
[0107] In some embodiments, the HVR1 region comprises residues 24-79 of any one of SEQ ID NOs: 21-27.
[0108] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 7-153 of any one of SEQ ID NOs: 21-27.
[0109] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-153 of any one of SEQ ID NOs: 21-27.
[0110] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-153 of any one of SEQ ID NOs: 21-27.
[0111] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-153 of any one of SEQ ID NOs: 21-27.
[0112] 11 Atty Docket No. P893392090WO (01344)In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-153 of any one of SEQ ID NOs: 21-27.
[0113] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-153 of any one of SEQ ID NOs: 21-27.
[0114] In some embodiments, the residue at position 1 of any one of SEQ ID NOs: 21-27 is modified from M to another amino acid.
[0115] In some embodiments, the residue at position 1 is modified from M to A.
[0116] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 1-153 of any one of SEQ ID NOs: 21-27.
[0117] In some embodiments, the first subunit comprises a residue corresponding to residue 19 of any one of SEQ ID NOs: 21-27.
[0118] In some embodiments, the first subunit comprises a residue corresponding to residue 139 of any one of SEQ ID NOs: 21, 22, or 24-26.
[0119] In some embodiments, the first subunit comprises residues 7-153 of any one of SEQ ID NOs: 21-27.
[0120] In some embodiments, the first subunit comprises residues 6-153 of any one of SEQ ID NOs: 21-27.
[0121] In some embodiments, the first subunit comprises residues 5-153 of any one of SEQ ID NOs: 21-27.
[0122] In some embodiments, the first subunit comprises residues 4-153 of any one of SEQ ID NOs: 21-27.
[0123] In some embodiments, the first subunit comprises residues 3-153 of any one of SEQ ID NOs: 21-27.
[0124] In some embodiments, the first subunit comprises residues 2-153 of any one of SEQ ID NOs: 21-27.
[0125] In some embodiments, the first subunit comprises residues 1-153 of any one of SEQ ID NOs: 21-27.
[0126] 12 Atty Docket No. P893392090WO (01344)In some embodiments, the HVR2 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 215-270 of any one of SEQ ID NOs: 21-27.
[0127] In some embodiments, the HVR2 region comprises one or more residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of any one of SEQ ID NOs: 21-27.
[0128] In some embodiments, the HVR2 region comprises residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of any one of SEQ ID NOs: 21-27.
[0129] In some embodiments, the HVR2 region comprises Y, R, K, or D at a residue corresponding to residue 257 of any one of SEQ ID NOs: 21-27.
[0130] In some embodiments, the HVR2 region comprises residues 215-270 of any one of SEQ ID NOs: 21-27.
[0131] In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 198-344 of any one of SEQ ID NOs: 21-27.
[0132] In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 196-354 of any one of SEQ ID NOs: 21-27.
[0133] In some embodiments, the second subunit comprises a residue corresponding to residue 271 of SEQ ID NO: 23 or SEQ ID NO: 24.
[0134] In some embodiments, the second subunit comprises a residue corresponding to residue 330 of any one of SEQ ID NOs: 21, 22, or 24-26.
[0135] In some embodiments, the second subunit comprises G, S, or A at a residue corresponding to residue 210 of any one of SEQ ID NOs: 21-27.
[0136] In some embodiments, the second subunit comprises E, Q, or K at a residue corresponding to residue 271 of any one of SEQ ID NOs: 21-27.
[0137] In some embodiments, the second subunit comprises residues 198-344 of any one of SEQ ID NOs: 21-27.
[0138] In some embodiments, the second subunit comprises residues 196-354 of any one of SEQ ID NOs: 21-27.
[0139] 13 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease is a single-chain meganuclease comprising a polypeptide linker, wherein the polypeptide linker covalently joins the first subunit and the second subunit.
[0140] In some embodiments, the polypeptide linker comprises an amino acid sequence of SEQ ID NO: 49.
[0141] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to any one of SEQ ID NOs: 21-27.
[0142] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-354 of any one of SEQ ID NOs: 21-27.
[0143] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-354 of any one of SEQ ID NOs: 21-27.
[0144] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-354 of any one of SEQ ID NOs: 21-27.
[0145] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-354 of any one of SEQ ID NOs: 21-27.
[0146] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-354 of any one of SEQ ID NOs: 21-27.
[0147] In some embodiments, the engineered meganuclease comprises an amino acid sequence of any one of SEQ ID NOs: 21-27.
[0148] In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 6-354 of any one of SEQ ID NOs: 21-27.
[0149] 14 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 5-354 of any one of SEQ ID NOs: 21-27.
[0150] In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 4-354 of any one of SEQ ID NOs: 21-27.
[0151] In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 3-354 of any one of SEQ ID NOs: 21-27.
[0152] In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 2-354 of any one of SEQ ID NOs: 21-27.
[0153] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to a nucleic acid sequence of any one of SEQ ID NOs: 42-48.
[0154] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence of any one of SEQ ID NOs: 42-48.
[0155] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% or 99% sequence identity to SEQ ID NO: 21 or SEQ ID NO: 22.
[0156] In some embodiments, the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 21 or SEQ ID NO: 22.
[0157] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% or 99% sequence identity to residues 2-354 of SEQ ID NO: 21 or SEQ ID NO: 22.
[0158] In some embodiments, the engineered meganuclease comprises an amino acid sequence comprising residues 2-354 of SEQ ID NO: 21 or SEQ ID NO: 22.
[0159] In one aspect, the present disclosure provides an engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 21.
[0160] In one aspect, the present disclosure provides an engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein the engineered meganuclease comprises an amino acid sequence comprising residues 2-354 of SEQ ID NO: 21.
[0161] In one aspect, the present disclosure provides an engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 22.
[0162] 15 Atty Docket No. P893392090WO (01344)In one aspect, the present disclosure provides an engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein the engineered meganuclease comprises an amino acid sequence comprising residues 2-354 of SEQ ID NO: 22.
[0163] In some embodiments, the engineered meganuclease comprises a nuclear localization signal.
[0164] In some embodiments, the nuclear localization signal is at the N-terminus of the engineered meganuclease.
[0165] In some embodiments, the nuclear localization signal is at the C-terminus of the engineered meganuclease.
[0166] In some embodiments, the engineered meganuclease comprises a first nuclear localization signal at the N-terminus and a second nuclear localization signal at the C-terminus.
[0167] In some embodiments, the nuclear localization signal comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 51 or SEQ ID NO: 52.
[0168] In some embodiments, the nuclear localization signal comprises SEQ ID NO: 51 or SEQ ID NO: 52.
[0169] In one aspect, the present disclosure provides a polynucleotide comprising a nucleic acid sequence encoding the engineered meganuclease provided herein.
[0170] In some embodiments, the polynucleotide is an mRNA.
[0171] In one aspect, the present disclosure provides a recombinant DNA construct comprising the polynucleotide provided herein.
[0172] In some embodiments, the recombinant DNA construct is a plasmid DNA.
[0173] In some embodiments, the recombinant DNA construct encodes a recombinant virus comprising the polynucleotide.
[0174] In some embodiments, the recombinant virus is a recombinant adenovirus, a recombinant lentivirus, a recombinant retrovirus, or a recombinant adeno-associated virus (AAV).
[0175] In some embodiments, the recombinant virus is a recombinant AAV.
[0176] In some embodiments, the polynucleotide comprises a promoter operably linked to the nucleic acid sequence encoding the engineered meganuclease.
[0177] In some embodiments, the promoter is a liver-specific promoter.
[0178] In one aspect, the present disclosure provides a recombinant virus comprising the polynucleotide provided herein.
[0179] 16 Atty Docket No. P893392090WO (01344)In some embodiments, the recombinant virus is a recombinant adenovirus, a recombinant lentivirus, a recombinant retrovirus, or a recombinant AAV.
[0180] In some embodiments, the recombinant virus is a recombinant AAV.
[0181] In some embodiments, the polynucleotide comprises a promoter operably linked to the nucleic acid sequence encoding the engineered meganuclease.
[0182] In some embodiments, the promoter is a liver-specific promoter.
[0183] In one aspect, the present disclosure provides a lipid nanoparticle composition comprising lipid nanoparticles comprising the polynucleotide provided herein.
[0184] In one aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the engineered meganuclease provided herein.
[0185] In one aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the polynucleotide provided herein.
[0186] In one aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the recombinant DNA construct provided herein.
[0187] In one aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the recombinant virus provided herein.
[0188] In one aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the lipid nanoparticle composition provided herein.
[0189] In one aspect, the present disclosure provides a host cell comprising the polynucleotide provided herein.
[0190] In one aspect, the present disclosure provides a method for producing a genetically-modified eukaryotic cell comprising an exogenous sequence of interest inserted into an HBsAg gene comprised in the genome of the genetically-modified eukaryotic cell, the method comprising introducing into a eukaryotic cell one or more polynucleotides comprising a first nucleic acid sequence encoding an engineered meganuclease described herein, and a second nucleic acid sequence comprising the sequence of interest, wherein the engineered meganuclease produces a cleavage site in the HBsAg gene at a recognition sequence comprising SEQ ID NO: 3, and wherein the sequence of interest is inserted into the HBsAg gene at the cleavage site.
[0191] In some embodiments, the second nucleic acid sequence comprises nucleic acid sequences homologous to nucleic acid sequences flanking the cleavage site and the sequence of interest is inserted at the cleavage site by homologous recombination.
[0192] In some embodiments, the eukaryotic cell is a mammalian cell.
[0193] In some embodiments, the mammalian cell is a human cell.
[0194] In some embodiments, the mammalian cell is a liver cell.
[0195] 17 Atty Docket No. P893392090WO (01344)In some embodiments, the liver cell is a hepatocyte.
[0196] In some embodiments, the one or more polynucleotides are introduced into the eukaryotic cell by a recombinant virus, a lipid nanoparticle, or by an mRNA.
[0197] In one aspect, the present disclosure provides a method for producing a genetically-modified eukaryotic cell comprising an exogenous sequence of interest inserted into an HbsAg gene comprised in the genome of the genetically-modified eukaryotic cell, the method comprising introducing into a eukaryotic cell an engineered meganuclease described herein and a polynucleotide comprising the sequence of interest, wherein the engineered meganuclease produces a cleavage site in the HBsAg gene at a recognition sequence comprising SEQ ID NO: 3, and wherein the sequence of interest is inserted into the HBsAg gene at the cleavage site.
[0198] In some embodiments, the polynucleotide comprises nucleic acid sequences homologous to nucleic acid sequences flanking the cleavage site and the sequence of interest is inserted at the cleavage site by homologous recombination.
[0199] In some embodiments, the eukaryotic cell is a mammalian cell.
[0200] In some embodiments, the mammalian cell is a human cell.
[0201] In some embodiments, the mammalian cell is a liver cell.
[0202] In some embodiments, the liver cell is a hepatocyte.
[0203] In some embodiments, the polynucleotide is introduced into the eukaryotic cell by a recombinant virus, a lipid nanoparticle, or by an mRNA.
[0204] In one aspect, the present disclosure provides a method for inactivating a hepatitis B virus surface antigen (HBsAg) gene of an HBV genome or an HBV genome fragment, the method comprising introducing into a eukaryotic cell comprising the HBV genome or HBV genome fragment: a polynucleotide comprising a nucleic acid sequence encoding the engineered meganuclease provided herein, wherein the engineered meganuclease is expressed in the eukaryotic cell; or the engineered meganuclease provided herein; wherein the engineered meganuclease produces a cleavage site at a recognition sequence comprising SEQ ID NO: 3 within the HBsAg gene, wherein the HBsAg gene is inactivated by introduction of an insertion or deletion (indel) at the cleavage site, or wherein the HBsAg gene is inactivated by elimination of the HBV genome or the HBV genome fragment.
[0205] In some embodiments, the HBV genome or the HBV genome fragment is comprised by covalently closed circular DNA (cccDNA). In some embodiments, the cccDNA is eliminated following generation of the cleavage site. In some embodiments, the HBsAg gene is inactivated in the cccDNA by introduction of the indel at the cleavage site. In some embodiments, the indel is
[0206] 18 Atty Docket No. P893392090WO (01344)introduced by non-homologous end joining (NHEJ). In some embodiments, the inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
[0207] In some embodiments, the HBV genome or the HBV genome fragment is comprised in the genome of the eukaryotic cell. In some embodiments, the genome is the nuclear genome. In some embodiments, the genome is the mitochondrial genome. In some embodiments, the indel is introduced by NHEJ. In some embodiments, the inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
[0208] In some embodiments, the eukaryotic cell is a human cell. In some embodiments, the human cell is a liver cell. In some embodiments, the liver cell is a hepatocyte.
[0209] In some embodiments, the polynucleotide is the polynucleotide provided herein.
[0210] In some embodiments, the polynucleotide is introduced into the eukaryotic cell by an mRNA or a recombinant virus.
[0211] In some embodiments, the polynucleotide is the mRNA provided herein. In some embodiments, the mRNA is introduced into the eukaryotic cell by contacting the eukaryotic cell with a lipid nanoparticle comprising the mRNA.
[0212] In some embodiments, the recombinant virus is the recombinant virus provided herein. In some embodiments, the recombinant virus is a recombinant AAV. In some embodiments, the recombinant AAV has a serotype of AAV8.
[0213] In one aspect, provided herein is a method for inactivating an HBsAg gene of an HBV genome or an HBV genome fragment in a target cell in a subject, the method comprising delivering to the target cell comprising the HBV genome or HBV genome fragment: a polynucleotide comprising a nucleic acid sequence encoding the engineered meganuclease provided herein, wherein the engineered meganuclease is expressed in the target cell; or the engineered meganuclease provided herein; wherein the engineered meganuclease produces a cleavage site at a recognition sequence comprising SEQ ID NO: 3 within the HBsAg gene, wherein the HBsAg gene is inactivated by introduction of an indel at the cleavage site, or wherein the HBsAg gene is inactivated by elimination of the HBV genome or the HBV genome fragment.
[0214] In some embodiments, the HBV genome or the HBV genome fragment is comprised by cccDNA. In some embodiments, the cccDNA is eliminated following generation of the cleavage site. In some embodiments, wherein the HBsAg gene is inactivated in the cccDNA by introduction of the indel at the cleavage site. In some embodiments, the indel is introduced by NHEJ. In some embodiments, the inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
[0215] 19 Atty Docket No. P893392090WO (01344)In some embodiments, the HBV genome or the HBV genome fragment is comprised in the genome of the target cell. In some embodiments, the genome is the nuclear genome. In some embodiments, the genome is the mitochondrial genome. In some embodiments, the indel is introduced by NHEJ. In some embodiments, the inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
[0216] In some embodiments, the serum concentration of HBsAg is reduced in the subject.
[0217] In some embodiments, the target cell is a liver cell. In some embodiments, the liver cell is a hepatocyte.
[0218] In some embodiments, the polynucleotide is the polynucleotide provided herein.
[0219] In some embodiments, the polynucleotide is an mRNA or is comprised in the genome of a recombinant virus.
[0220] In some embodiments, the polynucleotide is the mRNA provided herein. In some embodiments, the mRNA is delivered to the target cell using a lipid nanoparticle comprising the mRNA.
[0221] In some embodiments, the polynucleotide is delivered to the target cell using a recombinant virus comprising the polynucleotide in its genome. In some embodiments, the recombinant virus is the recombinant virus provided herein. In some embodiments, the recombinant virus is a recombinant AAV. In some embodiments, the recombinant AAV has a serotype of AAV8.
[0222] In one aspect, the present disclosure provides a method for treating a disease associated with hepatitis B virus infection, the method comprising delivering to a target cell in the subject: (a) a therapeutically effective amount of a polynucleotide comprising a nucleic acid sequence encoding the engineered meganuclease provided herein, wherein the engineered meganuclease is expressed in the target cell; or (b) a therapeutically effective amount of the engineered meganuclease provided herein; wherein the target cell comprises an HBV genome or HBV genome fragment comprising an HBsAg gene, wherein the engineered meganuclease produces a cleavage site at a recognition sequence comprising SEQ ID NO: 3 within the HBsAg gene, wherein the HBsAg gene is inactivated by introduction of an indel at the cleavage site, or wherein the HBsAg gene is inactivated by elimination of the HBV genome or the HBV genome fragment.
[0223] In some embodiments, the disease is chronic hepatitis B, hepatocellular carcinoma, and / or cirrhosis.
[0224] In some embodiments, the HBV genome or the HBV genome fragment is comprised by cccDNA. In some embodiments, the cccDNA is eliminated following generation of the cleavage site. In some embodiments, the HBsAg gene is inactivated in the cccDNA by introduction of the indel at the cleavage site. In some embodiments, the indel is introduced by NHEJ. In some
[0225] 20 Atty Docket No. P893392090WO (01344)embodiments, the inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
[0226] In some embodiments, the HBV genome or the HBV genome fragment is comprised in the genome of the target cell. In some embodiments, the genome is the nuclear genome. In some embodiments, the genome is the mitochondrial genome. In some embodiments, the indel is introduced by NHEJ. In some embodiments, the inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
[0227] In some embodiments, the serum concentration of HBsAg is reduced in the subject.
[0228] In some embodiments, the target cell is a liver cell. In some embodiments, the liver cell is a hepatocyte.
[0229] In some embodiments, the polynucleotide is the polynucleotide provided herein.
[0230] In some embodiments, the polynucleotide is an mRNA or is comprised in the genome of a recombinant virus. In some embodiments, the polynucleotide is the mRNA provided herein. In some embodiments, the mRNA is delivered to the target cell using a lipid nanoparticle comprising the mRNA.
[0231] In some embodiments, the polynucleotide is delivered to the target cell using a recombinant virus comprising the polynucleotide in its genome. In some embodiments, the recombinant virus is the recombinant virus provided herein. In some embodiments, the recombinant virus is a recombinant AAV. In some embodiments, the recombinant AAV has a serotype of AAV8.
[0232] In some embodiments, the subject is also administered one, two, three, four or more additional therapeutic agents selected from HBV combination drugs, HBV vaccines, HBV DNA polymerase inhibitors, immunomodulators, toll-like receptor (TLR) modulators, interferon alpha receptor ligands, hyaluronidase inhibitors, HBV antigen inhibitors (e.g., HBV core antigen (HBcAg) inhibitors, HBV surface antigen (HBsAg) inhibitors, HBx inhibitors, HBV E antigen inhibitors), anti-HBV antigen antibodies, inhibitory nucleic acids targeting HBV (e.g., antisense oligonucleotide, short interfering RNA (siRNA), DNA-directed RNA interference (ddRNAi)), HBsAg secretion or assembly inhibitors, HBV viral entry inhibitors, immune checkpoint inhibitor, cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitors, cyclophilin inhibitors, endonuclease modulators, ribonucleotide reductase inhibitors, covalently closed circular DNA (cccDNA) inhibitors, famesoid X receptor (FXR) agonists, STING agonists, anti-HBV antibodies, CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein modulators, retinoic acid-inducible gene 1 stimulators, N0D2 stimulators, phosphatidylinositol 3 -kinase (PI3K) inhibitors, indoleamine-2, 3 -dioxygenase (IDO) pathway inhibitors, PD-1 inhibitors, PD-L1 inhibitors, recombinant thymosin alpha- 1, Bruton’s tyrosine kinase (BTK) inhibitors, KDM
[0233] 21 Atty Docket No. P893392090WO (01344)inhibitors, HBV replication inhibitors, arginase inhibitors, gene therapy and cell therapy, gene editors, cellular therapy, and TCR-T cell therapy.
[0234] In some embodiments, the subject is also administered one, two, three, four or more additional therapeutic agents selected from 3 -dioxygenase (IDO) inhibitors, apolipoprotein Al modulator, arginase inhibitors, B- and T-lymphocyte attenuator inhibitors, Bruton’s tyrosine kinase (BTK) inhibitors, CCR2 chemokine antagonist, CD137 inhibitors, CD160 inhibitors, CD305 inhibitors, CD4 agonist and modulator, compounds targeting hepatitis B core antigen (HBcAg), core protein allosteric modulators, covalently closed circular DNA (cccDNA) inhibitors, cyclophilin inhibitors, cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitors, DNA polymerase inhibitor, endonuclease modulators, epigenetic modifiers, farnesoid X receptor (FXR) agonists, HBV DNA polymerase inhibitors, HBV replication inhibitors, HBV RNAse inhibitors, HBV viral entry inhibitors, HBx inhibitors, Hepatitis B large envelope protein modulator, Hepatitis B large envelope protein stimulator, Hepatitis B structural protein modulator, hepatitis B surface antigen (HBsAg) inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, hepatitis B virus E antigen inhibitors, hepatitis B virus replication inhibitors, Hepatitis virus structural protein inhibitor, HIV-1 reverse transcriptase inhibitor, Hyaluronidase inhibitor, inhibitor of apoptosis proteins family proteins (IAPS) inhibitors, IL-2 agonist, IL-7 agonist, immunomodulators, indoleamine-2 inhibitors, inhibitors of ribonucleotide reductase, Interleukin-2 ligand, ipi4 inhibitors, lysine demethylase inhibitors, histone demethylase inhibitors, KDM1 inhibitors, KDM5 inhibitors, killer cell lectin-like receptor subfamily G member 1 inhibitors, lymphocyte-activation gene 3 inhibitors, lymphotoxin beta receptor activators, modulators of Axl, modulators of B7-H3, modulators of B7-H4, modulators of CD160, modulators of CD161, modulators of CD27, modulators of CD47, modulators of CD70, modulators of GITR, modulators of HEVEM, modulators of ICOS, modulators of Mer, modulators of NKG2A, modulators of NKG2D, modulators of 0X40, modulators of SIRPalpha, modulators of TIGIT, modulators of Tim-4, modulators of Tyro, Na+ -taurocholate cotransporting polypeptide (NTCP) inhibitors, natural killer cell receptor 2B4 inhibitors, N0D2 gene stimulator, Nucleoprotein inhibitor, nucleoprotein modulators, OX-40 receptor agonist, PD-1 inhibitors, PD-L1 inhibitors, peptidylprolyl isomerase inhibitor, phosphatidylinositol-3 kinase (PI3K) inhibitors, Retinoic acidinducible gene 1 stimulator, Reverse transcriptase inhibitor, Ribonuclease inhibitor, RNA DNA polymerase inhibitor, SLC10A1 gene inhibitor, SMAC mimetics, Src tyrosine kinase inhibitor, stimulator of interferon gene (STING) agonists, stimulators of NODI, T cell surface glycoprotein CD28 inhibitor, T-cell surface glycoprotein CD8 modulator, Thymosin agonist, Thymosin alpha 1
[0235] 22 Atty Docket No. P893392090WO (01344)ligand, Tim-3 inhibitors, TLR-3 agonists, TLR-7 agonists, TLR-9 agonists, TLR9 gene stimulator, toll-like receptor (TLR) modulators, and viral ribonucleotide reductase inhibitor.
[0236] In some embodiments, the subject is administered an antiviral or an immune modulator. In some embodiments, the subject is administered one or more pharmaceuticals selected from tenofovir disoproxil, tenofovir alafenamide, entecavir, bulevirtide, telbivudine, adefovir dipivoxil, lamivudine, pegylated interferon, and interferon alpha.
[0237] In some embodiments of the methods above, the method comprises introducing into the eukaryotic cell or delivering to the target cell (e.g., in a subject): (a) a second nucleic acid sequence encoding a second engineered meganuclease, wherein the second engineered meganuclease is expressed in the eukaryotic cell; or (b) a second engineered meganuclease; wherein the second engineered meganuclease binds and cleaves a second recognition sequence within the HBV genome or the HBV genome fragment to generate a second cleavage site.
[0238] In some embodiments, the method comprises introducing into the eukaryotic cell or delivering to the target cell (e.g., in a subject): (a) a first polynucleotide comprising a first nucleic acid sequence encoding the engineered meganuclease provided herein, wherein the engineered meganuclease is expressed in the eukaryotic cell; and (b) a second polynucleotide comprising a second nucleic acid sequence encoding the second engineered meganuclease, wherein the second engineered meganuclease is expressed in the eukaryotic cell.
[0239] In some embodiments, the first polynucleotide is a first mRNA and the second polynucleotide is a second mRNA.
[0240] In some embodiments, the first mRNA and the second mRNA are comprised by lipid nanoparticles that are contacted with the eukaryotic cell.
[0241] In some embodiments, the first polynucleotide is comprised by a first recombinant AAV and the second polynucleotide is comprised by a second recombinant AAV, wherein the first recombinant AAV and the second recombinant AAV are contacted with the eukaryotic cell.
[0242] In some embodiments, the method comprises introducing into the eukaryotic cell or delivering to the target cell (e.g., in a subject) a polynucleotide comprising (a) a first nucleic acid sequence encoding the engineered meganuclease provided herein, wherein the engineered meganuclease is expressed in the eukaryotic cell; and (b) a second nucleic acid sequence encoding sad second engineered meganuclease, wherein the second engineered meganuclease is expressed in the eukaryotic cell.
[0243] In some embodiments, the polynucleotide is an mRNA. In some embodiments, the mRNA is comprised by lipid nanoparticles that are contacted with the eukaryotic cell.
[0244] 23 Atty Docket No. P893392090WO (01344)In some embodiments, the polynucleotide is comprised by a recombinant AAV that is contacted with the eukaryotic cell.
[0245] In some embodiments, the second recognition sequence is within the HBsAg gene.
[0246] In some embodiments, the second recognition sequence is not within the HBsAg gene. In some embodiments, the second recognition sequence is within the HBV polymerase (pol) gene. In some embodiments, the second recognition sequence comprises SEQ ID NO: 57. In some embodiments, the second engineered meganuclease comprises an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 78. In some embodiments, the second engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 78. In some embodiments, the second engineered meganuclease comprises residues 2-343 of SEQ ID NO: 78.
[0247] In some embodiments, the intervening genomic sequence between the cleavage site generated by the first engineered meganuclease and the second cleavage site is excised from the HBV genome or the HBV genome fragment, resulting in inactivation of the HBsAg gene.
[0248] In some embodiments, an indel is formed at the cleavage site generated by the first engineered meganuclease and at the second cleavage site, resulting in inactivation of the HBsAg gene.
[0249] In some embodiments, the HBV genome or the HBV genome fragment is eliminated.
[0250] BRIEF DESCRIPTION OF THE FIGURES
[0251] Figure 1. HBV 27-28 recognition sequence in the HBV gene. The HBV 27-28 recognition sequence, targeted by engineered meganucleases of the present disclosure, comprises two recognition half-sites. Each recognition half-site comprises 9 base pairs, separated by a 4 base pair central sequence. The HBV 27-28 recognition sequence (SEQ ID NO: 3) comprises two recognition half-sites referred to as HBV27 and HBV28.
[0252] Figure 2. Provides a diagram of the hepatitis B virus genome for genotype A, showing the position of the HBV 27-28 recognition sequence within the hepatitis B surface antigen (HBsAg) gene and the polymerase (pol) gene.
[0253] Figure 3A-3B. Provides an alignment of the HBV 27-28 engineered meganuclease amino acid sequences. Figure 3 A illustrates alignments of meganucleases comprising Linker 1923 and subunit modifications. Figure 3B illustrates alignments of meganucleases comprising Linkerl.
[0254] Figure 4. Provides results from a CHO reporter cell assay evaluating the on-target activity of first-generation HBV 27-28 meganuclease candidates.
[0255] 24 Atty Docket No. P893392090WO (01344)Figure 5. Provides results showing indel formation generated by first-generation HBV 27-28 meganucleases in a HepG2-sAg cell line comprising an integrated HBV 27-28 recognition sequence. Indel formation was evaluated at days 2, 6, and 9.
[0256] Figure 6. Provides results from a CHO reporter cell assay evaluating the on-target activity of second-generation HBV 27-28 meganuclease candidates.
[0257] Figure 7. Provides a schematic of the oligocapture assay used to determine off-target effects of an engineered nuclease (e.g., an engineered meganuclease described herein). As shown, the integration cassette or oligo anneals with a double-strand break (DSB) in the gnome that may be due to engineered nuclease cleavage. The DNA is then sheared by sonication, adapters are ligated, and PCR amplified, followed by sequence analysis to determine location of the DSB.
[0258] Figure 8. Provides results from a CHO reporter cell assay evaluating the off-target activity of second-generation HBV 27-28 meganuclease candidates against an nfl off-target site.
[0259] Figure 9. Provides results showing indel formation generated by second-generation HBV 27-28 meganucleases, and the parental HBV 27-28x.l63 meganuclease, in aHepG2-sAg cell line comprising an integrated HBV 27-28 recognition sequence. Indel formation was evaluated at days 2, 6, and 9.
[0260] Figure 10. Provides results from a CHO reporter cell assay evaluating the on-target activity of third-generation HBV 27-28 meganuclease candidates.
[0261] Figure 11. Provides results from a CHO reporter cell assay evaluating the off-target activity of third-generation HBV 27-28 meganuclease candidates against an nfl off-target site.
[0262] Figure 12. Provides results showing indel formation generated by third-generation HBV 27-28 meganucleases, and the parental HBV 27-28L.190 meganuclease, in a HepG2-sAg cell line comprising an integrated HBV 27-28 recognition sequence. Indel formation was evaluated at days 3, 6, and 9.
[0263] Figure 13. Provides results from a CHO reporter cell assay evaluating the on-target activity of fourth-generation HBV 27-28 meganuclease candidates.
[0264] Figure 14. Provides results from a CHO reporter cell assay evaluating the off-target activity of fourth-generation HBV 27-28 meganuclease candidates against an nf4 off-target site.
[0265] Figure 15. Provides results showing indel formation generated by fourth-generation HBV 27-28 meganucleases, and the parental HBV 27-28L.190 and HBV 27-28L.319 meganucleases, in a HepG2-sAg cell line comprising an integrated HBV 27-28 recognition sequence. Indel formation was evaluated at days 2, 5, and 8.
[0266] Figure 16. Provides results showing indel formation generated by fourth-generation HBV 27-28 meganucleases, and the parental HBV 27-28L.190 and HBV 27-28L.319 meganucleases, in a
[0267] 25 Atty Docket No. P893392090WO (01344)Hep3B cell line comprising multiple hepatitis B genome integrations. Indel formation was evaluated at days 2, 5, and 8.
[0268] Figure 17. Provides results from a CHO reporter cell assay evaluating the on-target activity of fifth-generation HBV 27-28 meganuclease candidates.
[0269] Figure 18. Provides results from a CHO reporter cell assay evaluating the off-target activity of fifth-generation HBV 27-28 meganuclease candidates against an nf7 off-target site.
[0270] Figure 19. Provides results from a CHO reporter cell assay evaluating the off-target activity of fifth-generation HBV 27-28 meganuclease candidates against an nf8 off-target site.
[0271] Figure 20. Provides results from a CHO reporter cell assay evaluating the off-target activity of fifth-generation HBV 27-28 meganuclease candidates against an nf9 off-target site.
[0272] Figure 21. Provides dose-response curves for indel formation in a HepG2-sAg cell line comprising an integrated HBV 27-28 recognition sequence by fourth- and fifth-generation HBV 27-28 meganucleases. These doses response curves were used to determine ECso and EC90 values for each meganuclease.
[0273] Figure 22. Provides results from a CHO reporter cell assay evaluating the on-target activity of sixth-generation HBV 27-28 meganuclease candidates.
[0274] Figure 23. Provides results from a CHO reporter cell assay evaluating the off-target activity of sixth-generation HBV 27-28 meganuclease candidates against an nflO off-target site.
[0275] Figure 24. Provides results from a CHO reporter cell assay evaluating the off-target activity of sixth-generation HBV 27-28 meganuclease candidates against an nfl 1 off-target site.
[0276] Figure 25. Provides results from a CHO reporter cell assay evaluating the off-target activity of sixth-generation HBV 27-28 meganuclease candidates against an nfl2 off-target site.
[0277] Figure 26. Provides results from a CHO reporter cell assay characterizing the activity of the variants of the HBV 27-28L.385 meganuclease and the HAO 25-26L.1434 meganuclease, each comprising Linkerl or comprising Linker 1923 and subunit modifications.
[0278] Figures 27A-C. Provides results showing indel formation generated by fourth-, fifth- and sixth-generation HBV 27-28 meganucleases, each comprising Linkerl (OL) or comprising Linkerl 923 with subunit modifications (NL), in a HepG2-sAg cell line comprising an integrated HBV 27-28 recognition sequence. Figure 27A shows results from an mRNA dose of 1 ng. Figure 27B shows results from an mRNA dose of 10 ng. Figure 27C shows results from an mRNA dose of 50 ng.
[0279] Figure 28. Provides dose-response curve for indel formation in a HepG2-sAg cell line comprising an integrated HBV 27-28 recognition sequence by sixth-generation HBV 27-28 meganucleases, each comprising Linkerl (OL) or comprising Linkerl 923 with subunit
[0280] 26 Atty Docket No. P893392090WO (01344)modifications (NL). These doses response curves were used to determine ECso and EC90 values for each meganuclease.
[0281] Figure 29. Provides a graph depicting results from an oligocapture assay to identify off target cutting induced by fourth- fifth- or sixth-generation HBV 27-28 meganucleases, or an oligo control. Variants of each HBV 27-28 meganuclease were evaluated using Linkerl (OL) or Linkerl923 with subunit modifications (NL). Circled dots in each lane indicate the on-target HBV 27-28 site.
[0282] Figure 30A-C. Provides dose-response curves for indel formation in a HepG2-sAg cell line comprising an integrated HBV 27-28 recognition sequence by sixth-generation HBV 27-28 meganucleases that are codon-optimized (MAX) and comprising Linkerl 923 with subunit modifications (1 / 2). Figure 30A shows dose-response curves at a day-3 time point. Figure 30B shows dose-response curves at a day-6 time pont. Figure 30C provides a table summarizing the EC50 and EC90 values for each meganuclease.
[0283] Figure 31. Provides a graph depicting results from an oligocapture assay in HepG2-sAg cells to identify off target cutting induced by codon-optimized sixth-generation HBV 27-28 meganucleases, or an oligo control. Circled dots in each lane indicate the on-target HBV 27-28 site.
[0284] Figure 32. Provides a graph depicting results from an oligocapture assay in Hep3B cells to identify off target cutting induced by codon-optimized sixth-generation HBV 27-28 meganucleases, or an oligo control. Circled dots in each lane indicate the on-target HBV 27-28 site.
[0285] Figures 33A-B. Provide graphs depicting results from a dose-response curve for indel formation and inhibition of HBsAg expression in HepG2-sAg cells. Figure 33A shows a doseresponse cruve at a day-2 time point. Figure 33B shows a dose-response curve of HBsAg inhibition at a day-2 time point.
[0286] Figure 34. Provides a graph depicting the inhition of HBsAg from HepG2-sAg cells treated with an HBV 27-28 meganuclease alone, an HBV 11-12 meganuclease alone, or a combination of an HBV 27-28 and an HBV 11-12 meganuclease. Results are shown for day-3 and day-7 time points.
[0287] Figure 35. Provides a graph depicting the inhition of HBsAg from HepG2-sAg cells treated with an HBV 27-28 meganuclease alone, an HBV 11-12 meganuclease alone, or a combination of an HBV 27-28 and an HBV 11-12 meganuclease at various ratios of each meganuclease to one another. Data are provided for a total dose of 1 ng and 2 ng at a day-7 time point.
[0288] Figure 36. Provides a graph depicting the inhition of HBsAg from HepG2-sAg cells treated with an HBV 27-28 meganuclease alone, an HBV 11-12 meganuclease alone, or a combination of
[0289] 27 Atty Docket No. P893392090WO (01344)an HBV 27-28 and an HBV 11-12 meganuclease at various ratios of each meganuclease to one another. Data are provided for a total dose of 1 ng and 2 ng at a day-7 time point.
[0290] BRIEF DESCRIPTION OF THE SEQUENCES SEQ ID NO: 1 sets forth the amino acid sequence of the wild-type I-Crel meganuclease from Chlamydomonas reinhardtii.
[0291] SEQ ID NO: 2 sets forth the amino acid sequence of the LAGLID ADG motif.
[0292] SEQ ID NO: 3 sets forth the nucleic acid sequence of the sense strand of the HBV 27-28 recognition sequence.
[0293] SEQ ID NO: 4 sets forth the nucleic acid sequence of the reverse complement (antisense strand) of the HBV 27-28 recognition sequence.
[0294] SEQ ID NO: 5 sets forth the amino acid sequence of the HBV 27-28L.753 1923(1 / 2) meganuclease.
[0295] SEQ ID NO: 6 sets forth the amino acid sequence of the HBV 27-28L.794 1923(1 / 2) meganuclease.
[0296] SEQ ID NO: 7 sets forth the amino acid sequence of the HBV 27-28L.455 1923(1 / 2) meganuclease.
[0297] SEQ ID NO: 8 sets forth the amino acid sequence of the HBV 27-28L.561 1923(1 / 2) meganuclease.
[0298] SEQ ID NO: 9 sets forth the amino acid sequence of the HBV27 subunit of the HBV 27-28L.753 1923(1 / 2) meganuclease.
[0299] SEQ ID NO: 10 sets forth the amino acid sequence of the HBV27 subunit of the HBV 27-28L.794 1923(1 / 2) meganuclease.
[0300] SEQ ID NO: 11 sets forth the amino acid sequence of the HBV27 subunit of the HBV 27-28L.455 1923(1 / 2) meganuclease.
[0301] SEQ ID NO: 12 sets forth the amino acid sequence of the HBV27 subunit of the HBV 27-28L.561 1923(1 / 2) meganuclease.
[0302] SEQ ID NO: 13 sets forth the amino acid sequence of the HBV28 subunit of the HBV 27-28L.753 1923(1 / 2) meganuclease.
[0303] SEQ ID NO: 14 sets forth the amino acid sequence of the HBV28 subunit of the HBV 27-28L.794 1923(1 / 2) meganuclease.
[0304] SEQ ID NO: 15 sets forth the amino acid sequence of the HBV28 subunit of the HBV 27-28L.455 1923(1 / 2) meganuclease.
[0305] 28 Atty Docket No. P893392090WO (01344)SEQ ID NO: 16 sets forth the amino acid sequence of the HBV28 subunit of the HBV 27-28L.561 1923(1 / 2) meganuclease.
[0306] SEQ ID NO: 17 sets forth a nucleic acid sequence of the HBV 27-28L.753 1923(1 / 2) meganuclease.
[0307] SEQ ID NO: 18 sets forth a nucleic acid sequence encoding the HBV 27-28L.794 1923(1 / 2) meganuclease.
[0308] SEQ ID NO: 19 sets forth a nucleic acid sequence encoding the HBV 27-28L.455 1923(1 / 2) meganuclease.
[0309] SEQ ID NO: 20 sets forth a nucleic acid sequence encoding the HBV 27-28L.561 1923(1 / 2) meganuclease.
[0310] SEQ ID NO: 21 sets forth the amino acid sequence of the HBV 27-28L.753 meganuclease, SEQ ID NO: 22 sets forth the amino acid sequence of the HBV 27-28L.794 meganuclease, SEQ ID NO: 23 sets forth the amino acid sequence of the HBV 27-28x.l63 meganuclease, SEQ ID NO: 24 sets forth the amino acid sequence of the HBV 27-28L.190 meganuclease, SEQ ID NO: 25 sets forth the amino acid sequence of the HBV 27-28L.319 meganuclease, SEQ ID NO: 26 sets forth the amino acid sequence of the HBV 27-28L.455 meganuclease, SEQ ID NO: 27 sets forth the amino acid sequence of the HBV 27-28L.561 meganuclease, SEQ ID NO: 28 sets forth the amino acid sequence of the HB N l subunit of the HBV 27-28L.753 meganuclease.
[0311] SEQ ID NO: 29 sets forth the amino acid sequence of the HB V27 subunit of the HBV 27-28L.794 meganuclease.
[0312] SEQ ID NO: 30 sets forth the amino acid sequence of the HB V27 subunit of the HBV 27-28x.l63 meganuclease.
[0313] SEQ ID NO: 31 sets forth the amino acid sequence of the HB V27 subunit of the HBV 27-28L.190 meganuclease.
[0314] SEQ ID NO: 32 sets forth the amino acid sequence of the HB V27 subunit of the HBV 27-28L.319 meganuclease.
[0315] SEQ ID NO: 33 sets forth the amino acid sequence of the HB V27 subunit of the HBV 27-28L.455 meganuclease.
[0316] SEQ ID NO: 34 sets forth the amino acid sequence of the HB V28 subunit of the HBV 27-28L.561 meganuclease.
[0317] SEQ ID NO: 35 sets forth the amino acid sequence of the HB V28 subunit of the HBV 27-28L.753 meganuclease.
[0318] 29 Atty Docket No. P893392090WO (01344)SEQ ID NO: 36 sets forth the amino acid sequence of the HBV28 subunit of the HBV 27-28L.794 meganuclease.
[0319] SEQ ID NO: 37 sets forth the amino acid sequence of the HBV28 subunit of the HBV 27-28x.l63 meganuclease.
[0320] SEQ ID NO: 38 sets forth the amino acid sequence of the HBV28 subunit of the HBV 27-28L.190 meganuclease.
[0321] SEQ ID NO: 39 sets forth the amino acid sequence of the HBV28 subunit of the HBV 27-28L.319 meganuclease.
[0322] SEQ ID NO: 40 sets forth the amino acid sequence of the HBV28 subunit of the HBV 27-28L.455 meganuclease.
[0323] SEQ ID NO: 41 sets forth the amino acid sequence of the HBV28 subunit of the HBV 27-28L.561 meganuclease.
[0324] SEQ ID NO: 42 sets forth a nucleic acid sequence encoding the HBV 27-28L.753 meganuclease.
[0325] SEQ ID NO: 43 sets forth a nucleic acid sequence encoding the HBV 27-28L.794 meganuclease.
[0326] SEQ ID NO: 44 sets forth a nucleic acid sequence encoding the HBV 27-28x.l63 meganuclease.
[0327] SEQ ID NO: 45 sets forth a nucleic acid sequence encoding the HBV 27-28L.190 meganuclease.
[0328] SEQ ID NO: 46 sets forth a nucleic acid sequence encoding the HBV 27-28L.319 meganuclease.
[0329] SEQ ID NO: 47 sets forth a nucleic acid sequence encoding the HBV 27-28L.455 meganuclease.
[0330] SEQ ID NO: 48 sets forth the nucleic acid sequence encoding the HBV 27-28L.561 meganuclease.
[0331] SEQ ID NO: 49 sets forth the amino acid sequence of the Linker 1 polypeptide linker.
[0332] SEQ ID NO: 50 sets forth the amino acid sequence of the Linkerl923 polypeptide linker. SEQ ID NO: 51 sets forth the amino acid sequence of a minimal SV40 nuclear localization signal (NLS).
[0333] SEQ ID NO: 52 sets forth the amino acid sequence of an SV40 NLS.
[0334] SEQ ID NO: 53 sets forth a nucleic acid sequence of a 5’ ALB untranslated sequence region (UTR).
[0335] SEQ ID NO: 54 sets forth a nucleic acid sequence of a 3’ SNRPB UTR.
[0336] 30 Atty Docket No. P893392090WO (01344)SEQ ID NO: 55 sets forth a nucleic acid sequence of a poly A termination sequence.
[0337] SEQ ID NO: 56 sets forth a nucleic acid sequence of a Kozak sequence.
[0338] SEQ ID NO: 57 sets forth the nucleic acid sequence of the sense strand of the HBV 11-12 recognition sequence.
[0339] SEQ ID NO: 58 sets forth a nucleic acid sequence of a 5’ HBA2 UTR.
[0340] SEQ ID NO: 59 sets forth a nucleic acid sequence of a 3’ WPRE UTR.
[0341] SEQ ID NO: 60 sets forth the nucleic acid sequence of a primer Pl.
[0342] SEQ ID NO: 61 sets forth the nucleic acid sequence of a primer Fl.
[0343] SEQ ID NO: 62 sets forth the nucleic acid sequence of a primer Rl.
[0344] SEQ ID NO: 63 sets forth the nucleic acid sequence of a primer P2.
[0345] SEQ ID NO: 64 sets forth the nucleic acid sequence of a primer F2.
[0346] SEQ ID NO: 65 sets forth the nucleic acid sequence of a primer R2.
[0347] SEQ ID NO: 66 sets forth the nucleic acid sequence of a primer Pl.
[0348] SEQ ID NO: 67 sets forth the nucleic acid sequence of a primer P2.
[0349] SEQ ID NO: 68 sets forth the nucleic acid sequence of a primer F2.
[0350] SEQ ID NO: 69 sets forth the nucleic acid sequence of a primer R2.
[0351] SEQ ID NO: 70 sets forth the amino acid sequence of the HBV 27-28L.385 meganuclease. SEQ ID NO: 71 sets forth the amino acid sequence of the HBV 27-28L.385 1923(1 / 2) meganuclease.
[0352] SEQ ID NO: 72 sets forth the amino acid sequence of the HAO 25-26L.1434 meganuclease. SEQ ID NO: 73 sets forth the amino acid sequence of the HAO 25-26L.1434 1923(1 / 2) meganuclease.
[0353] SEQ ID NO: 74 sets forth the nucleic acid sequence of the sense strand of the HAO 25-26 recognition sequence.
[0354] SEQ ID NO: 75 sets forth a nucleic acid sequence of a 5’ ALB UTR.
[0355] SEQ ID NO: 76 sets forth a nucleic acid sequence of a 3’ SNRPB UTR.
[0356] SEQ ID NO: 77 sets forth a nucleic acid sequence of a Kozak sequence.
[0357] SEQ ID NO: 78 sets for the amino acid sequence of the HBV 11-12L.1090QE 1923(1 / 2) meganuclease.
[0358] DETAILED DESCRIPTION OF THE INVENTION
[0359] 1.1 References and Definitions
[0360] The patent and scientific literature referred to herein establishes knowledge that is available to those of skill in the art. The issued US patents, allowed applications, published foreign
[0361] 31 Atty Docket No. P893392090WO (01344)applications, and references, including GenBank database sequences, which are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference.
[0362] The present disclosure can be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art. For example, features illustrated with respect to one embodiment can be incorporated into other embodiments, and features illustrated with respect to a particular embodiment can be deleted from that embodiment. In addition, numerous variations and additions to the embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the instant disclosure.
[0363] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used in the description of the disclosure herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure.
[0364] All publications, patent applications, patents, and other references mentioned herein are incorporated by reference herein in their entirety.
[0365] As used herein, “a,” “an,” or “the” can mean one or more than one. For example, “a” cell can mean a single cell or a multiplicity of cells.
[0366] As used herein, unless specifically indicated otherwise, the word “or” is used in the inclusive sense of “and / or” and not the exclusive sense of “either / or.”
[0367] As used herein, the terms “nuclease” and “endonuclease” are used interchangeably to refer to naturally-occurring or engineered enzymes, which cleave a phosphodiester bond within a polynucleotide chain.
[0368] As used herein, the terms “cleave” or “cleavage” refer to the hydrolysis of phosphodiester bonds within the backbone of a recognition sequence within a target sequence that results in a double-stranded break within the target sequence, referred to herein as a “cleavage site”.
[0369] As used herein, the term “meganuclease” refers to an endonuclease that binds doublestranded DNA at a recognition sequence that is greater than 12 base pairs. In some embodiments, the recognition sequence for a meganuclease of the present disclosure is 22 base pairs. A meganuclease can be an endonuclease that is derived from I-Crel (SEQ ID NO: 1), and can refer to an engineered variant of I-Crel that has been modified relative to natural I-Crel with respect to, for example, DNA-binding specificity, DNA cleavage activity, DNA-binding affinity, or dimerization properties. Methods for producing such modified variants of I-Crel are known in the art (e.g., WO
[0370] 32 Atty Docket No. P893392090WO (01344)2007 / 047859, incorporated by reference in its entirety). A meganuclease as used herein binds to double-stranded DNA as a heterodimer. A meganuclease may also be a “single-chain meganuclease” in which a pair of DNA-binding domains is joined into a single polypeptide using a peptide linker. The term “homing endonuclease” is synonymous with the term “meganuclease.” Meganucleases of the present disclosure are substantially non-toxic when expressed in the targeted cells as described herein such that cells can be transfected and maintained at 37°C without observing deleterious effects on cell viability or significant reductions in meganuclease cleavage activity when measured using the methods described herein.
[0371] As used herein, the term “single-chain meganuclease” refers to a polypeptide comprising a pair of nuclease subunits joined by a linker. A single-chain meganuclease has the organization: N-terminal subunit - Linker - C-terminal subunit. The two meganuclease subunits will generally be non-identical in amino acid sequence and will bind non-identical DNA sequences. Thus, singlechain meganucleases typically cleave pseudo-palindromic or non-palindromic recognition sequences. A single-chain meganuclease may be referred to as a “single-chain heterodimer” or “single-chain heterodimeric meganuclease” although it is not, in fact, dimeric. For clarity, unless otherwise specified, the term “meganuclease” can refer to a dimeric or single-chain meganuclease.
[0372] As used herein, the term “linker” refers to an exogenous peptide sequence used to join two meganuclease subunits into a single polypeptide. A linker may have a propensity to form a specific three-dimensional structure under physiological conditions, such as turns and / or coils. In some embodiments, the linker is 31 amino acids in length. In some embodiments, a linker may have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 50. In some embodiments, the linker is 42 amino acids in length. In some embodiments, a linker may have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 49.
[0373] As used herein, the terms “recombinant” or “engineered,” with respect to a protein, means having an altered amino acid sequence as a result of the application of genetic engineering techniques to nucleic acids that encode the protein and cells or organisms that express the protein. With respect to a nucleic acid, the term “recombinant” or “engineered” means having an altered nucleic acid sequence as a result of the application of genetic engineering techniques. Genetic engineering techniques include, but are not limited to, PCR and DNA cloning technologies; transfection, transformation, and other gene transfer technologies; homologous recombination; site-directed mutagenesis; and gene fusion. In accordance with this definition, a protein having an
[0374] 33 Atty Docket No. P893392090WO (01344)amino acid sequence identical to a naturally-occurring protein, but produced by cloning and expression in a heterologous host, is not considered recombinant or engineered.
[0375] As used herein, the term “wild-type” refers to the most common naturally occurring allele (i.e., polynucleotide sequence) in the allele population of the same type of gene, wherein a polypeptide encoded by the wild-type allele has its original functions. The term “wild-type” also refers to a polypeptide encoded by a wild-type allele. Wild-type alleles (i.e., polynucleotides) and polypeptides are distinguishable from mutant or variant alleles and polypeptides, which comprise one or more mutations and / or substitutions relative to the wild-type sequence(s). Whereas a wildtype allele or polypeptide can confer a normal phenotype in an organism, a mutant or variant allele or polypeptide can, in some instances, confer an altered phenotype. Wild-type nucleases are distinguishable from recombinant or non-naturally-occurring nucleases. The term “wild-type” can also refer to a cell, an organism, and / or a subject which possesses a wild-type allele of a particular gene, or a cell, an organism, and / or a subject used for comparative purposes.
[0376] As used herein, the term “genetically-modified” refers to a cell or organism in which, or in an ancestor of which, a genomic DNA sequence has been deliberately modified by recombinant technology. As used herein, the term “genetically-modified” encompasses the term “transgenic.” As used herein, the term with respect to recombinant proteins, the term “modification” means any insertion, deletion, or substitution of an amino acid residue in the recombinant sequence relative to a reference sequence (e.g., a wild-type or a native sequence).
[0377] As used herein, the terms “recognition sequence” or “recognition site” refers to a DNA sequence that is bound and cleaved by a nuclease. In the case of a meganuclease, a recognition sequence comprises a pair of inverted, 9 basepair “half sites” which are separated by four basepairs. In the case of a single-chain meganuclease, the N-terminal domain of the protein contacts a first half-site and the C-terminal domain of the protein contacts a second half-site. Cleavage by a meganuclease produces four basepair 3’ “overhangs”. “Overhangs,” or “sticky ends” are short, single-stranded DNA segments that can be produced by endonuclease cleavage of a doublestranded DNA sequence. In the case of meganucleases and single-chain meganucleases derived from I-Crel, the overhang comprises bases 10-13 of the 22 basepair recognition sequence.
[0378] As used herein, the terms “target site” or “target sequence” refers to a region of the chromosomal DNA of a cell comprising a recognition sequence for a nuclease.
[0379] As used herein, the terms “DNA-binding affinity” or “binding affinity” means the tendency of a meganuclease to non-covalently associate with a reference DNA molecule (e.g., a recognition sequence or an arbitrary sequence). Binding affinity is measured by a dissociation constant, Kd. As used herein, a nuclease has “altered” binding affinity if the Kd of the nuclease for a reference
[0380] 34 Atty Docket No. P893392090WO (01344)recognition sequence is increased or decreased by a statistically significant percent change relative to a reference nuclease.
[0381] As used herein, the term “specificity” refers to the ability of a nuclease to bind and cleave double-stranded DNA molecules only at a particular sequence of base pairs referred to as the recognition sequence, or only at a particular set of recognition sequences. The set of recognition sequences will share certain conserved positions or sequence motifs, but may be degenerate at one or more positions. A highly-specific nuclease is capable of cleaving only one or a very few recognition sequences. Specificity can be determined by any method known in the art, such as unbiased identification of DSBs enabled by sequencing (GUIDE-seq), oligonucleotide (oligo) capture assay, whole genome sequencing, and long-range next generation sequencing of the recognition sequence. In some embodiments, specificity is measured using GUIDE-seq. As used herein, “specificity” is synonymous with a low incidence of cleavage of sequences different from the target sequences (non-target sequences), i.e., off-target cutting. A low incidence of off-target cutting may comprise an incidence of cleavage of non-target sequences of less than 25%, less than 20%, less than 18%, less than 15%, less than 12.5%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2.5%, less than 2%, less than 1.5%, less than 1%, less than 0.75%, less than 0.5%, or less than 0.25%.
[0382] As used herein, a meganuclease has “altered” specificity if it binds to and cleaves a recognition sequence which is not bound to and cleaved by a reference meganuclease (e.g., a wildtype) under physiological conditions, or if the rate of cleavage of a recognition sequence is increased or decreased by a biologically significant amount (e.g., at least 2x, or 2x-10x) relative to a reference meganuclease.
[0383] In some embodiments, the presently disclosed engineered meganucleases have specificity for the target recognition sequence that comprises SEQ ID NO: 3 (i.e., HBV 27-28). Engineered meganucleases that have specificity for the target recognition sequence can exhibit reduced off-target cleavage. Off-target cleavage by a meganuclease can be measured using any method known in the art, including for example, oligo capture analysis as described here, a T7 endonuclease (T7E) assay as described herein, digital PCR as described herein, targeted sequencing of particular off-target sites, exome sequencing, whole genome sequencing, direct in situ breaks labeling enrichment on streptavidin and next-generation sequencing (BLESS), genome-wide, GUIDE-seq, and linear amplification-mediated high-throughput genome-wide translocation sequencing (LAM-HTGTS) (see, e.g., Zischewski et al. (2017), Biotechnology Advances 35(1):95- 104, which is incorporated by reference in its entirety).
[0384] 35 Atty Docket No. P893392090WO (01344)As used herein, the term “efficiency of cleavage” refers to the incidence by which a meganuclease cleaves a recognition sequence in a double-stranded DNA molecule relative to the incidence of all cleavage events by the meganuclease on the DNA molecule. “Efficiency of cleavage” is synonymous with DNA editing efficiency or on-target editing. Efficiency of cleavage and / or indel formation by a meganuclease can be measured using any method known in the art, including T7E assay, digital PCR (ddPCR), mismatch detection assays, mismatch cleavage assay, high-resolution melting analysis (HRMA), heteroduplex mobility assay, sequencing, and fluorescent PCR capillary gel electrophoresis (see, e.g., Zischewski et al. (2017) Biotechnology Advances 35(1):95-104, which is incorporated by reference in its entirety). In some embodiments, efficiency of cleavage is measured by ddPCR. In some embodiments, the disclosed meganucleases generate efficiencies of cleavage of at least about 35%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, or 99% at the recognition sequence.
[0385] An “indel”, as used herein, refers to the insertion or deletion of a nucleobase within a nucleic acid, such as DNA. In some embodiments, it is desirable to generate one or more insertions or deletions (i.e., indels) in the nucleic acid, e.g., in a foreign nucleic acid such as viral DNA.
[0386] Accordingly, as used herein, “efficiency of indel formation” refers to the incidence by which a meganuclease generates one or more indels through cleavage of a recognition sequence relative to the incidence of all cleavage events by the meganuclease on the DNA molecule. In some embodiments, efficiency of indel formation is measured by ddPCR. In some embodiments, the disclosed meganucleases generate efficiencies of indel formation of at least about 35%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, or 99% at the recognition sequence. The disclosed meganucleases may generate efficiencies of cleavage and / or efficiencies of indel formation of at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80% at the recognition sequence.
[0387] As used herein, the term “homologous recombination” or “HR” refers to the natural, cellular process in which a double-stranded DNA-break is repaired using a homologous DNA sequence as the repair template (see, e.g. Cahill et al. (2006), Front. Biosci. 11:1958-1976). The homologous DNA sequence may be an endogenous chromosomal sequence or an exogenous nucleic acid that was delivered to the cell.
[0388] As used herein, the term “non-homologous end-joining” or “NHEJ” refers to the natural, cellular process in which a double-stranded DNA-break is repaired by the direct joining of two non-homologous DNA segments (see, e.g. Cahill et al. (2006), Front. Biosci. 11:1958-1976). DNA repair by non-homologous end-joining is error-prone and frequently results in the untemplated addition or deletion of DNA sequences at the site of repair. In some instances, cleavage at a target
[0389] 36 Atty Docket No. P893392090WO (01344)recognition sequence results in NHEJ at a target recognition site. Nuclease-induced cleavage of a target site in the coding sequence of a gene followed by DNA repair by NHEJ can introduce mutations into the coding sequence, such as frameshift mutations, that disrupt gene function. Thus, engineered meganucleases can be used to effectively knock-out a gene in a population of cells.
[0390] As used herein, the term “homology arms” or “sequences homologous to sequences flanking a meganuclease cleavage site” refer to sequences flanking the 5’ and 3’ ends of a nucleic acid molecule which promote insertion of the nucleic acid molecule into a cleavage site generated by a meganuclease. In general, homology arms can have a length of at least 50 base pairs, preferably at least 100 base pairs, and up to 2000 base pairs or more, and can have at least 90%, preferably at least 95%, or more, sequence homology to their corresponding sequences in the genome. In some embodiments, the homology arms are about 500 base pairs.
[0391] As used herein with respect to both amino acid sequences and nucleic acid sequences, the terms “percent identity,” “sequence identity,” “percentage similarity,” “sequence similarity” and the like refer to a measure of the degree of similarity of two sequences based upon an alignment of the sequences that maximizes similarity between aligned amino acid residues or nucleotides, and which is a function of the number of identical or similar residues or nucleotides, the number of total residues or nucleotides, and the presence and length of gaps in the sequence alignment. A variety of algorithms and computer programs are available for determining sequence similarity using standard parameters. As used herein, sequence similarity is measured using the BLASTp program for amino acid sequences and the BLASTn program for nucleic acid sequences, both of which are available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov / ), and are described in, for example, Altschul et al. (1990), J. Mol. Biol. 215:403-410; Gish and States (1993), Nature Genet. 3:266-272; Madden et al. (1996), Meth. Enzymol.266: 131-141; Altschul et al. (1997), Nucleic Acids Res. 25:33 89-3402); Zhang et al. (2000), J. Comput. Biol. 7(l-2):203-14. As used herein, percent similarity of two amino acid sequences is the score based upon the following parameters for the BLASTp algorithm: word size=3; gap opening penalty=-l 1; gap extension penalty=-l; and scoring matrix=BLOSUM62. As used herein, percent similarity of two nucleic acid sequences is the score based upon the following parameters for the BLASTn algorithm: word size=ll; gap opening penalty=-5; gap extension penalty=-2; match reward=l; and mismatch penalty=-3.
[0392] As used herein, the term “corresponding to” with respect to modifications of two proteins or amino acid sequences, is used to indicate that a specified modification in the first protein is a substitution of the same amino acid residue as in the modification in the second protein, and that the amino acid position of the modification in the first protein corresponds to or aligns with the
[0393] 37 Atty Docket No. P893392090WO (01344)amino acid position of the modification in the second protein when the two proteins are subjected to standard sequence alignments (e.g., using the BLASTp program) and aligned for maximum sequence identity across the entire subunit or protein. Thus, the modification of residue “X” to amino acid “A” in the first protein will correspond to the modification of residue “Y” to amino acid “A” in the second protein if residues X and Y correspond to each other in a sequence alignment, and despite the fact that X and Y may be at different positions relative to the N-terminus or C-terminus.
[0394] As used herein, the term “recognition half-site,” “recognition sequence half-site,” or simply “half-site” means a nucleic acid sequence in a double-stranded DNA molecule that is recognized and bound by a monomer of a homodimeric or heterodimeric meganuclease or by one subunit of a single-chain meganuclease or by one subunit of a single-chain meganuclease.
[0395] As used herein, the term “hypervariable region” refers to a localized sequence within a meganuclease monomer or subunit that comprises amino acids with relatively high variability. A hypervariable region can comprise about 50-60 contiguous residues, about 53-57 contiguous residues, or preferably about 56 residues. In some embodiments, the residues of a hypervariable region may correspond to positions 24-79 or positions 204-259 of any one of SEQ ID NOs: 5-8. In some embodiments, the residues of a hypervariable region may correspond to positions 24-79 or positions 215-270 of any one of SEQ ID NOs: 21-27. A hypervariable region can comprise one or more residues that contact DNA bases in a recognition sequence and can be modified to alter base preference of the monomer or subunit. A hypervariable region can also comprise one or more residues that bind to the DNA backbone when the meganuclease associates with a double-stranded DNA recognition sequence. Such residues can be modified to alter the binding affinity of the meganuclease for the DNA backbone and the target recognition sequence. In different embodiments, a hypervariable region may comprise between 1-20 residues that exhibit variability and can be modified to influence base preference and / or DNA-binding affinity. In particular embodiments, a hypervariable region comprises between about 15-20 residues that exhibit variability and can be modified to influence base preference and / or DNA-binding affinity.
[0396] In some embodiments, variable residues within a hypervariable region correspond to one or more of positions 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 5-8, e.g., SEQ ID NO: 5 or 6. In some embodiments, variable residues within a hypervariable region correspond to one or more of positions 50, 71, or 72 of any one of SEQ ID NOs: 5-8, e.g., SEQ ID NO: 5 or 6.
[0397] In some embodiments, variable residues within a hypervariable region correspond to one or more of positions 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of
[0398] 38 Atty Docket No. P893392090WO (01344)any one of SEQ ID NOs: 5-8, e.g., SEQ ID NO: 5 or 6. In some embodiments, variable residues within a hypervariable region further correspond to one or more of positions 237 and 241 of any one of SEQ ID NOs: 5-8, e g., SEQ ID NO: 5 or 6.
[0399] In some embodiments, variable residues within a hypervariable region correspond to one or more of positions 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 21-27, e.g., SEQ ID NO: 21 or 22. In some embodiments, variable residues within a hypervariable region correspond to one or more of positions 48, 50, 71, or 72 of any one of SEQ ID NOs: 21-27, e.g., SEQ ID NO: 21 or 22.
[0400] In some embodiments, variable residues within a hypervariable region correspond to one or more of positions 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of any one of SEQ ID NOs: 21-27, e.g., SEQ ID NO: 21 or 22.
[0401] The terms “recombinant DNA construct,” “recombinant construct,” “expression cassette,” “cassette,” “expression construct,” “chimeric construct,” “construct,” and “recombinant DNA fragment” are used interchangeably herein and are single or double-stranded polynucleotides. A recombinant construct comprises an artificial combination of nucleic acid fragments, including, without limitation, regulatory and coding sequences that are not found together in nature. For example, a recombinant DNA construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source and arranged in a manner different than that found in nature. Such a construct may be used by itself or may be used in conjunction with a vector.
[0402] As used herein, a “vector” or “recombinant DNA vector” may be a construct that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. If a vector is used, then the choice of vector is dependent upon the method that will be used to transform host cells as is well known to those skilled in the art. Vectors can include, without limitation, plasmid vectors and recombinant AAV vectors, or any other vector known in the art suitable for delivering a gene to a target cell. The skilled artisan is well aware of the genetic elements that must be present on the vector in order to successfully transform, select and propagate host cells comprising any of the isolated nucleotides or nucleic acid sequences described herein. In some embodiments, a “vector” also refers to a viral vector. Viral vectors can include, without limitation, recombinant retroviruses, recombinant lentiviruses, recombinant adenoviruses, and recombinant adeno-associated viruses (AAV).
[0403] As used herein, a “polycistronic” mRNA refers to a single messenger RNA that comprises two or more coding sequences (i.e., cistrons) and encodes more than one protein. A polycistronic mRNA can comprise any element known in the art to allow for the translation of two or more genes
[0404] 39 Atty Docket No. P893392090WO (01344)from the same mRNA molecule including, but not limited to, an IRES element, a T2A element, a P2A element, an E2A element, and an F2A element.
[0405] As used herein, the term “operably linked” is intended to mean a functional linkage between two or more elements. For example, an operable linkage between a nucleic acid sequence encoding a nuclease as described herein and a regulatory sequence (e.g., a promoter) is a functional link that allows for expression of the nucleic acid sequence encoding the nuclease. Operably linked elements may be contiguous or non-contiguous. When used to refer to the joining of two protein coding regions, by operably linked is intended that the coding regions are in the same reading frame.
[0406] As used herein, “uridine depletion” refers to the removal or replacement of uridine residues from an RNA molecule (e.g., mRNA) or thymidine residues from a DNA molecule that encodes for an RNA molecule. The uridines can be replaced with any other residue, such as adenosine or pseudouridine, within any region of the RNA molecule, but in some embodiments, the uridines are removed and replaced within the non-coding region of an RNA molecule. In some embodiments, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the uridines in an RNA molecule are removed or replaced.
[0407] As used herein, “codon-optimized” refers to a coding sequence that has been modified to improve gene expression and increase the translational efficiency by accommodating the codon bias of the host organism or tissue, wherein the limitations associated with species-specific and tissue-specific differences in codon usage and transfer RNA (tRNA) abundance are lessened. The coding sequence can be codon-optimized for expression in mammalian cells and / or specific tissues. As it has been shown that the codon usage bias of genes specifically expressed in the human liver differ from the codon usage bias of the human genome coding DNA sequences (Dittmar et al. (2006) PLoS Genet. 2:e221), in some embodiments, sequences encoding an engineered meganuclease described herein are optimized for expression in liver.
[0408] As used herein, “inactivating” in reference to a gene refers to either the introduction of a mutation into the gene such that the resultant inactivated gene does not encode an active and / or full-length protein or the gene is eliminated (i.e., degraded). An HBV genome or fragment thereof can be eliminated, thus inactivating any HBV genes present in the HBV genome or fragment thereof, through the cleavage of the genome or genome fragment that results in the subsequent degradation of the genome or fragment thereof.
[0409] As used herein, a “control” or “control cell” refers to a cell that provides a reference point for measuring changes in genotype or phenotype of a genetically-modified cell. A control cell may comprise, for example: (a) a wild-type cell, i.e., of the same genotype as the starting material for the genetic alteration which resulted in the genetically-modified cell; (b) a cell of the same
[0410] 40 Atty Docket No. P893392090WO (01344)genotype as the genetically-modified cell but which has been transformed with a null construct (i.e., with a construct which has no known effect on the trait of interest); or, (c) a cell genetically identical to the genetically-modified cell but which is not exposed to conditions or stimuli or further genetic modifications that would induce expression of altered genotype or phenotype. A control subject may comprise, for example: a wild-type subject, i.e., a subject not having an HBV infection, which is not exposed to conditions or stimuli or further genetic modifications (e.g., administration of an engineered meganuclease described herein). Alternatively, a control subject may comprise, for example: a subject having an HBV infection, which is not exposed to conditions or stimuli or further genetic modifications (e.g., administration of an engineered meganuclease described herein) that can alter the HBV infection status of the subject.
[0411] As used herein, the terms “treatment” or “treating a subject” refers to the administration of an engineered meganuclease of the disclosure, or a nucleic acid encoding an engineered meganuclease of the disclosure to a subject infected with HBV for the purpose of slowing or stopping the rate of HBV proliferation of the virus by cleaving the genome of at least one HBV particle. Such treatment reduces or prevents transfection and replication of HBV in the subject, and provides either partial or complete relief of one or more symptoms of HBV infection or a disease associated with HBV infection in the subject. Means to assess alleviation of symptoms of HBV infection or a disease associated with HBV infection may include measurement of liver functions by determining levels of the enzyme alanine aminotransferase (ALT) or by measuring sero conversion, namely disappearance and / or reduction of the circulating HBeAg and / or HBsAg levels. Further, alleviation or reduction of symptoms of HBV infection or a disease associated with HBV infection can be determined by examining liver biopsies and measuring the level of tissue fibrosis by methods well known in the art. The number of circulating viral particles can be determined for example by measuring HBV DNA levels using PCR or by detecting HBsAg levels in the blood. The terms “treatment” or “treating a subject” can further refer to the administration of a cell (e.g., hepatocyte cell) comprising a nucleic acid encoding an engineered meganuclease, wherein the cell is delivered to a target tissue (e.g., liver) and produces the engineered meganuclease in an amount sufficient to treat an HBV infection or a disease associated with an HBV infection in the subject, thereby resulting in either partial or complete relief of one or more symptoms of the HBV infection or the disease associated with the HBV infection. In some aspects, an engineered meganuclease of the disclosure or a nucleic acid encoding the same is administered during treatment in the form of a pharmaceutical composition of the disclosure.
[0412] The term “a disease associated with hepatitis B virus infection” refers to any condition related to or resulting from infection with a hepatitis B virus, such as chronic liver
[0413] 41 Atty Docket No. P893392090WO (01344)diseases / disorders, inflammations, fibrotic conditions, and proliferative disorders, such as liver cancers. Chronic persistent HBV infection can cause fatigue, liver damage, cirrhosis of the liver, and hepatocellular carcinoma, a primary liver cancer.
[0414] The terms “proliferating” and “proliferation” as used herein refer to HBV viruses or HBV covalently closed circular DNA (cccDNA) actively dividing and / or infecting human cells. Thus, reduction in proliferation refers to any decrease in the proliferation of HBV including reduction of at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% when compared to an appropriate control not having been administered the engineered meganuclease, or nucleic acid encoding the engineered meganuclease, described herein. Throughout this application, the term “proliferative disorder” refers to any disease / disorder marked by unwanted or aberrant proliferation of cells or tissue. As used herein, the term “proliferative disorder” also refers to conditions in which the unregulated and / or abnormal growth of cells can lead to the development of an unwanted condition or disease, which can be cancerous or non-cancerous.
[0415] As used herein, the term “effective amount” or “therapeutically effective amount” refers to an amount sufficient to effect beneficial or desirable biological and / or clinical results. The therapeutically effective amount will vary depending on the formulation or composition used, the disease and its severity and the age, weight, physical condition, and responsiveness of the subject to be treated. In specific embodiments, an effective amount of the engineered meganuclease or pharmaceutical compositions described herein reduces the level or proliferation of HBV or reduces at least one symptom of a disease associated with HBV infection in a subject with an HBV infection.
[0416] The term “gc / kg” or “gene copies / kilogram” refers to the number of copies of a nucleic acid encoding an engineered meganuclease described herein per weight in kilograms of a subject that is administered the nucleic acid encoding the engineered meganuclease.
[0417] The term “lipid nanoparticle” refers to a lipid composition having a typically spherical structure with an average diameter between 10 and 1000 nanometers. In some formulations, lipid nanoparticles can comprise at least one cationic lipid, at least one non-cationic lipid, and at least one conjugated lipid. Lipid nanoparticles known in the art that are suitable for encapsulating nucleic acids, such as mRNA, are contemplated for use.
[0418] As used herein, the recitation of a numerical range for a variable is intended to convey that the present disclosure may be practiced with the variable equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable can be equal to any integer value within the numerical range, including the end-points of the range. Similarly, for a variable
[0419] 42 Atty Docket No. P893392090WO (01344)which is inherently continuous, the variable can be equal to any real value within the numerical range, including the end-points of the range. As an example, and without limitation, a variable which is described as having values between 0 and 2 can take the values 0, 1 or 2 if the variable is inherently discrete, and can take the values 0.0, 0.1, 0.01, 0.001, or any other real values =0 and =2 if the variable is inherently continuous.
[0420] 2, 1 Principle of the Invention
[0421] The present disclosure is based, in part, on the discovery of HBV 27-28 meganucleases that are capable of binding and cleaving the HBV 27-28 recognition sequence in cells comprising an HBV genome or HBV genome fragment. The HBV 27-28 recognition sequence is advantageously positioned within both the HBsAg gene and the HBV polymerase gene; thus, cleavage at this site allows for inactivation of both genes simultaneously.
[0422] The presently disclosed HBV 27-28 meganucleases recognize the HBV 27-28 recognition sequence (SEQ ID NO: 3), located within the HBV surface antigen (HBsAg) gene encoding the HBsAg protein, which plays an important role in chronic HBV infection by suppressing the immune system. This site differs from the HBV 11-12 recognition sequence (SEQ ID NO: 57), located only within the polymerase (pol) gene of the HBV genome that encodes the viral DNA polymerase. The HBV 27-28 recognition sequence is conserved across at least genotypes A, B, C, D, E, G, I, and J, which advantageously allows for the presently disclosed engineered meganucleases to target HBV infections around the globe.
[0423] The presently disclosed HBV 27-28 meganucleases include, but are not limited to, HBV 27-28L.753 1923(1 / 2), which is set forth as SEQ ID NO: 5, HBV 27-28L.794 1923(1 / 2), which is set forth as SEQ ID NO: 6, HBV 27-28L.455 1923(1 / 2), which is set forth as SEQ ID NO: 7, HBV 27-28L.561 1923(1 / 2), which is set forth as SEQ ID NO: 8, HBV 27-28L.753, which is set forth as SEQ ID NO: 21, HBV 27-28L.794, which is set forth as SEQ ID NO: 22, HBV 27-28x.l63, which is set forth as SEQ ID NO: 23, HBV 27-28L.190, which is set forth as SEQ ID NO: 24, HBV 27-28L.319, which is set forth as SEQ ID NO: 25, HBV 27-28L.455, which is set forth as SEQ ID NO: 26, and HBV 27-28L.561, which is set forth as SEQ ID NO: 27.
[0424] The sequence of Linker 1923 that joins the first and second subunits of certain engineered meganucleases disclosed herein (i.e., SEQ ID NOs: 5-8) is set forth as SEQ ID NO: 50, and the sequence of Linker 1 that joins the first and second subunits of certain engineered meganucleases disclosed herein (i.e., SEQ ID NOs: 21-27) is set forth as SEQ ID NO: 49. Linkerl923 is shorter in length (i.e., 31 amino acid residues) than Linkerl (i.e., 42 amino acid residues). The term “(1 / 2)” or “1923(1 / 2)” refers to the presence of amino acid modifications in the first and second subunits of
[0425] 43 Atty Docket No. P893392090WO (01344)an engineered meganuclease when the subunits are joined by the Linker 1923 sequence. In the HBV 27-28L.753 1923(1 / 2), HBV 27-28L.794 1923(1 / 2), HBV 27-28L.455 1923(1 / 2), and HBV 27-28L.561 1923(1 / 2) meganucleases described herein that comprise the Linkerl923 sequence, the N-terminal subunit includes an A at position 96, an A at position 99, and a D at position 100, and the C-terminal subunit includes a Y at a position corresponding to position 57 of SEQ ID NO: 1 (i.e., position 237 of SEQ ID NOs: 5-8) and a T at a position corresponding to position 61 of SEQ ID NO: 1 (i.e., position 241 of SEQ ID NOs: 5-8). While not being held to any particular theory or mechanism of action, it is believed that the Linkerl923 interacts with these modified “(1 / 2)” residues within the I-Crel scaffold, leading to stabilization of the engineered meganuclease.
[0426] Cleavage at the HBV 27-28 recognition sequence can allow for non-homologous end joining (NHEJ) at the cleavage site and can disrupt expression of one or more viral proteins (e.g., HBsAg protein, which suppresses the immune system in HBV infection) due to NHEJ at the cleavage site that results in insertions, deletions, or frameshift mutations. Alternatively, cleavage of the HBV genome at the HBV 27-28 recognition sequence may promote modification of immune reaction against HBV infection, or degradation of the HBV genome and / or HBV cccDNA.
[0427] Disruption of the expression of the viral protein(s) can reduce or eliminate the infection and / or proliferation of HBV.
[0428] Additionally, cleavage at the HBV 27-28 recognition sequence can further allow for homologous recombination of exogenous nucleic acid sequences directly into the HBV genome to disrupt the expression of one or more viral proteins. For example, a “suicide gene” can be introduced into an HBV genome via homologous recombination.
[0429] Thus, the present disclosure encompasses engineered meganucleases that bind and cleave the HBV 27-28 recognition sequence within an HBV genome. The present disclosure also encompasses methods for inactivating an HBsAg gene of an HBV genome or an HBV genome fragment (for example in a target cell or in a subject), methods for treating an HBV infection or a disease associated with HBV infection, and methods for producing a genetically-modified eukaryotic cell comprising an exogenous sequence of interest inserted into an HBsAg gene comprised in the genome of the genetically-modified eukaryotic cell. Further, the present disclosure encompasses polynucleotides, recombinant DNA constructs, recombinant viruses, cells, lipid nanoparticle compositions, and pharmaceutical compositions containing or encoding the engineered meganucleases, and the use of such compositions for the treatment of HBV infection and diseases associated with HBV infection (e.g., hepatocellular carcinoma).
[0430] 44 Atty Docket No. P893392090WO (01344)3 , 1 Meganucleases that Bind and Cleave the HB V 27-28 Recognition Sequence Within the Hepatitis B Viral Genome
[0431] Recognition Sequences
[0432] It is known in the art that it is possible to use a site-specific nuclease to make a DNA break in the genome of a virus, and that such a DNA break can result in degradation of the viral genome or permanent modification of the genome via mutagenic NHEJ repair or via homologous recombination with a transgenic DNA sequence such that the HBV virion can no longer divide / replicate or infect human cells.
[0433] Engineered meganucleases of the disclosure have been designed to bind and cleave an HBV 27-28 recognition sequence (SEQ ID NO: 3). The HBV 27-28 recognition sequence is positioned within the HBsAg gene ORF of multiple HBV genotypes, including at least genotypes A, B, C, D, E, G, I, and J.
[0434] Engineered Meganucleases
[0435] It is known in the art that it is possible to use a site-specific nuclease to make a DNA break in the genome of a virus, and that such a DNA break can result in permanent modification of the genome via NHEJ such that the HBV virion can no longer divide / replicate or infect human cells. Generating a DNA break in a viral genome can also lead to degradation of the viral genome, rendering it unable to divide, replicate, or be infective.
[0436] Thus, the present disclosure provides engineered meganucleases. In particular embodiments, the meganucleases are single-chain meganucleases. A single-chain meganuclease comprises an N-terminal subunit and a C-terminal subunit joined by a polypeptide linker. Each of the two domains recognizes half of the recognition sequence (i.e., a recognition half-site) and the site of DNA cleavage is at the middle of the recognition sequence near the interface of the two subunits. DNA strand breaks are offset by four base pairs such that DNA cleavage by a meganuclease generates a pair of four base pair, 3’ single-strand overhangs.
[0437] Engineered meganucleases described herein were designed to bind and cleave a recognition sequence referred to as HBV 27-28 (SEQ ID NO: 3). The HBV 27-28 recognition sequence is advantageously positioned within both the HBsAg gene and the HBV polymerase gene. As such, cleavage at this site allows for inactivation of both genes simultaneously. Thus, in particular embodiments, the presently disclosed engineered meganucleases, when delivered to a population of HBV-infected target cells, is able generate to virions or cells with a cleavage and / or an indel in the HBV genome (either incorporated or unincorporated). In some of these embodiments, the
[0438] 45 Atty Docket No. P893392090WO (01344)population of HBV or target cells comprises at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of HBV or target cells comprising a cleavage and / or an indel in the HBV genome (either incorporated or unincorporated). Cleavage and / or indel formation by a meganuclease can be measured using any method known in the art, including T7E assay, digital PCR, mismatch detection assays, mismatch cleavage assay, high-resolution melting analysis (HRMA), heteroduplex mobility assay, sequencing, and fluorescent PCR capillary gel electrophoresis (see, e.g., Zischewski et al. (2017) Biotechnology Advances 35(1):95-104, which is incorporated by reference in its entirety).
[0439] In some embodiments, the target cell is a liver cell. In some embodiments, the liver cell is a hepatocyte. In some embodiments, the target cell is a primary human hepatocyte (PHH). In some embodiments, the target cell is a non-human, mammalian hepatocyte.
[0440] Engineered meganucleases described herein comprise a first subunit, comprising a first hypervariable (HVR1) region, and a second subunit, comprising a second hypervariable (HVR2) region. Further, the first subunit binds to a first recognition half-site in the recognition sequence (i.e., the HBV27 half-site), and the second subunit binds to a second recognition half-site in the recognition sequence (i.e., the HBV28 half-site). In embodiments where the engineered meganuclease is a single-chain meganuclease, the first and second subunits can be oriented such that the first subunit, which comprises the HVR1 region and binds the first half-site, is positioned as the N-terminal subunit, and the second subunit, which comprises the HVR2 region and binds the second half-site, is positioned as the C-terminal subunit. In alternative embodiments, the first and second subunits can be oriented such that the first subunit, which comprises the HVR1 region and binds the first half-site, is positioned as the C-terminal subunit, and the second subunit, which comprises the HVR2 region and binds the second half-site, is positioned as the N-terminal subunit.
[0441] The meganucleases provided herein can comprise a first subunit and a second subunit, described herein, joined by a peptide linker that joins the C-terminus of the first subunit to the N-terminus of the second subunit. In some embodiments, the linker can be Linker 1923 set forth as SEQ ID NO: 50, or Linkerl set forth as SEQ ID NO: 49. Linkers, such as Linkerl923 and Linkerl, can be selected based on the desired activity of the meganuclease and can be used to modify activity of the meganuclease.
[0442] In specific embodiments, wherein the engineered meganucleases comprise Linkerl923, the engineered meganuclease includes modifications referred to herein as “(1 / 2)” modifications, which indicates the presence of specific modifications present in both the first and second subunits. These
[0443] 46 Atty Docket No. P893392090WO (01344)(1 / 2) modifications include 3 modifications of K96A, Q99A, and K100D in the first N-terminal subunit, and 2 modifications in the second C-terminal subunit that correspond to K57Y and E61T in the wild-type I-Crel meganuclease set forth as SEQ ID NO: 1. The actual positions of the modifications in the C-terminal subunit are at positions 237 and 241 in the engineered meganucleases exemplified herein.
[0444] In some examples, meganucleases can have a linker having an amino acid sequence of SEQ ID NO: 50 (i.e., Linkerl923), a first subunit having an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to any one of SEQ ID NOs: 9-12, and a second subunit having an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to any one of SEQ ID NO: 13-16. In some examples, meganucleases can have a linker having the amino acid sequence of SEQ ID NO: 50, and an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to any one of SEQ ID NO: 5-8.
[0445] Alternatively, in some examples, meganucleases can have a linker having an amino acid sequence of SEQ ID NO: 49, a first subunit having an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to any one of SEQ ID NO: 28-34, and a second subunit having an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to any one of SEQ ID NO: 35-41. In some examples, meganucleases can have a linker having an amino acid sequence of SEQ ID NO: 49, and an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to any one of SEQ ID NO: 21-27.
[0446] In certain embodiments of the engineered meganucleases described herein, the first subunit (i.e., comprising HVR1) can be positioned as the N-terminal subunit, and the second subunit (i.e., comprising HVR2) can be positioned as the C-terminal subunit. In some embodiments of such a configuration, such as those exemplified in SEQ ID NOs: 5-8 and 21-27, the first subunit (i.e., the N-terminal subunit) can lack residues at its C-terminus that correspond to residues 154-163 of wild-
[0447] 47 Atty Docket No. P893392090WO (01344)type I-Crel because the binding site of the polypeptide linker is at the D residue corresponding to position 153 of wild-type I-Crel. The first subunit can further comprise one or more residues at its N-terminus that correspond to one or more of residues 1-6 of wild-type I-Crel (e.g., residues 1-6, 2-6, 3-6, 4-6, or 5-6). Also, in some embodiments of such a configuration, the second subunit (i.e., the C-terminal subunit) can lack residues at its N-terminus that correspond to residues 1-4 of wildtype I-Crel because the binding site of the polypeptide linker is at the Y residue corresponding to position 5 of wild-type I-Crel. The second subunit can further comprise residues at its C-terminus that correspond to residues 154-163 of wild-type I-Crel.
[0448] In other embodiments of the engineered meganucleases described herein, the first subunit (i.e., comprising HVR1) can be positioned as the C-terminal subunit, and the second subunit (i.e., comprising HVR2) can be positioned as the N-terminal subunit. In some embodiments of such a configuration, the first subunit (i.e., the C-terminal subunit) can lack residues at its N-terminus that correspond to residues 1-4 of wild-type I-Crel because the binding site of the polypeptide linker is at the Y residue corresponding to position 5 of wild-type I-Crel. The first subunit can further comprise residues at its C-terminus that correspond to residues 154-163 of wild-type I-Crel. Also, in some embodiments of such a configuration, the second subunit (i.e., the N-terminal subunit) can lack residues at its C-terminus that correspond to residues 154-163 of wild-type I-Crel because the binding site of the polypeptide linker is at the D residue corresponding to position 153 of wild-type I-Crel. The second subunit can further comprise one or more residues at its N-terminus that correspond to one or more of residues 1-6 of wild-type I-Crel (e.g., residues 1-6, 2-6, 3-6, 4-6, or 5-6).
[0449] In some embodiments, the disclosed engineered meganucleases comprise (i) an inactivating amino acid in the N-terminal subunit that reduces or abolishes cleavage activity; (ii) an inactivating amino acid in the C-terminal subunit that reduces or abolishes cleavage activity; or (iii) an inactivating amino acid in the N-terminal subunit that reduces or abolishes cleavage activity and an inactivating amino acid in the C-terminal subunit that reduces or abolishes cleavage activity.
[0450] As used here, an inactivating amino acid that “reduces” cleavage activity of an engineered meganuclease inactivates only the subunit comprising that amino acid, while not affecting the ability of the other subunit to cleave its DNA strand. For example, in cases where only one subunit comprises an inactivating amino acid that reduces cleavage activity, the other subunit remains active and the engineered meganuclease becomes a nickase that remains capable of cleaving one strand of the double-stranded DNA. In other cases where both subunits comprise an inactivating amino acid that reduces cleavage activity, neither subunit is active, the engineered meganuclease
[0451] 48 Atty Docket No. P893392090WO (01344)does not comprise any cleavage activity, and it cannot generate a single-strand or double-strand break in the DNA.
[0452] By comparison, an inactivating amino acid that “abolishes” cleavage activity of an engineered meganuclease can be present in only one subunit but will inactivate both subunits of the engineered meganuclease, such that it does not comprise any cleavage activity and cannot generate a single-strand or double-strand break in the DNA.
[0453] In some embodiments, the inactivating amino acid is an A at a position corresponding to position 20 or position 200 of any one of SEQ ID NOs: 5-8, or position 20 or position 211 of any of of SEQ ID NOs: 21-27. In some embodiments, the inactivating amino acid is an E at a position corresponding to position 47 or position 227 of any one of SEQ ID NOs: 5-8, or position 47 or position 238 of any one of SEQ ID NOs: 21-27.
[0454] In some embodiments, the N-terminal subunit comprises an E at a position corresponding to position 47 of SEQ ID NOs: 5-8 and 21-27, and the C-terminal subunit comprises an E at a position corresponding to position 227 of SEQ ID NOs: 5-8 or position 238 of SEQ ID NOs: 21-27, wherein the engineered meganuclease does not comprise cleavage activity (i.e., activity is abolished).
[0455] In some embodiments, the N-terminal subunit comprises an A at a position corresponding to position 20 of SEQ ID NOs: 5-8 and 21-27, and / or the C-terminal subunit comprises an A at a position corresponding to position 200 of SEQ ID NOs: 5-8 or position 211 of SEQ ID NOs: 21-27, wherein the engineered meganuclease does not comprise cleavage activity (i.e., activity is abolished).
[0456] In some embodiments, the N-terminal subunit comprises an E at a position corresponding to position 47 of SEQ ID NOs: 5-8 and 21-27 and the C-terminal subunit does not comprise an inactivating amino acid, wherein the engineered meganuclease is a nickase that is only capable of cleaving the antisense strand of a dsDNA target site.
[0457] In some embodiments, the C-terminal subunit comprises an E at a position corresponding to position 227 of SEQ ID NOs: 5-8 or position 238 of SEQ ID NOs: 21-27 and the N-terminal subunit does not comprise an inactivating amino acid, wherein the engineered meganuclease is a nickase that is only capable of cleaving the sense strand of a dsDNA target site.
[0458] In those embodiments wherein the engineered meganuclease does not comprise cleavage activity (i.e., activity is abolished) due to one or more inactivating amino acid modifications, such engineered meganucleases are capable of binding to a double-stranded DNA comprising the recognition sequence of SEQ ID NO: 3 (i.e., HBV 27-28) without cleaving the double-stranded DNA. In those embodiments wherein the engineered meganuclease comprises an inactivating amino acid modification such that only one subunit has cleavage activity, and the engineered
[0459] 49 Atty Docket No. P893392090WO (01344)meganuclease is a nickase, such engineered meganucleases are capable of binding to a doublestranded DNA comprising the recognition sequence of SEQ ID NO: 3 (i.e., HBV 27-28) and cleaving either the sense or antisense strand of the DNA.
[0460] Engineered meganucleases of the present disclosure that bind and cleave the HBV 27-28 recognition sequence are provided, for example, in SEQ ID NOs: 5-8 and 21-27, which are summarized in Table 1 and Table 2 and are further described below.
[0461] Table 1. Exemplary engineered meganucleases that bind and cleave the HBV 27-28 recognition sequence (SEQ ID NO: 3) and comprise Linkerl923 (SEQ ID NO: 50) and (1 / 2) subunit modifications.
[0462] AA HBV27 HBV27 *HBV27 HBV28 HBV28 *HBV28 Meganuclease SEQ Subunit Subunit Subunit Subunit Subunit Subunit ID Residues SEQ ID % Residues SEQ ID % HBV 27-28L.753
[0463] 5 7-153 9 100 187-333 13 100 1923(1 / 2)
[0464] HBV 27-28L.794
[0465] 6 7-153 10 98.64 187-333 14 99.32 1923(1 / 2)
[0466] HBV 27-28L.455
[0467] 7 7-153 11 94.56 187-333 15 99.32 1923(1 / 2)
[0468] HBV 27-28L.561
[0469] 8 7-153 12 97.28 187-333 16 98.64
[0470]
[0471] 1923(1 / 2)
[0472] “HBV27 Subunit %” and “HB V28 Subunit %” represent the amino acid sequence identity between the HBV27-binding and HBv28-binding subunit regions of each meganuclease and the HBV27-binding and HBV28-binding subunit regions, respectively, of the HBV 27-28L.753 1923(1 / 2) meganuclease.
[0473] Table 2. Exemplary engineered meganucleases that bind and cleave the HBV 27-28 recognition sequence (SEQ ID NO: 3) and comprise Linkerl (SEQ ID NO: 49).
[0474] AA HBV27 HBV27 *HBV27 HBV28 HBV28 *HBV28 Meganuclease SEQ Subunit Subunit Subunit Subunit Subunit Subunit ID Residues SEQ ID % Residues SEQ ID % HBV 27-28L.753 21 7-153 28 100 198-344 35 100 HBV 27-28L.794 22 7-153 29 98.64 198-344 36 99.32 HBV 27-28x463 23 7-153 30 93.2 198-344 37 95.92 HBV 27-28L.190 24 7-153 31 94.56 198-344 38 95.92 HBV 27-28L.319 25 7-153 32 94.56 198-344 39 97.96 HBV 27-28L.455 26 7-153 33 94.56 198-344 40 99.32
[0475]
[0476] HBV 27-28L.561 27 7-153 34 97.28 198-344 41 98.64
[0477] 50 Atty Docket No. P893392090WO (01344)“HBV27 Subunit %” and “HB V28 Subunit %” represent the amino acid sequence identity between the HBV27-binding and HBv28-binding subunit regions of each meganuclease and the HBV27-binding and HBV28-binding subunit regions, respectively, of the HBV 27-28L.753 meganuclease.
[0478] HBV 27-28L.753 1923(1 / 2) (SEP ID NO: 5)
[0479] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 24-79 of SEQ ID NO: 5.
[0480] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 90% sequence identity to residues 24-79 of SEQ ID NO: 5. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 95% sequence identity to residues 24-79 of SEQ ID NO: 5. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 98% sequence identity to residues 24-79 of SEQ ID NO: 5.
[0481] In some embodiments, the HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 5.
[0482] In some embodiments, the HVR1 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 5.
[0483] In some embodiments, the HVR1 region comprises a residue corresponding to residue 50 of SEQ ID NO: 5.
[0484] In some embodiments, the HVR1 region comprises a residue corresponding to residue 71 of SEQ ID NO: 5.
[0485] In some embodiments, the HVR1 region comprises a residue corresponding to residue 72 of SEQ ID NO: 5.
[0486] In some embodiments, the HVR1 region comprises Y, R, K, or D at a residue corresponding to residue 66 of SEQ ID NO: 5.
[0487] In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 5.
[0488] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 7-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 7-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid
[0489] 51 Atty Docket No. P893392090WO (01344)sequence having at least 98% sequence identity to residues 7-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 7-153 of SEQ ID NO: 5.
[0490] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 6-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 6-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 6-153 of SEQ ID NO: 5.
[0491] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-153 of SEQ ID NO: 5. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 5-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 5-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 5-153 of SEQ ID NO: 5.
[0492] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-153 of SEQ ID NO: 5. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 4-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 4-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 4-153 of SEQ ID NO: 5.
[0493] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-153 of SEQ ID NO: 5. For example, the first
[0494] 52 Atty Docket No. P893392090WO (01344)subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 3-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 3-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 3-153 of SEQ ID NO: 5.
[0495] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-153 of SEQ ID NO: 5. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 2-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 2-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 2-153 of SEQ ID NO: 5.
[0496] In some embodiments, the residue at position 1 of SEQ ID NO: 5 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A.
[0497] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 1-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 1-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 1-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 1-153 of SEQ ID NO: 5.
[0498] In some embodiments, the first subunit comprises a residue corresponding to residue 19 of SEQ ID NO: 5.
[0499] In some embodiments, the first subunit comprises a residue corresponding to residue 96 of SEQ ID NO: 5.
[0500] In some embodiments, the first subunit comprises a residue corresponding to residue 99 of SEQ ID NO: 5.
[0501] In some embodiments, the first subunit comprises a residue corresponding to residue 100 of SEQ ID NO: 5.
[0502] 53 Atty Docket No. P893392090WO (01344)In some embodiments, the first subunit comprises a residue corresponding to residue 139 of SEQ ID NO: 5.
[0503] In some embodiments, the first subunit comprises G, S, or A at a residue corresponding to residue 19 of SEQ ID NO: 5.
[0504] In some embodiments, the first subunit comprises E, Q, or K at a residue corresponding to residue 80 of SEQ ID NO: 5.
[0505] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises residues 6-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises residues 5-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises residues 4-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises residues 3-153 of SEQ ID NO: 5. In some embodiments, the first subunit comprises residues 2-153 of SEQ ID NO: 5. In some embodiments, the residue at position 1 of SEQ ID NO: 5 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A. In some embodiments, the first subunit comprises residues 1-153 of SEQ ID NO: 5.
[0506] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 204-259 of SEQ ID NO: 5. In some embodiments, the HVR2 region comprises an amino acid sequence having at least 97% sequence identity to residues 204-259 of SEQ ID NO: 5. In some embodiments, the HVR2 region comprises an amino acid sequence having at least 98% sequence identity to residues 204-259 of SEQ ID NO: 5.
[0507] In some embodiments, the HVR2 region comprises one or more residues corresponding to residues 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of SEQ ID NO: 5.
[0508] In some embodiments, the HVR2 region comprises residues corresponding to residues 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of SEQ ID NO: 5.
[0509] In some embodiments, the HVR2 region comprises a residue corresponding to residue 237 of SEQ ID NO: 5.
[0510] In some embodiments, the HVR2 region comprises a residue corresponding to residue 241 of SEQ ID NO: 5.
[0511] In some embodiments, the HVR2 region comprises Y, R, K, or D at a residue corresponding to residue 246 of SEQ ID NO: 5.
[0512] In some embodiments, the HVR2 region comprises residues 204-259 of SEQ ID NO: 5.
[0513] 54 Atty Docket No. P893392090WO (01344)In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 187-333 of SEQ ID NO: 5.
[0514] In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 187-333 of SEQ ID NO: 5.
[0515] In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 185-343 of SEQ ID NO: 5.
[0516] In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 185-343 of SEQ ID NO: 5.
[0517] In some embodiments, the second subunit comprises a residue corresponding to residue 319 of SEQ ID NO: 5.
[0518] In some embodiments, the second subunit comprises G, S, or A at a residue corresponding to residue 199 of SEQ ID NO: 5.
[0519] In some embodiments, the second subunit comprises E, Q, or K at a residue corresponding to residue 260 of SEQ ID NO: 5.
[0520] In some embodiments, the second subunit comprises residues 187-333 of SEQ ID NO: 5. In some embodiments, the second subunit comprises residues 185-343 of SEQ ID NO: 5. In some embodiments, the engineered meganuclease is a single-chain meganuclease comprising a linker and wherein the linker covalently joins the first subunit and the second subunit.
[0521] In some embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 49 or SEQ ID NO: 50. In specific embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 50.
[0522] In some embodiments, the N-terminus of the linker is fused to the residue (i.e., a D residue) corresponding to residue 153 of SEQ ID NO: 5, and the C-terminus of the linker is fused to the residue (i.e., a Y residue) corresponding to residue 185 of SEQ ID NO: 5.
[0523] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 7-153 of SEQ ID NO: 5; a linker comprising an amino acid sequence set forth in SEQ ID NO: 50, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 187-333 of SEQ ID NO: 5.
[0524] 55 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 1-153 of SEQ ID NO: 5; a linker comprising an amino acid sequence set forth in SEQ ID NO: 50, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 185-343 of SEQ ID NO: 5.
[0525] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-343 of SEQ ID NO: 5.
[0526] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 92% sequence identity to residues 6-343 of SEQ ID NO: 5.
[0527] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-343 of SEQ ID NO: 5.
[0528] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 92% sequence identity to residues 5-343 of SEQ ID NO: 5.
[0529] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-343 of SEQ ID NO: 5.
[0530] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 92% sequence identity to residues 4-343 of SEQ ID NO: 5.
[0531] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-343 of SEQ ID NO: 5.
[0532] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 92% sequence identity to residues 3-343 of SEQ ID NO: 5.
[0533] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-343 of SEQ ID NO: 5.
[0534] 56 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 2-343 of SEQ ID NO: 5. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 2-343 of SEQ ID NO: 5.
[0535] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 5. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 5. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 5.
[0536] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 6-343 of SEQ ID NO: 5.
[0537] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 5-343 of SEQ ID NO: 5.
[0538] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 4-343 of SEQ ID NO: 5.
[0539] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 3-343 of SEQ ID NO: 5.
[0540] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 2-343 of SEQ ID NO: 5.
[0541] In some embodiments, the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 5.
[0542] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to a nucleic acid sequence of SEQ ID NO: 17.
[0543] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence of SEQ ID NO: 17.
[0544] In some embodiments, the engineered meganuclease comprises a nuclear localization signal.
[0545] In some embodiments, the nuclear localization signal is at the N-terminus of the engineered meganuclease.
[0546] 57 Atty Docket No. P893392090WO (01344)In some embodiments, the nuclear localization signal is at the C-terminus of the engineered meganuclease.
[0547] In some embodiments, the engineered meganuclease comprises a first nuclear localization signal at the N-terminus and a second nuclear localization signal at the C-terminus.
[0548] In some embodiments, the nuclear localization signal comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 51 or SEQ ID NO: 52. In some embodiments, the nuclear localization signal comprises SEQ ID NO: 51 or SEQ ID NO: 52.
[0549] HBV 27-28L.7941923(1 / 2) (SEQ ID NO: 6)
[0550] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 24-79 of SEQ ID NO: 6.
[0551] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 90% sequence identity to residues 24-79 of SEQ ID NO: 6. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 95% sequence identity to residues 24-79 of SEQ ID NO: 6. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 98% sequence identity to residues 24-79 of SEQ ID NO: 6.
[0552] In some embodiments, the HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 6.
[0553] In some embodiments, the HVR1 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 6.
[0554] In some embodiments, the HVR1 region comprises a residue corresponding to residue 50 of SEQ ID NO: 6.
[0555] In some embodiments, the HVR1 region comprises a residue corresponding to residue 71 of SEQ ID NO: 6.
[0556] In some embodiments, the HVR1 region comprises Y, R, K, or D at a residue corresponding to residue 66 of SEQ ID NO: 6.
[0557] In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 6.
[0558] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at
[0559] 58 Atty Docket No. P893392090WO (01344)least 99%, or more sequence identity to residues 7-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 7-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 7-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 7-153 of SEQ ID NO: 6.
[0560] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 6-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 6-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 6-153 of SEQ ID NO: 6.
[0561] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-153 of SEQ ID NO: 6. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 5-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 5-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 5-153 of SEQ ID NO: 6.
[0562] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-153 of SEQ ID NO: 6. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 4-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 4-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 4-153 of SEQ ID NO: 6.
[0563] 59 Atty Docket No. P893392090WO (01344)In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-153 of SEQ ID NO: 6. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 3-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 3-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 3-153 of SEQ ID NO: 6.
[0564] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-153 of SEQ ID NO: 6. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 2-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 2-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 2-153 of SEQ ID NO: 6.
[0565] In some embodiments, the residue at position 1 of SEQ ID NO: 6 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A.
[0566] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 1-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 1-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 1-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 1-153 of SEQ ID NO: 6.
[0567] In some embodiments, the first subunit comprises a residue corresponding to residue 19 of SEQ ID NO: 6.
[0568] In some embodiments, the first subunit comprises a residue corresponding to residue 96 of SEQ ID NO: 6.
[0569] 60 Atty Docket No. P893392090WO (01344)In some embodiments, the first subunit comprises a residue corresponding to residue 99 of SEQ ID NO: 6.
[0570] In some embodiments, the first subunit comprises a residue corresponding to residue 100 of SEQ ID NO: 6.
[0571] In some embodiments, the first subunit comprises a residue corresponding to residue 139 of SEQ ID NO: 6.
[0572] In some embodiments, the first subunit comprises G, S, or A at a residue corresponding to residue 19 of SEQ ID NO: 6.
[0573] In some embodiments, the first subunit comprises E, Q, or K at a residue corresponding to residue 80 of SEQ ID NO: 6.
[0574] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises residues 6-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises residues 5-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises residues 4-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises residues 3-153 of SEQ ID NO: 6. In some embodiments, the first subunit comprises residues 2-153 of SEQ ID NO: 6. In some embodiments, the residue at position 1 of SEQ ID NO: 6 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A. In some embodiments, the first subunit comprises residues 1-153 of SEQ ID NO: 6.
[0575] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 204-259 of SEQ ID NO: 6. In some embodiments, the HVR2 region comprises an amino acid sequence having at least 97% sequence identity to residues 204-259 of SEQ ID NO: 6. In some embodiments, the HVR2 region comprises an amino acid sequence having at least 98% sequence identity to residues 204-259 of SEQ ID NO: 6.
[0576] In some embodiments, the HVR2 region comprises one or more residues corresponding to residues 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of SEQ ID NO: 6.
[0577] In some embodiments, the HVR2 region comprises residues corresponding to residues 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of SEQ ID NO: 6.
[0578] In some embodiments, the HVR2 region comprises a residue corresponding to residue 237 of SEQ ID NO: 6.
[0579] 61 Atty Docket No. P893392090WO (01344)In some embodiments, the HVR2 region comprises a residue corresponding to residue 241 of SEQ ID NO: 6.
[0580] In some embodiments, the HVR2 region comprises Y, R, K, or D at a residue corresponding to residue 246 of SEQ ID NO: 6.
[0581] In some embodiments, the HVR2 region comprises residues 204-259 of SEQ ID NO: 6. In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 187-333 of SEQ ID NO: 6.
[0582] In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 187-333 of SEQ ID NO: 6.
[0583] n some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 185-343 of SEQ ID NO: 6.
[0584] In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 185-343 of SEQ ID NO: 6.
[0585] In some embodiments, the second subunit comprises a residue corresponding to residue 319 of SEQ ID NO: 6.
[0586] In some embodiments, the second subunit comprises G, S, or A at a residue corresponding to residue 199 of SEQ ID NO: 6.
[0587] In some embodiments, the second subunit comprises E, Q, or K at a residue corresponding to residue 260 of SEQ ID NO: 6.
[0588] In some embodiments, the second subunit comprises residues 187-333 of SEQ ID NO: 6. In some embodiments, the second subunit comprises residues 185-343 of SEQ ID NO: 6. In some embodiments, the engineered meganuclease is a single-chain meganuclease comprising a linker and wherein the linker covalently joins the first subunit and the second subunit.
[0589] In some embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 49 or SEQ ID NO: 50. In specific embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 50.
[0590] In some embodiments, the N-terminus of the linker is fused to the residue (i.e., a D residue) corresponding to residue 153 of SEQ ID NO: 6, and the C-terminus of the linker is fused to the residue (i.e., a Y residue) corresponding to residue 185 of SEQ ID NO: 6.
[0591] 62 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 7-153 of SEQ ID NO: 5; a linker comprising an amino acid sequence set forth in SEQ ID NO: 50, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 187-333 of SEQ ID NO: 6.
[0592] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 1-153 of SEQ ID NO: 5; a linker comprising an amino acid sequence set forth in SEQ ID NO: 50, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 185-343 of SEQ ID NO: 6.
[0593] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-343 of SEQ ID NO: 6.
[0594] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 92% sequence identity to residues 6-343 of SEQ ID NO: 6.
[0595] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-343 of SEQ ID NO: 6.
[0596] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 92% sequence identity to residues 5-343 of SEQ ID NO: 6.
[0597] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-343 of SEQ ID NO: 6.
[0598] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 92% sequence identity to residues 4-343 of SEQ ID NO: 6.
[0599] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-343 of SEQ ID NO: 6.
[0600] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 92% sequence identity to residues 3-343 of SEQ ID NO: 6.
[0601] 63 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-343 of SEQ ID NO: 6.
[0602] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 2-343 of SEQ ID NO: 6. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 2-343 of SEQ ID NO: 6.
[0603] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 6. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 6. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 6.
[0604] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 6-343 of SEQ ID NO: 6.
[0605] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 5-343 of SEQ ID NO: 6.
[0606] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 4-343 of SEQ ID NO: 6.
[0607] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 3-343 of SEQ ID NO: 6.
[0608] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 2-343 of SEQ ID NO: 6.
[0609] In some embodiments, the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 6.
[0610] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to a nucleic acid sequence of SEQ ID NO: 18.
[0611] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence of SEQ ID NO: 18.
[0612] 64 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease comprises a nuclear localization signal.
[0613] In some embodiments, the nuclear localization signal is at the N-terminus of the engineered meganuclease.
[0614] In some embodiments, the nuclear localization signal is at the C-terminus of the engineered meganuclease.
[0615] In some embodiments, the engineered meganuclease comprises a first nuclear localization signal at the N-terminus and a second nuclear localization signal at the C-terminus.
[0616] In some embodiments, the nuclear localization signal comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 51 or SEQ ID NO: 52. In some embodiments, the nuclear localization signal comprises SEQ ID NO: 51 or SEQ ID NO: 52.
[0617] HBV 27-28L.4551923(1 / 2) (SEQ ID NO: 7)
[0618] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 24-79 of SEQ ID NO: 7.
[0619] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 95% sequence identity to residues 24-79 of SEQ ID NO: 7. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 98% sequence identity to residues 24-79 of SEQ ID NO: 7.
[0620] In some embodiments, the HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 7.
[0621] In some embodiments, the HVR1 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 7.
[0622] In some embodiments, the HVR1 region comprises a residue corresponding to residue 50 of SEQ ID NO: 7.
[0623] In some embodiments, the HVR1 region comprises a residue corresponding to residue 72 of SEQ ID NO: 7.
[0624] In some embodiments, the HVR1 region comprises Y, R, K, or D at a residue corresponding to residue 66 of SEQ ID NO: 7.
[0625] In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 7.
[0626] 65 Atty Docket No. P893392090WO (01344)In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 7-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 7-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 7-153 of SEQ ID NO: 7.
[0627] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 6-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 6-153 of SEQ ID NO: 7.
[0628] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-153 of SEQ ID NO: 7. For example, the first subunit can comprise an amino acid sequence having at least 98% sequence identity to residues 5-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 5-153 of SEQ ID NO: 7.
[0629] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-153 of SEQ ID NO: 7. For example, the first subunit can comprise an amino acid sequence having at least 98% sequence identity to residues 4-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 4-153 of SEQ ID NO: 7.
[0630] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-153 of SEQ ID NO: 7. For example, the first subunit can comprise an amino acid sequence having at least 98% sequence identity to residues 3-
[0631] 66 Atty Docket No. P893392090WO (01344)153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 3-153 of SEQ ID NO: 7.
[0632] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-153 of SEQ ID NO: 7. For example, the first subunit can comprise an amino acid sequence having at least 98% sequence identity to residues 2-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 2-153 of SEQ ID NO: 7.
[0633] In some embodiments, the residue at position 1 of SEQ ID NO: 7 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A.
[0634] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 1-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 1-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 1-153 of SEQ ID NO: 7.
[0635] In some embodiments, the first subunit comprises a residue corresponding to residue 19 of SEQ ID NO: 7.
[0636] In some embodiments, the first subunit comprises a residue corresponding to residue 96 of SEQ ID NO: 7.
[0637] In some embodiments, the first subunit comprises a residue corresponding to residue 99 of SEQ ID NO: 7.
[0638] In some embodiments, the first subunit comprises a residue corresponding to residue 100 of SEQ ID NO: 7.
[0639] In some embodiments, the first subunit comprises a residue corresponding to residue 139 of SEQ ID NO: 7.
[0640] In some embodiments, the first subunit comprises G, S, or A at a residue corresponding to residue 19 of SEQ ID NO: 7.
[0641] In some embodiments, the first subunit comprises E, Q, or K at a residue corresponding to residue 80 of SEQ ID NO: 7.
[0642] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises residues 6-153 of SEQ ID NO: 7. In some embodiments,
[0643] 67 Atty Docket No. P893392090WO (01344)the first subunit comprises residues 5-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises residues 4-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises residues 3-153 of SEQ ID NO: 7. In some embodiments, the first subunit comprises residues 2-153 of SEQ ID NO: 7. In some embodiments, the residue at position 1 of SEQ ID NO: 7 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A. In some embodiments, the first subunit comprises residues 1-153 of SEQ ID NO: 7.
[0644] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 204-259 of SEQ ID NO: 7.
[0645] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 98% sequence identity to residues 204-259 of SEQ ID NO: 7.
[0646] In some embodiments, the HVR2 region comprises one or more residues corresponding to residues 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of SEQ ID NO: 7.
[0647] In some embodiments, the HVR2 region comprises residues corresponding to residues 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of SEQ ID NO: 7.
[0648] In some embodiments, the HVR2 region comprises a residue corresponding to residue 237 of SEQ ID NO: 7.
[0649] In some embodiments, the HVR2 region comprises a residue corresponding to residue 241 of SEQ ID NO: 7.
[0650] In some embodiments, the HVR2 region comprises Y, R, K, or D at a residue corresponding to residue 246 of SEQ ID NO: 7.
[0651] In some embodiments, the HVR2 region comprises residues 204-259 of SEQ ID NO: 7. In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 187-333 of SEQ ID NO: 7.
[0652] In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 187-333 of SEQ ID NO: 7.
[0653] In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%,
[0654] 68 Atty Docket No. P893392090WO (01344)at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 185-343 of SEQ ID NO: 7.
[0655] In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 185-343 of SEQ ID NO: 7.
[0656] In some embodiments, the second subunit comprises a residue corresponding to residue 319 of SEQ ID NO: 7.
[0657] In some embodiments, the second subunit comprises G, S, or A at a residue corresponding to residue 199 of SEQ ID NO: 7.
[0658] In some embodiments, the second subunit comprises E, Q, or K at a residue corresponding to residue 260 of SEQ ID NO: 7.
[0659] In some embodiments, the second subunit comprises residues 187-333 of SEQ ID NO: 7. In some embodiments, the second subunit comprises residues 185-343 of SEQ ID NO: 7. In some embodiments, the engineered meganuclease is a single-chain meganuclease comprising a linker and wherein the linker covalently joins the first subunit and the second subunit.
[0660] In some embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 49 or SEQ ID NO: 50. In specific embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 50.
[0661] In some embodiments, the N-terminus of the linker is fused to the residue (i.e., a D residue) corresponding to residue 153 of SEQ ID NO: 7, and the C-terminus of the linker is fused to the residue (i.e., a Y residue) corresponding to residue 185 of SEQ ID NO: 7.
[0662] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 7-153 of SEQ ID NO: 7; a linker comprising an amino acid sequence set forth in SEQ ID NO: 50, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 187-333 of SEQ ID NO: 7.
[0663] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 1-153 of SEQ ID NO: 5; a linker comprising an amino acid sequence set forth in SEQ ID NO: 50, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 185-343 of SEQ ID NO: 7.
[0664] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-343 of SEQ ID NO: 7.
[0665] 69 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 6-343 of SEQ ID NO: 7. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 6-343 of SEQ ID NO: 7.
[0666] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-343 of SEQ ID NO: 7.
[0667] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 5-343 of SEQ ID NO: 7. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 5-343 of SEQ ID NO: 7.
[0668] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-343 of SEQ ID NO: 7.
[0669] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 4-343 of SEQ ID NO: 7. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 4-343 of SEQ ID NO: 7.
[0670] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-343 of SEQ ID NO: 7.
[0671] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 3-343 of SEQ ID NO: 7. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 3-343 of SEQ ID NO: 7.
[0672] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-343 of SEQ ID NO: 7.
[0673] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 2-343 of SEQ ID NO: 7. In some embodiments,
[0674] 70 Atty Docket No. P893392090WO (01344)the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 2-343 of SEQ ID NO: 7.
[0675] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 7. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 7. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 7.
[0676] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 6-343 of SEQ ID NO: 7. In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 5-343 of SEQ ID NO: 7. In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 4-343 of SEQ ID NO: 7. In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 3-343 of SEQ ID NO: 7. In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 2-343 of SEQ ID NO: 7. In some embodiments, the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 7.
[0677] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to a nucleic acid sequence of SEQ ID NO: 19.
[0678] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence of SEQ ID NO: 19.
[0679] In some embodiments, the engineered meganuclease comprises a nuclear localization signal.
[0680] In some embodiments, the nuclear localization signal is at the N-terminus of the engineered meganuclease.
[0681] In some embodiments, the nuclear localization signal is at the C-terminus of the engineered meganuclease.
[0682] In some embodiments, the engineered meganuclease comprises a first nuclear localization signal at the N-terminus and a second nuclear localization signal at the C-terminus.
[0683] In some embodiments, the nuclear localization signal comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%,
[0684] 71 Atty Docket No. P893392090WO (01344)at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 51 or SEQ ID NO: 52. In some embodiments, the nuclear localization signal comprises SEQ ID NO: 51 or SEQ ID NO: 52.
[0685] HBV 27-28L.561 1923(1 / 2) (SEQ ID NO: 8)
[0686] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 24-79 of SEQ ID NO: 8.
[0687] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 90% sequence identity to residues 24-79 of SEQ ID NO: 8. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 95% sequence identity to residues 24-79 of SEQ ID NO: 8. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 98% sequence identity to residues 24-79 of SEQ ID NO: 8.
[0688] In some embodiments, the HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 8.
[0689] In some embodiments, the HVR1 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 8.
[0690] In some embodiments, the HVR1 region comprises a residue corresponding to residue 50 of SEQ ID NO: 8.
[0691] In some embodiments, the HVR1 region comprises a residue corresponding to residue 72 of SEQ ID NO: 8.
[0692] In some embodiments, the HVR1 region comprises Y, R, K, or D at a residue corresponding to residue 66 of SEQ ID NO: 8.
[0693] In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 8.
[0694] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 7-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 7-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 7-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 7-153 of SEQ ID NO: 8.
[0695] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%,
[0696] 72 Atty Docket No. P893392090WO (01344)at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 6-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 6-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 6-153 of SEQ ID NO: 8.
[0697] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-153 of SEQ ID NO: 8. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 5-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 5-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 5-153 of SEQ ID NO: 8.
[0698] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-153 of SEQ ID NO: 8. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 4-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 4-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 4-153 of SEQ ID NO: 8.
[0699] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-153 of SEQ ID NO: 8. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 3-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 3-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 3-153 of SEQ ID NO: 8.
[0700] 73 Atty Docket No. P893392090WO (01344)In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-153 of SEQ ID NO: 8. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 2-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 2-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 2-153 of SEQ ID NO: 8.
[0701] In some embodiments, the residue at position 1 of SEQ ID NO: 8 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A.
[0702] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 1-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 1-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 1-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 1-153 of SEQ ID NO: 8.
[0703] In some embodiments, the first subunit comprises a residue corresponding to residue 19 of SEQ ID NO: 8.
[0704] In some embodiments, the first subunit comprises a residue corresponding to residue 96 of SEQ ID NO: 8.
[0705] In some embodiments, the first subunit comprises a residue corresponding to residue 99 of SEQ ID NO: 8.
[0706] In some embodiments, the first subunit comprises a residue corresponding to residue 100 of SEQ ID NO: 8.
[0707] In some embodiments, the first subunit comprises a residue corresponding to residue 139 of SEQ ID NO: 8.
[0708] In some embodiments, the first subunit comprises G, S, or A at a residue corresponding to residue 19 of SEQ ID NO: 8.
[0709] In some embodiments, the first subunit comprises E, Q, or K at a residue corresponding to residue 80 of SEQ ID NO: 8.
[0710] 74 Atty Docket No. P893392090WO (01344)In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises residues 6-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises residues 5-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises residues 4-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises residues 3-153 of SEQ ID NO: 8. In some embodiments, the first subunit comprises residues 2-153 of SEQ ID NO: 8. In some embodiments, the residue at position 1 of SEQ ID NO: 8 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A. In some embodiments, the first subunit comprises residues 1-153 of SEQ ID NO: 8.
[0711] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 204-259 of SEQ ID NO: 8.
[0712] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 98% sequence identity to residues 204-259 of SEQ ID NO: 8.
[0713] In some embodiments, the HVR2 region comprises one or more residues corresponding to residues 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of SEQ ID NO: 8.
[0714] In some embodiments, the HVR2 region comprises residues corresponding to residues 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of SEQ ID NO: 8.
[0715] In some embodiments, the HVR2 region comprises a residue corresponding to residue 237 of SEQ ID NO: 8.
[0716] In some embodiments, the HVR2 region comprises a residue corresponding to residue 241 of SEQ ID NO: 8.
[0717] In some embodiments, the HVR2 region comprises Y, R, K, or D at a residue corresponding to residue 246 of SEQ ID NO: 8.
[0718] In some embodiments, the HVR2 region comprises residues 204-259 of SEQ ID NO: 8. In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 187-333 of SEQ ID NO: 8.
[0719] In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 187-333 of SEQ ID NO: 8.
[0720] 75 Atty Docket No. P893392090WO (01344)n some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 185-343 of SEQ ID NO: 8.
[0721] In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 185-343 of SEQ ID NO: 8.
[0722] In some embodiments, the second subunit comprises G, S, or A at a residue corresponding to residue 199 of SEQ ID NO: 8.
[0723] In some embodiments, the second subunit comprises E, Q, or K at a residue corresponding to residue 260 of SEQ ID NO: 8.
[0724] In some embodiments, the second subunit comprises residues 187-333 of SEQ ID NO: 8. In some embodiments, the second subunit comprises residues 185-343 of SEQ ID NO: 8. In some embodiments, the engineered meganuclease is a single-chain meganuclease comprising a linker and wherein the linker covalently joins the first subunit and the second subunit.
[0725] In some embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 49 or SEQ ID NO: 50. In specific embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 50.
[0726] In some embodiments, the N-terminus of the linker is fused to the residue (i.e., a D residue) corresponding to residue 153 of SEQ ID NO: 8, and the C-terminus of the linker is fused to the residue (i.e., a Y residue) corresponding to residue 185 of SEQ ID NO: 8.
[0727] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 7-153 of SEQ ID NO: 8; a linker comprising an amino acid sequence set forth in SEQ ID NO: 50, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 187-333 of SEQ ID NO: 8.
[0728] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 1-153 of SEQ ID NO: 8; a linker comprising an amino acid sequence set forth in SEQ ID NO: 50, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 185-343 of SEQ ID NO: 8.
[0729] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-343 of SEQ ID NO: 8.
[0730] 76 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 92% sequence identity to residues 6-343 of SEQ ID NO: 8.
[0731] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-343 of SEQ ID NO: 8.
[0732] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 92% sequence identity to residues 5-343 of SEQ ID NO: 8.
[0733] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-343 of SEQ ID NO: 8.
[0734] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 4-343 of SEQ ID NO: 8. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 4-343 of SEQ ID NO: 8.
[0735] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-343 of SEQ ID NO: 8.
[0736] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 3-343 of SEQ ID NO: 8. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 3-343 of SEQ ID NO: 8.
[0737] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-343 of SEQ ID NO: 8.
[0738] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 2-343 of SEQ ID NO: 8. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 2-343 of SEQ ID NO: 8.
[0739] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least
[0740] 77 Atty Docket No. P893392090WO (01344)90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 8. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 8. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 8.
[0741] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 6-343 of SEQ ID NO: 8.
[0742] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 5-343 of SEQ ID NO: 8.
[0743] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 4-343 of SEQ ID NO: 8.
[0744] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 3-343 of SEQ ID NO: 8.
[0745] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 2-343 of SEQ ID NO: 8.
[0746] In some embodiments, the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 8.
[0747] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to a nucleic acid sequence of SEQ ID NO: 20.
[0748] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence of SEQ ID NO: 20.
[0749] In some embodiments, the engineered meganuclease comprises a nuclear localization signal.
[0750] In some embodiments, the nuclear localization signal is at the N-terminus of the engineered meganuclease.
[0751] In some embodiments, the nuclear localization signal is at the C-terminus of the engineered meganuclease.
[0752] In some embodiments, the engineered meganuclease comprises a first nuclear localization signal at the N-terminus and a second nuclear localization signal at the C-terminus.
[0753] In some embodiments, the nuclear localization signal comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%,
[0754] 78 Atty Docket No. P893392090WO (01344)at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 51 or SEQ ID NO: 52. In some embodiments, the nuclear localization signal comprises SEQ ID NO: 51 or SEQ ID NO: 52.
[0755] HBV27-28L.753 (SEQ ID NO: 21)
[0756] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 24-79 of SEQ ID NO: 21.
[0757] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 90% sequence identity to residues 24-79 of SEQ ID NO: 21. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 95% sequence identity to residues 24-79 of SEQ ID NO: 21. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 98% sequence identity to residues 24-79 of SEQ ID NO: 21.
[0758] In some embodiments, the HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 21.
[0759] In some embodiments, the HVR1 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 21.
[0760] In some embodiments, the HVR1 region comprises a residue corresponding to residue 50 of SEQ ID NO: 21.
[0761] In some embodiments, the HVR1 region comprises a residue corresponding to residue 71 of SEQ ID NO: 21.
[0762] In some embodiments, the HVR1 region comprises a residue corresponding to residue 72 of SEQ ID NO: 21.
[0763] In some embodiments, the HVR1 region comprises Y, R, K, or D at a residue corresponding to residue 66 of SEQ ID NO: 21.
[0764] In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 7-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 7-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 7-153 of SEQ ID NO: 21. In some
[0765] 79 Atty Docket No. P893392090WO (01344)embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 7-153 of SEQ ID NO: 21.
[0766] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 6-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 6-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 6-153 of SEQ ID NO: 21.
[0767] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-153 of SEQ ID NO: 21. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 5-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 5-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 5-153 of SEQ ID NO: 21.
[0768] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-153 of SEQ ID NO: 21. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 4-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 4-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 4-153 of SEQ ID NO: 21.
[0769] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-153 of SEQ ID NO: 21. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 3-
[0770] 80 Atty Docket No. P893392090WO (01344)153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 3-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 3-153 of SEQ ID NO: 21.
[0771] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-153 of SEQ ID NO: 21. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 2-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 2-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 2-153 of SEQ ID NO: 21.
[0772] In some embodiments, the residue at position 1 of SEQ ID NO: 21 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A.
[0773] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 1-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 1-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 1-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 1-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises a residue corresponding to residue 19 of SEQ ID NO: 21.
[0774] In some embodiments, the first subunit comprises a residue corresponding to residue 139 of SEQ ID NO: 21.
[0775] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises residues 6-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises residues 5-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises residues 4-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises residues 3-153 of SEQ ID NO: 21. In some embodiments, the first subunit comprises residues 2-153 of SEQ ID NO: 21. In some embodiments, the residue at position 1 of SEQ ID NO: 21 is modified from M to another amino acid. In some embodiments, the residue at
[0776] 81 Atty Docket No. P893392090WO (01344)position 1 is modified from M to A. In some embodiments, the first subunit comprises residues 1-153 of SEQ IDNO: 21.
[0777] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 215-270 of SEQ ID NO: 21.
[0778] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 97% sequence identity to residues 215-270 of SEQ ID NO: 21. In some embodiments, the HVR2 region comprises an amino acid sequence having at least 98% sequence identity to residues 215-270 of SEQ IDNO: 21.
[0779] In some embodiments, the HVR2 region comprises one or more residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 21.
[0780] In some embodiments, the HVR2 region comprises residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 21.
[0781] In some embodiments, the HVR2 region comprises Y, R, K, or D at a residue corresponding to residue 257 of SEQ ID NO: 21.
[0782] In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 21. In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 198-344 of SEQ ID NO: 21.
[0783] In some embodiments, the second subunit that comprises an amino acid sequence having at least 99% sequence identity to residues 198-344 of SEQ ID NO: 21.
[0784] In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 196-354 of SEQ ID NO: 21.
[0785] In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 196-354 of SEQ ID NO: 21.
[0786] In some embodiments, the second subunit comprises a residue corresponding to residue 330 of SEQ ID NO: 21.
[0787] In some embodiments, the second subunit comprises G, S, or A at a residue corresponding to residue 210 of SEQ ID NO: 21.
[0788] 82 Atty Docket No. P893392090WO (01344)In some embodiments, the second subunit comprises E, Q, or K at a residue corresponding to residue 271 of SEQ ID NO: 21.
[0789] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 21. In some embodiments, the second subunit comprises residues 196-354 of SEQ ID NO: 21. In some embodiments, the engineered meganuclease is a single-chain meganuclease comprising a linker, such as polypeptide linker and wherein the linker covalently joins the first subunit and the second subunit.
[0790] In some embodiments, the linker is a polypeptide linker and comprises an amino acid sequence set forth in SEQ ID NO: 49 or SEQ ID NO: 50. In specific embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 49.
[0791] In some embodiments, the N-terminus of the linker is fused to the residue (i.e., a D residue) corresponding to residue 153 of SEQ ID NO: 21, and the C-terminus of the linker is fused to the residue (i.e., a Y residue) corresponding to residue 196 of SEQ ID NO: 21.
[0792] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 7-153 of SEQ ID NO: 21; a linker comprising an amino acid sequence set forth in SEQ ID NO: 49, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 198-344 of SEQ ID NO: 21.
[0793] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 1-153 of SEQ ID NO: 21; a linker comprising an amino acid sequence set forth in SEQ ID NO: 49, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 196-354 of SEQ ID NO: 21.
[0794] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-354 of SEQ ID NO: 21.
[0795] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 6-354 of SEQ ID NO: 21. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 6-354 of SEQ ID NO: 21.
[0796] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least
[0797] 83 Atty Docket No. P893392090WO (01344)90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-354 of SEQ ID NO: 21.
[0798] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 5-354 of SEQ ID NO: 21. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 5-354 of SEQ ID NO: 21.
[0799] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-354 of SEQ ID NO: 21.
[0800] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 4-354 of SEQ ID NO: 21. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 4-354 of SEQ ID NO: 21.
[0801] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-354 of SEQ ID NO: 21.
[0802] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 3-354 of SEQ ID NO: 21. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 3-354 of SEQ ID NO: 21.
[0803] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-354 of SEQ ID NO: 21.
[0804] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 2-354 of SEQ ID NO: 21. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 2-354 of SEQ ID NO: 21.
[0805] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 21. In some embodiments,
[0806] 84 Atty Docket No. P893392090WO (01344)the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 21. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 21.
[0807] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 6-354 of SEQ ID NO: 21.
[0808] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 5-354 of SEQ ID NO: 21.
[0809] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 4-354 of SEQ ID NO: 21.
[0810] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 3-354 of SEQ ID NO: 21.
[0811] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 2-354 of SEQ ID NO: 21.
[0812] In some embodiments, the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 21.
[0813] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to a nucleic acid sequence of SEQ ID NO: 42.
[0814] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence of SEQ ID NO: 42.
[0815] In some embodiments, the engineered meganuclease comprises a nuclear localization signal.
[0816] In some embodiments, the nuclear localization signal is at the N-terminus of the engineered meganuclease.
[0817] In some embodiments, the nuclear localization signal is at the C-terminus of the engineered meganuclease.
[0818] In some embodiments, the engineered meganuclease comprises a first nuclear localization signal at the N-terminus and a second nuclear localization signal at the C-terminus.
[0819] In some embodiments, the nuclear localization signal comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 51 or SEQ ID NO: 52. In some embodiments, the nuclear localization signal comprises SEQ ID NO: 51 or SEQ ID NO: 52.
[0820] 85 Atty Docket No. P893392090WO (01344)HBV 27-28L.794 (SEO ID NO: 22)
[0821] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 24-79 of SEQ ID NO: 22.
[0822] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 90% sequence identity to residues 24-79 of SEQ ID NO: 22. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 95% sequence identity to residues 24-79 of SEQ ID NO: 22. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 98% sequence identity to residues 24-79 of SEQ ID NO: 22.
[0823] In some embodiments, the HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 22.
[0824] In some embodiments, the HVR1 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 22.
[0825] In some embodiments, the HVR1 region comprises a residue corresponding to residue 50 of SEQ ID NO: 22.
[0826] In some embodiments, the HVR1 region comprises a residue corresponding to residue 71 of SEQ ID NO: 22.
[0827] In some embodiments, the HVR1 region comprises Y, R, K, or D at a residue corresponding to residue 66 of SEQ ID NO: 22.
[0828] In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 7-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 7-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 7-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 7-153 of SEQ ID NO: 22.
[0829] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at
[0830] 86 Atty Docket No. P893392090WO (01344)least 99%, or more sequence identity to residues 6-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 6-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 6-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 6-153 of SEQ ID NO: 22.
[0831] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-153 of SEQ ID NO: 22. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 5-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 5-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 5-153 of SEQ ID NO: 22.
[0832] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-153 of SEQ ID NO: 22. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 4-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 4-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 4-153 of SEQ ID NO: 22.
[0833] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-153 of SEQ ID NO: 22. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 3-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 3-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 3-153 of SEQ ID NO: 22.
[0834] 87 Atty Docket No. P893392090WO (01344)In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-153 of SEQ ID NO: 22. For example, the first subunit can comprise an amino acid sequence having at least 95% sequence identity to residues 2-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 2-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 2-153 of SEQ ID NO: 22.
[0835] In some embodiments, the residue at position 1 of SEQ ID NO: 22 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A.
[0836] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 1-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 95% sequence identity to residues 1-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 1-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 1-153 of SEQ ID NO: 22.
[0837] In some embodiments, the first subunit comprises a residue corresponding to residue 19 of SEQ ID NO: 22.
[0838] In some embodiments, the first subunit comprises a residue corresponding to residue 139 of SEQ ID NO: 22.
[0839] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises residues 6-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises residues 5-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises residues 4-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises residues 3-153 of SEQ ID NO: 22. In some embodiments, the first subunit comprises residues 2-153 of SEQ ID NO: 22. In some embodiments, the residue at position 1 of SEQ ID NO: 22 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A. In some embodiments, the first subunit comprises residues 1-153 of SEQ ID NO: 22.
[0840] 88 Atty Docket No. P893392090WO (01344)In some embodiments, the HVR2 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 215-270 of SEQ ID NO: 22.
[0841] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 97% sequence identity to residues 215-270 of SEQ ID NO: 22. In some embodiments, the HVR2 region comprises an amino acid sequence having at least 98% sequence identity to residues 215-270 of SEQ ID NO: 22.
[0842] In some embodiments, the HVR2 region comprises one or more residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 22.
[0843] In some embodiments, the HVR2 region comprises residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 22.
[0844] In some embodiments, the HVR2 region comprises Y, R, K, or D at a residue corresponding to residue 257 of SEQ ID NO: 22.
[0845] In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 22. In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 198-344 of SEQ ID NO: 22.
[0846] In some embodiments, the second subunit that comprises an amino acid sequence having at least 99% sequence identity to residues 198-344 of SEQ ID NO: 22.
[0847] In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 196-354 of SEQ ID NO: 22.
[0848] In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 196-354 of SEQ ID NO: 22.
[0849] In some embodiments, the second subunit comprises a residue corresponding to residue 330 of SEQ ID NO: 22.
[0850] In some embodiments, the second subunit comprises G, S, or A at a residue corresponding to residue 210 of SEQ ID NO: 22.
[0851] In some embodiments, the second subunit comprises E, Q, or K at a residue corresponding to residue 271 of SEQ ID NO: 22.
[0852] 89 Atty Docket No. P893392090WO (01344)In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 22. In some embodiments, the second subunit comprises residues 196-354 of SEQ ID NO: 22. In some embodiments, the engineered meganuclease is a single-chain meganuclease comprising a linker, such as polypeptide linker and wherein the linker covalently joins the first subunit and the second subunit.
[0853] In some embodiments, the linker is a polypeptide linker and comprises an amino acid sequence set forth in SEQ ID NO: 49 or SEQ ID NO: 50. In specific embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 49.
[0854] In some embodiments, the N-terminus of the linker is fused to the residue (i.e., a D residue) corresponding to residue 153 of SEQ ID NO: 22, and the C-terminus of the linker is fused to the residue (i.e., a Y residue) corresponding to residue 196 of SEQ ID NO: 22.
[0855] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 7-153 of SEQ ID NO: 22; a linker comprising an amino acid sequence set forth in SEQ ID NO: 49, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 198-344 of SEQ ID NO: 22.
[0856] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 1-153 of SEQ ID NO: 22; a linker comprising an amino acid sequence set forth in SEQ ID NO: 49, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 196-354 of SEQ ID NO: 22.
[0857] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-354 of SEQ ID NO: 22.
[0858] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 6-354 of SEQ ID NO: 22. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 6-354 of SEQ ID NO: 22.
[0859] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-354 of SEQ ID NO: 22.
[0860] 90 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 5-354 of SEQ ID NO: 22. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 5-354 of SEQ ID NO: 22.
[0861] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-354 of SEQ ID NO: 22.
[0862] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 4-354 of SEQ ID NO: 22. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 4-354 of SEQ ID NO: 22.
[0863] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-354 of SEQ ID NO: 22.
[0864] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 3-354 of SEQ ID NO: 22. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 3-354 of SEQ ID NO: 22.
[0865] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-354 of SEQ ID NO: 22.
[0866] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 2-354 of SEQ ID NO: 22. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 2-354 of SEQ ID NO: 22.
[0867] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 22.
[0868] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 22. In some embodiments, the engineered
[0869] 91 Atty Docket No. P893392090WO (01344)meganuclease comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 22.
[0870] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 6-354 of SEQ ID NO: 22.
[0871] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 5-354 of SEQ ID NO: 22.
[0872] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 4-354 of SEQ ID NO: 22.
[0873] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 3-354 of SEQ ID NO: 22.
[0874] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 2-354 of SEQ ID NO: 22.
[0875] In some embodiments, the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 22.
[0876] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to a nucleic acid sequence of SEQ ID NO: 43.
[0877] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence of SEQ ID NO: 43.
[0878] In some embodiments, the engineered meganuclease comprises a nuclear localization signal.
[0879] In some embodiments, the nuclear localization signal is at the N-terminus of the engineered meganuclease.
[0880] In some embodiments, the nuclear localization signal is at the C-terminus of the engineered meganuclease.
[0881] In some embodiments, the engineered meganuclease comprises a first nuclear localization signal at the N-terminus and a second nuclear localization signal at the C-terminus.
[0882] In some embodiments, the nuclear localization signal comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 51 or SEQ ID NO: 52. In some embodiments, the nuclear localization signal comprises SEQ ID NO: 51 or SEQ ID NO: 52.
[0883] 92 Atty Docket No. P893392090WO (01344)HBV 27-28x.l63 (SEQ ID NO: 23)
[0884] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 24-79 of SEQ ID NO: 23.
[0885] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 95% sequence identity to residues 24-79 of SEQ ID NO: 23. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 98% sequence identity to residues 24-79 of SEQ ID NO: 23.
[0886] In some embodiments, the HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 23.
[0887] In some embodiments, the HVR1 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 23.
[0888] In some embodiments, the HVR1 region comprises a residue corresponding to residue 48 of SEQ ID NO: 23.
[0889] In some embodiments, the HVR1 region comprises a residue corresponding to residue 50 of SEQ ID NO: 23.
[0890] In some embodiments, the HVR1 region comprises Y, R, K, or D at a residue corresponding to residue 66 of SEQ ID NO: 23.
[0891] In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 7-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 96% sequence identity to residues 7-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 7-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 7-153 of SEQ ID NO: 23.
[0892] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 96% sequence identity to
[0893] 93 Atty Docket No. P893392090WO (01344)residues 6-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 6-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 6-153 of SEQ ID NO: 23.
[0894] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-153 of SEQ ID NO: 23. For example, the first subunit can comprise an amino acid sequence having at least 96% sequence identity to residues 5-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 5-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 5-153 of SEQ ID NO: 23.
[0895] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-153 of SEQ ID NO: 23. For example, the first subunit can comprise an amino acid sequence having at least 96% sequence identity to residues 4-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 4-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 4-153 of SEQ ID NO: 23.
[0896] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-153 of SEQ ID NO: 23. For example, the first subunit can comprise an amino acid sequence having at least 96% sequence identity to residues 3-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 3-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 3-153 of SEQ ID NO: 23.
[0897] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at
[0898] 94 Atty Docket No. P893392090WO (01344)least 99%, or more sequence identity to residues 2-153 of SEQ ID NO: 23. For example, the first subunit can comprise an amino acid sequence having at least 96% sequence identity to residues 2-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 2-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 2-153 of SEQ ID NO: 23.
[0899] In some embodiments, the residue at position 1 of SEQ ID NO: 23 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A.
[0900] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 1-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 96% sequence identity to residues 1-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 1-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 1-153 of SEQ ID NO: 23.
[0901] In some embodiments, the first subunit comprises a residue corresponding to residue 19 of SEQ ID NO: 23.
[0902] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises residues 6-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises residues 5-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises residues 4-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises residues 3-153 of SEQ ID NO: 23. In some embodiments, the first subunit comprises residues 2-153 of SEQ ID NO: 23. In some embodiments, the residue at position 1 of SEQ ID NO: 23 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A. In some embodiments, the first subunit comprises residues 1-153 of SEQ ID NO: 23.
[0903] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 215-270 of SEQ ID NO: 23.
[0904] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 95% sequence identity to residues 215-270 of SEQ ID NO: 23. In some embodiments, the HVR2
[0905] 95 Atty Docket No. P893392090WO (01344)region comprises an amino acid sequence having at least 98% sequence identity to residues 215-270 of SEQ IDNO: 23.
[0906] In some embodiments, the HVR2 region comprises one or more residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 23.
[0907] In some embodiments, the HVR2 region comprises residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 23.
[0908] In some embodiments, the HVR2 region comprises Y, R, K, or D at a residue corresponding to residue 257 of SEQ ID NO: 23.
[0909] In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 23. In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 198-344 of SEQ ID NO: 23.
[0910] In some embodiments, the second subunit that comprises an amino acid sequence having at least 97% sequence identity to residues 198-344 of SEQ ID NO: 23. In some embodiments, the second subunit that comprises an amino acid sequence having at least 98% sequence identity to residues 198-344 of SEQ ID NO: 23. In some embodiments, the second subunit that comprises an amino acid sequence having at least 99% sequence identity to residues 198-344 of SEQ ID NO: 23.
[0911] In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 196-354 of SEQ ID NO: 23.
[0912] In some embodiments, the second subunit comprises an amino acid sequence having at least 97% sequence identity to residues 196-354 of SEQ ID NO: 23. In some embodiments, the second subunit comprises an amino acid sequence having at least 98% sequence identity to residues 196-354 of SEQ ID NO: 23. In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 196-354 of SEQ ID NO: 23.
[0913] In some embodiments, the second subunit comprises a residue corresponding to residue 271 of SEQ ID NO: 23.
[0914] In some embodiments, the second subunit comprises G, S, or A at a residue corresponding to residue 210 of SEQ ID NO: 23.
[0915] In some embodiments, the second subunit comprises E, Q, or K at a residue corresponding to residue 271 of SEQ ID NO: 23.
[0916] 96 Atty Docket No. P893392090WO (01344)In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 23. In some embodiments, the second subunit comprises residues 196-354 of SEQ ID NO: 23. In some embodiments, the engineered meganuclease is a single-chain meganuclease comprising a linker, such as polypeptide linker and wherein the linker covalently joins the first subunit and the second subunit.
[0917] In some embodiments, the linker is a polypeptide linker and comprises an amino acid sequence set forth in SEQ ID NO: 49 or SEQ ID NO: 50. In specific embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 49.
[0918] In some embodiments, the N-terminus of the linker is fused to the residue (i.e., a D residue) corresponding to residue 153 of SEQ ID NO: 23, and the C-terminus of the linker is fused to the residue (i.e., a Y residue) corresponding to residue 196 of SEQ ID NO: 23.
[0919] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 7-153 of SEQ ID NO: 23; a linker comprising an amino acid sequence set forth in SEQ ID NO: 49, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 198-344 of SEQ ID NO: 23.
[0920] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 1-153 of SEQ ID NO: 23; a linker comprising an amino acid sequence set forth in SEQ ID NO: 49, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 196-354 of SEQ ID NO: 23.
[0921] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-354 of SEQ ID NO: 23.
[0922] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to residues 6-354 of SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 6-354 of SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 6-354 of SEQ ID NO: 23.
[0923] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least
[0924] 97 Atty Docket No. P893392090WO (01344)90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-354 of SEQ ID NO: 23.
[0925] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to residues 5-354 of SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 5-354 of SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 5-354 of SEQ ID NO: 23.
[0926] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-354 of SEQ ID NO: 23.
[0927] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to residues 4-354 of SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 4-354 of SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 4-354 of SEQ ID NO: 23.
[0928] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-354 of SEQ ID NO: 23.
[0929] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to residues 3-354 of SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 3-354 of SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 3-354 of SEQ ID NO: 23.
[0930] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-354 of SEQ ID NO: 23.
[0931] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to residues 2-354 of SEQ ID NO: 23. In some embodiments,
[0932] 98 Atty Docket No. P893392090WO (01344)the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 2-354 of SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 2-354 of SEQ ID NO: 23.
[0933] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 23. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 23.
[0934] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 6-354 of SEQ ID NO: 23.
[0935] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 5-354 of SEQ ID NO: 23.
[0936] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 4-354 of SEQ ID NO: 23.
[0937] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 3-354 of SEQ ID NO: 23.
[0938] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 2-354 of SEQ ID NO: 23.
[0939] In some embodiments, the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 23.
[0940] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to a nucleic acid sequence of SEQ ID NO: 44.
[0941] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence of SEQ ID NO: 44.
[0942] In some embodiments, the engineered meganuclease comprises a nuclear localization signal.
[0943] 99 Atty Docket No. P893392090WO (01344)In some embodiments, the nuclear localization signal is at the N-terminus of the engineered meganuclease.
[0944] In some embodiments, the nuclear localization signal is at the C-terminus of the engineered meganuclease.
[0945] In some embodiments, the engineered meganuclease comprises a first nuclear localization signal at the N-terminus and a second nuclear localization signal at the C-terminus.
[0946] In some embodiments, the nuclear localization signal comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 51 or SEQ ID NO: 52. In some embodiments, the nuclear localization signal comprises SEQ ID NO: 51 or SEQ ID NO: 52.
[0947] HBV 27-28L.190 (SEQ ID NO: 24)
[0948] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 24-79 of SEQ ID NO: 24.
[0949] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 90% sequence identity to residues 24-79 of SEQ ID NO: 24. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 95% sequence identity to residues 24-79 of SEQ ID NO: 24. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 98% sequence identity to residues 24-79 of SEQ ID NO: 24.
[0950] In some embodiments, the HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 24.
[0951] In some embodiments, the HVR1 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 24.
[0952] In some embodiments, the HVR1 region comprises a residue corresponding to residue 48 of SEQ ID NO: 24.
[0953] In some embodiments, the HVR1 region comprises a residue corresponding to residue 50 of SEQ ID NO: 24.
[0954] In some embodiments, the HVR1 region comprises Y, R, K, or D at a residue corresponding to residue 66 of SEQ ID NO: 24.
[0955] In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 24.
[0956] 100 Atty Docket No. P893392090WO (01344)In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 7-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 96% sequence identity to residues 7-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 7-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 7-153 of SEQ ID NO: 24.
[0957] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 96% sequence identity to residues 6-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 6-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 6-153 of SEQ ID NO: 24.
[0958] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-153 of SEQ ID NO: 24. For example, the first subunit can comprise an amino acid sequence having at least 96% sequence identity to residues 5-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 5-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 5-153 of SEQ ID NO: 24.
[0959] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-153 of SEQ ID NO: 24. For example, the first subunit can comprise an amino acid sequence having at least 96% sequence identity to residues 4-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 4-153 of SEQ ID NO: 24. In some embodiments,
[0960] 101 Atty Docket No. P893392090WO (01344)the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 4-153 of SEQ ID NO: 24.
[0961] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-153 of SEQ ID NO: 24. For example, the first subunit can comprise an amino acid sequence having at least 96% sequence identity to residues 3-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 3-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 3-153 of SEQ ID NO: 24.
[0962] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-153 of SEQ ID NO: 24. For example, the first subunit can comprise an amino acid sequence having at least 96% sequence identity to residues 2-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 2-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 2-153 of SEQ ID NO: 24.
[0963] In some embodiments, the residue at position 1 of SEQ ID NO: 24 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A.
[0964] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 1-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 96% sequence identity to residues 1-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 1-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 1-153 of SEQ ID NO: 24.
[0965] In some embodiments, the first subunit comprises a residue corresponding to residue 19 of SEQ ID NO: 24.
[0966] 102 Atty Docket No. P893392090WO (01344)In some embodiments, the first subunit comprises a residue corresponding to residue 139 of SEQ ID NO: 24.
[0967] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises residues 6-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises residues 5-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises residues 4-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises residues 3-153 of SEQ ID NO: 24. In some embodiments, the first subunit comprises residues 2-153 of SEQ ID NO: 24. In some embodiments, the residue at position 1 of SEQ ID NO: 24 is modified from M to another amino acid. In some embodiments, the residue at position 1 is modified from M to A. In some embodiments, the first subunit comprises residues 1-153 of SEQ ID NO: 24.
[0968] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 215-270 of SEQ ID NO: 24.
[0969] In some embodiments, the HVR2 region comprises an amino acid sequence having at least 95% sequence identity to residues 215-270 of SEQ ID NO: 24. In some embodiments, the HVR2 region comprises an amino acid sequence having at least 98% sequence identity to residues 215-270 of SEQ ID NO: 24.
[0970] In some embodiments, the HVR2 region comprises one or more residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 24.
[0971] In some embodiments, the HVR2 region comprises residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 24.
[0972] In some embodiments, the HVR2 region comprises Y, R, K, or D at a residue corresponding to residue 257 of SEQ ID NO: 24.
[0973] In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 24. In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 198-344 of SEQ ID NO: 24.
[0974] In some embodiments, the second subunit that comprises an amino acid sequence having at least 97% sequence identity to residues 198-344 of SEQ ID NO: 24. In some embodiments, the second subunit that comprises an amino acid sequence having at least 98% sequence identity to
[0975] 103 Atty Docket No. P893392090WO (01344)residues 198-344 of SEQ ID NO: 24. In some embodiments, the second subunit that comprises an amino acid sequence having at least 99% sequence identity to residues 198-344 of SEQ ID NO: 24.
[0976] In some embodiments, the second subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 196-354 of SEQ ID NO: 24.
[0977] In some embodiments, the second subunit comprises an amino acid sequence having at least 97% sequence identity to residues 196-354 of SEQ ID NO: 24. In some embodiments, the second subunit comprises an amino acid sequence having at least 98% sequence identity to residues 196-354 of SEQ ID NO: 24. In some embodiments, the second subunit comprises an amino acid sequence having at least 99% sequence identity to residues 196-354 of SEQ ID NO: 24.
[0978] In some embodiments, the second subunit comprises a residue corresponding to residue 271 of SEQ ID NO: 24.
[0979] In some embodiments, the second subunit comprises a residue corresponding to residue 330 of SEQ ID NO: 24.
[0980] In some embodiments, the second subunit comprises G, S, or A at a residue corresponding to residue 210 of SEQ ID NO: 24.
[0981] In some embodiments, the second subunit comprises E, Q, or K at a residue corresponding to residue 271 of SEQ ID NO: 24.
[0982] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 24. In some embodiments, the second subunit comprises residues 196-354 of SEQ ID NO: 24. In some embodiments, the engineered meganuclease is a single-chain meganuclease comprising a linker, such as polypeptide linker and wherein the linker covalently joins the first subunit and the second subunit.
[0983] In some embodiments, the linker is a polypeptide linker and comprises an amino acid sequence set forth in SEQ ID NO: 49 or SEQ ID NO: 50. In specific embodiments, the linker comprises an amino acid sequence set forth in SEQ ID NO: 49.
[0984] In some embodiments, the N-terminus of the linker is fused to the residue (i.e., a D residue) corresponding to residue 153 of SEQ ID NO: 24, and the C-terminus of the linker is fused to the residue (i.e., a Y residue) corresponding to residue 196 of SEQ ID NO: 24.
[0985] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 7-153 of SEQ ID NO: 24; a linker comprising an amino acid sequence set forth in SEQ ID NO: 49, wherein the linker
[0986] 104 Atty Docket No. P893392090WO (01344)covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 198-344 of SEQ ID NO: 24.
[0987] In some embodiments, the engineered meganuclease comprises a first subunit comprising an amino acid sequence having at least 99% sequence identity residues 1-153 of SEQ ID NO: 24; a linker comprising an amino acid sequence set forth in SEQ ID NO: 49, wherein the linker covalently joins the first subunit and the second subunit; and a second subunit comprising an amino acid sequence having at least 99% sequence identity to residues 196-354 of SEQ ID NO: 24.
[0988] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 6-354 of SEQ ID NO: 24.
[0989] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to residues 6-354 of SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 6-354 of SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 6-354 of SEQ ID NO: 24.
[0990] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 5-354 of SEQ ID NO: 24.
[0991] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to residues 5-354 of SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 5-354 of SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 5-354 of SEQ ID NO: 24.
[0992] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 4-354 of SEQ ID NO: 24.
[0993] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to residues 4-354 of SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence
[0994] 105 Atty Docket No. P893392090WO (01344)identity to residues 4-354 of SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 4-354 of SEQ ID NO: 24.
[0995] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 3-354 of SEQ ID NO: 24.
[0996] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to residues 3-354 of SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 3-354 of SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 3-354 of SEQ ID NO: 24.
[0997] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 2-354 of SEQ ID NO: 24.
[0998] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to residues 2-354 of SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 2-354 of SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to residues 2-354 of SEQ ID NO: 24.
[0999] In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 24. In some embodiments, the engineered meganuclease comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 24.
[1000] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 6-354 of SEQ ID NO: 24.
[1001] 106 Atty Docket No. P893392090WO (01344)In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 5-354 of SEQ ID NO: 24.
[1002] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 4-354 of SEQ ID NO: 24.
[1003] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 3-354 of SEQ ID NO: 24.
[1004] In some embodiments, the engineered meganuclease comprises an amino acid sequence of residues 2-354 of SEQ ID NO: 24.
[1005] In some embodiments, the engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 24.
[1006] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to a nucleic acid sequence of SEQ ID NO: 45.
[1007] In some embodiments, the engineered meganuclease is encoded by a nucleic acid sequence of SEQ ID NO: 45.
[1008] In some embodiments, the engineered meganuclease comprises a nuclear localization signal.
[1009] In some embodiments, the nuclear localization signal is at the N-terminus of the engineered meganuclease.
[1010] In some embodiments, the nuclear localization signal is at the C-terminus of the engineered meganuclease.
[1011] In some embodiments, the engineered meganuclease comprises a first nuclear localization signal at the N-terminus and a second nuclear localization signal at the C-terminus.
[1012] In some embodiments, the nuclear localization signal comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 51 or SEQ ID NO: 52. In some embodiments, the nuclear localization signal comprises SEQ ID NO: 51 or SEQ ID NO: 52.
[1013] HBV 27-28L.319 (SEQ ID NO: 25)
[1014] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 90%, at least 91%, at least 92%,
[1015] 107 Atty Docket No. P893392090WO (01344)at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 24-79 of SEQ ID NO: 25.
[1016] In some embodiments, the HVR1 region comprises an amino acid sequence having at least 90% sequence identity to residues 24-79 of SEQ ID NO: 25. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 95% sequence identity to residues 24-79 of SEQ ID NO: 25. In some embodiments, the HVR1 region comprises an amino acid sequence having at least 98% sequence identity to residues 24-79 of SEQ ID NO: 25.
[1017] In some embodiments, the HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 25.
[1018] In some embodiments, the HVR1 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 25.
[1019] In some embodiments, the HVR1 region comprises a residue corresponding to residue 48 of SEQ ID NO: 25.
[1020] In some embodiments, the HVR1 region comprises a residue corresponding to residue 50 of SEQ ID NO: 25.
[1021] In some embodiments, the HVR1 region comprises Y, R, K, or D at a residue corresponding to residue 66 of SEQ ID NO: 25.
[1022] In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 25. In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to residues 7-153 of SEQ ID NO: 25. In some embodiments, the first subunit comprises an amino acid sequence having at least 96% sequence identity to residues 7-153 of SEQ ID NO: 25. In some embodiments, the first subunit comprises an amino acid sequence having at least 98% sequence identity to residues 7-153 of SEQ ID NO: 25. In some embodiments, the first subunit comprises an amino acid sequence having at least 99% sequence identity to residues 7-153 of SEQ ID NO: 25.
[1023] In some embodiments, the first subunit comprises an amino acid sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at l...
Claims
CLAIMS1. An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within a hepatitis B virus (HBV) genome, wherein said engineered meganuclease comprises a first subunit and a second subunit, wherein said first subunit binds to a first recognition half-site of said recognition sequence and comprises a first hypervariable (HVR1) region, and wherein said second subunit binds to a second recognition half-site of said recognition sequence and comprises a second hypervariable (HVR2) region.
2. The engineered meganuclease of claim 1, wherein said HVR1 region comprises an amino acid sequence having at least 80% sequence identity to residues 24-79 of any one of SEQ ID NOs: 5-8.
3. The engineered meganuclease of claim 1 or claim 2, wherein said HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 5-8.
4. The engineered meganuclease of any one of claims 1-3, wherein said HVR1 region comprises a residue corresponding to residue 50 of any one of SEQ ID NOs: 5-8.
5. The engineered meganuclease of any one of claims 1-4, wherein said HVR1 region comprises a residue corresponding to residue 71 of SEQ ID NO: 5 or SEQ ID NO: 6.
6. The engineered meganuclease of any one of claims 1-5, wherein said HVR1 region comprises a residue corresponding to residue 72 of any one of SEQ ID NOs: 5, 7, or 8.
7. The engineered meganuclease of any one of claims 1-6, wherein said HVR1 region comprises residues 24-79 of any one of SEQ ID NOs: 5-8.
8. The engineered meganuclease of any one of claims 1-7, wherein said first subunit comprises an amino acid sequence having at least 80% sequence identity to residues 7-153 of any one of SEQ ID NOs: 5-8.223 Atty Docket No. P893392090WO (01344)9. The engineered meganuclease of any one of claims 1-8, wherein said first subunit comprises a residue corresponding to residue 19 of any one of SEQ ID NOs: 5-8.
10. The engineered meganuclease of any one of claims 1-9, wherein said first subunit comprises a residue corresponding to residue 96 of any one of SEQ ID NOs: 5-8.
11. The engineered meganuclease of any one of claims 1-10, wherein said first subunit comprises a residue corresponding to residue 99 of any one of SEQ ID NOs: 5-8.
12. The engineered meganuclease of any one of claims 1-11, wherein said first subunit comprises a residue corresponding to residue 100 of any one of SEQ ID NOs: 5-8.
13. The engineered meganuclease of any one of claims 1-12, wherein said first subunit comprises a residue corresponding to residue 139 of any one of SEQ ID NOs: 5-7.
14. The engineered meganuclease of any one of claims 1-13, wherein said first subunit comprises residues 7-153 of any one of SEQ ID NOs: 5-8.
15. The engineered meganuclease of any one of claims 1-14, wherein said first subunit comprises residues 1-153 of any one of SEQ ID NOs: 5-8.
16. The engineered meganuclease of any one of claims 1-15, wherein said HVR2 region comprises an amino acid sequence having at least 80% sequence identity to residues 204-259 of any one of SEQ ID NOs: 5-8.
17. The engineered meganuclease of any one of claims 1-16, wherein said HVR2 region comprises one or more residues corresponding to residues 204, 206, 208, 210, 212, 213, 218, 220, 222, 224, 226, 248, 250, 255, and 257 of any one of SEQ ID NOs: 5-8.
18. The engineered meganuclease of any one of claims 1-17, wherein said HVR2 region comprises a residue corresponding to residue 237 of any one of SEQ ID NOs: 5-8.
19. The engineered meganuclease of any one of claims 1-18, wherein said HVR2 region comprises a residue corresponding to residue 241 of any one of SEQ ID NOs: 5-8.224 Atty Docket No. P893392090WO (01344)20. The engineered meganuclease of any one of claims 1-19, wherein said HVR2 region comprises residues 204-259 of any one of SEQ ID NOs: 5-8.
21. The engineered meganuclease of any one of claims 1-20, wherein said second subunit comprises an amino acid sequence having at least 80% sequence identity to residues 187-333 of any one of SEQ ID NOs: 5-8.
22. The engineered meganuclease of any one of claims 1-21, wherein said second subunit comprises an amino acid sequence having at least 80% sequence identity to residues 185-343 of any one of SEQ ID NOs: 5-8.
23. The engineered meganuclease of any one of claims 1-22, wherein said second subunit comprises a residue corresponding to residue 319 of any one of SEQ ID NOs: 5-7.
24. The engineered meganuclease of any one of claims 1-23, wherein said second subunit comprises residues 187-333 of any one of SEQ ID NOs: 5-8.
25. The engineered meganuclease of any one of claims 1-24, wherein said second subunit comprises residues 185-343 of any one of SEQ ID NOs: 5-8.
26. The engineered meganuclease of any one of claims 1-25, wherein said engineered meganuclease is a single-chain meganuclease comprising a polypeptide linker, wherein said polypeptide linker covalently joins said first subunit and said second subunit.
27. The engineered meganuclease of claim 26, wherein said polypeptide linker comprises the amino acid sequence of SEQ ID NO: 50.
28. The engineered meganuclease of any one of claims 1-27, wherein said engineered meganuclease comprises an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 5-8.225 Atty Docket No. P893392090WO (01344)29. The engineered meganuclease of any one of claims 1-27, wherein said engineered meganuclease comprises an amino acid sequence having at least 80% sequence identity to residues 2-343 of any one of SEQ ID NOs: 5-8.
30. The engineered meganuclease of any one of claims 1-27, wherein said engineered meganuclease comprises the amino acid sequence of any one of SEQ ID NOs: 5-8.
31. The engineered meganuclease of any one of claims 1-27, wherein said engineered meganuclease comprises an amino acid sequence comprising residues 2-343 of any one of SEQ ID NOs: 5-8.
32. The engineered meganuclease of any one of claims 1-27, wherein said engineered meganuclease is encoded by a nucleic acid sequence having at least 80% sequence identity to a nucleic acid sequence of any one of SEQ ID NOs: 17-20.
33. The engineered meganuclease of any one of claims 1-27, wherein said engineered meganuclease is encoded by the nucleic acid sequence of any one of SEQ ID NOs: 17-20.
34. The engineered meganuclease of any one of claims 1-27, wherein said engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6.
35. The engineered meganuclease of any one of claims 1-27, wherein said engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6.
36. The engineered meganuclease of any one of claims 1-27, wherein said engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 2-343 of SEQ ID NO: 5 or SEQ ID NO: 6.
37. The engineered meganuclease of any one of claims 1-27, wherein said engineered meganuclease comprises an amino acid sequence comprising residues 2-343 of SEQ ID NO: 5 or SEQ ID NO: 6.226 Atty Docket No. P893392090WO (01344)38. An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein said engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 5.
39. An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein said engineered meganuclease comprises an amino acid sequence comprising residues 2-343 of SEQ ID NO: 5.
40. An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein said engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 6.
41. An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein said engineered meganuclease comprises an amino acid sequence comprising residues 2-343 of SEQ ID NO: 6.
42. An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein said engineered meganuclease comprises a first subunit and a second subunit, wherein said first subunit binds to a first recognition half-site of said recognition sequence and comprises a first HVR1 region, and wherein said second subunit binds to a second recognition half-site of said recognition sequence and comprises a second HVR2 region.
43. The engineered meganuclease of claim 42, wherein said HVR1 region comprises an amino acid sequence having at least 80% sequence identity to residues 24-79 of any one of SEQ ID NOs: 21-27.
44. The engineered meganuclease of claim 42 or claim 43, wherein said HVR1 region comprises one or more residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 21-27.
45. The engineered meganuclease of any one of claims 42-44, wherein said HVR1 region comprises a residue corresponding to residue 48 of any one of SEQ ID NOs: 23, 24, or 25.227 Atty Docket No. P893392090WO (01344)46. The engineered meganuclease of any one of claims 42-45, wherein said HVR1 region comprises a residue corresponding to residue 50 of any one of SEQ ID NOs: 21-27.
47. The engineered meganuclease of any one of claims 42-46, wherein said HVR1 region comprises a residue corresponding to residue 71 of SEQ ID NO: 21 or SEQ ID NO: 22.
48. The engineered meganuclease of any one of claims 42-47, wherein said HVR1 region comprises a residue corresponding to residue 72 of any one of SEQ ID NOs: 21, 26, and 27.
49. The engineered meganuclease of any one of claims 42-48, wherein said HVR1 region comprises residues 24-79 of any one of SEQ ID NOs: 21-27.
50. The engineered meganuclease of any one of claims 42-49, wherein said first subunit comprises an amino acid sequence having at least 80% sequence identity to residues 7-153 of any one of SEQ ID NOs: 21-27.
51. The engineered meganuclease of any one of claims 42-50, wherein said first subunit comprises a residue corresponding to residue 19 of any one of SEQ ID NOs: 21-27.
52. The engineered meganuclease of any one of claims 42-51, wherein said first subunit comprises a residue corresponding to residue 139 of any one of SEQ ID NOs: 21, 22, or 24-26.
53. The engineered meganuclease of any one of claims 42-52, wherein said first subunit comprises residues 7-153 of any one of SEQ ID NOs: 21-27.
54. The engineered meganuclease of any one of claims 42-53, wherein the first subunit comprises residues 1-153 of any one of SEQ ID NOs: 21-27.
55. The engineered meganuclease of any one of claims 42-54, wherein said HVR2 region comprises an amino acid sequence having at least 80% sequence identity to residues 215-270 of any one of SEQ ID NOs: 21-27.228 Atty Docket No. P893392090WO (01344)56. The engineered meganuclease of any one of claims 42-55, wherein said HVR2 region comprises one or more residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of any one of SEQ ID NOs: 21-27.
57. The engineered meganuclease of any one of claims 42-56, wherein said HVR2 region comprises residues 215-270 of any one of SEQ ID NOs: 21-27.
58. The engineered meganuclease of any one of claims 42-57, wherein said second subunit comprises an amino acid sequence having at least 80% sequence identity to residues 198-344 of any one of SEQ ID NOs: 21-27.
59. The engineered meganuclease of any one of claims 42-58, wherein said second subunit comprises a residue corresponding to residue 271 of SEQ ID NO: 23 or SEQ ID NO: 24.
60. The engineered meganuclease of any one of claims 42-59, wherein said second subunit comprises a residue corresponding to residue 330 of any one of SEQ ID NOs: 21, 22, or 24-26.
61. The engineered meganuclease of any one of claims 42-60, wherein said second subunit comprises residues 198-344 of any one of SEQ ID NOs: 21-27.
62. The engineered meganuclease of any one of claims 42-61, wherein said second subunit comprises residues 196-354 of any one of SEQ ID NOs: 21-27.
63. The engineered meganuclease of any one of claims 42-62, wherein said engineered meganuclease is a single-chain meganuclease comprising a polypeptide linker, wherein said polypeptide linker covalently joins said first subunit and said second subunit.
64. The engineered meganuclease of claim 63, wherein said polypeptide linker comprises the amino acid sequence of SEQ ID NO: 49.
65. The engineered meganuclease of any one of claims 42-64, wherein said engineered meganuclease comprises an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 21-27.229 Atty Docket No. P893392090WO (01344)66. The engineered meganuclease of any one of claims 42-64, wherein said engineered meganuclease comprises an amino acid sequence having at least 80% sequence identity to residues 2-354 of any one of SEQ ID NOs: 21-27.
67. The engineered meganuclease of any one of claims 42-64, wherein said engineered meganuclease comprises the amino acid sequence of any one of SEQ ID NOs: 21-27.
68. The engineered meganuclease of any one of claims 42-64, wherein said engineered meganuclease comprises an amino acid sequence comprising residues 2-354 of any one of SEQ ID NOs: 21-27.
69. The engineered meganuclease of any one of claims 42-64, wherein said engineered meganuclease is encoded by a nucleic acid sequence having at least 80% sequence identity to a nucleic acid sequence of any one of SEQ ID NOs: 42-48.
70. The engineered meganuclease of any one of claims 42-64, wherein said engineered meganuclease is encoded by the nucleic acid sequence of any one of SEQ ID NOs: 42-48.
71. The engineered meganuclease of any one of claims 42-64, wherein said engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 21 or SEQ ID NO: 22.
72. The engineered meganuclease of any one of claims 42-64, wherein said engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 21 or SEQ ID NO: 22.
73. The engineered meganuclease of any one of claims 42-64, wherein said engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to residues 2-354 of SEQ ID NO: 21 or SEQ ID NO: 22.
74. The engineered meganuclease of any one of claims 42-64, wherein said engineered meganuclease comprises an amino acid sequence comprising residues 2-354 of SEQ ID NO: 21 or SEQ ID NO: 22.230 Atty Docket No. P893392090WO (01344)75. An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein said engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 21.
76. An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein said engineered meganuclease comprises an amino acid sequence comprising residues 2-354 of SEQ ID NO: 21.
77. An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein said engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 22.
78. An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 3 within an HBV genome, wherein said engineered meganuclease comprises an amino acid sequence comprising residues 2-354 of SEQ ID NO: 22.
79. The engineered meganuclease of any one of claims 1-78, wherein said engineered meganuclease comprises a nuclear localization signal.
80. The engineered meganuclease of claim 79, wherein said nuclear localization signal is at the N-terminus of said engineered meganuclease.
81. The engineered meganuclease of claim 79, wherein said nuclear localization signal is at the C-terminus of said engineered meganuclease.
82. The engineered meganuclease of claim 79, wherein said engineered meganuclease comprises a first nuclear localization signal at the N-terminus and a second nuclear localization signal at the C-terminus.
83. The engineered meganuclease of any one of claims 79-82, wherein said nuclear localization signal comprises an amino acid sequence having at least 80% or at least 90% sequence identity to SEQ ID NO: 51 or SEQ ID NO: 52.231 Atty Docket No. P893392090WO (01344)84. The engineered meganuclease of any one of claims 79-83, wherein said nuclear localization signal comprises the amino acid sequence of SEQ ID NO: 51 or SEQ ID NO: 52.
85. A polynucleotide comprising a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-84.
86. The polynucleotide of claim 85, wherein said polynucleotide is an mRNA.
87. A recombinant DNA construct comprising said polynucleotide of claim 85.
88. The recombinant DNA construct of claim 87, wherein said recombinant DNA construct is a plasmid DNA.
89. The recombinant DNA construct of claim 87 or claim 88, wherein said recombinant DNA construct encodes a recombinant virus comprising said polynucleotide.
90. The recombinant DNA construct of claim 89, wherein said recombinant virus is a recombinant adenovirus, a recombinant lentivirus, a recombinant retrovirus, or a recombinant adeno-associated virus (AAV).
91. The recombinant DNA construct of claim 89 or claim 90, wherein said recombinant virus is a recombinant AAV.
92. The recombinant DNA construct of any one of claims 87-91, wherein said polynucleotide comprises a promoter operably linked to said nucleic acid sequence encoding said engineered meganuclease.
93. The recombinant DNA construct of claim 92, wherein said promoter is a liver-specific promoter.
94. A recombinant virus comprising said polynucleotide of claim 85.
95. The recombinant virus of claim 94, wherein said recombinant virus is a recombinant adenovirus, a recombinant lentivirus, a recombinant retrovirus, or a recombinant AAV.232 Atty Docket No. P893392090WO (01344)96. The recombinant virus of claim 94 or claim 95, wherein said recombinant virus is a recombinant AAV.
97. The recombinant virus of any one of claims 94-96, wherein said polynucleotide comprises a promoter operably linked to said nucleic acid sequence encoding said engineered meganuclease.
98. The recombinant virus of claim 97, wherein said promoter is a liver-specific promoter.
99. A lipid nanoparticle composition comprising lipid nanoparticles comprising said polynucleotide of claim 85 or claim 86.
100. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and said engineered meganuclease of any one of claims 1-84.
101. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and said polynucleotide of claim 85 or claim 86.
102. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and said recombinant DNA construct of any one of claims 87-93.
103. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and said recombinant virus of any one of claims 94-98.
104. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and said lipid nanoparticle composition of claim 99.
105. A host cell comprising said polynucleotide of claim 85 or claim 86.
106. A method for inactivating a hepatitis B virus surface antigen (HBsAg) gene of an HBV genome or an HBV genome fragment, said method comprising introducing into a eukaryotic cell comprising said HBV genome or HBV genome fragment:233 Atty Docket No. P893392090WO (01344)(a) a polynucleotide comprising a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-84, wherein said engineered meganuclease is expressed in said eukaryotic cell; or(b) said engineered meganuclease of any one of claims 1-84;wherein said engineered meganuclease produces a cleavage site at a recognition sequence comprising SEQ ID NO: 3 within said HBsAg gene, wherein said HBsAg gene is inactivated by introduction of an insertion or deletion (indel) at said cleavage site, or wherein said HBsAg gene is inactivated by elimination of said HB V genome or said HBV genome fragment.
107. The method of claim 106, wherein said HBV genome or said HBV genome fragment is comprised by covalently closed circular DNA (cccDNA).
108. The method of claim 107, wherein said cccDNA is eliminated following generation of said cleavage site.
109. The method of claim 107, wherein said HBsAg gene is inactivated in said cccDNA by introduction of said indel at said cleavage site.
110. The method of claim 109, wherein said indel is introduced by non-homologous end joining (NHEJ).
111. The method of claim 109 or claim 110, wherein said inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
112. The method of claim 106, wherein said HBV genome or said HBV genome fragment is comprised in the genome of said eukaryotic cell.
113. The method of claim 112, wherein said genome is the nuclear genome.
114. The method of claim 112, wherein said genome is the mitochondrial genome.
115. The method of any one of claims 112-114, wherein said indel is introduced by NHEJ.234 Atty Docket No. P893392090WO (01344)116. The method of any one of claims 112-115, wherein said inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
117. The method of any one of claims 106-116, wherein said eukaryotic cell is a human cell.
118. The method of claim 117, wherein said human cell is a liver cell.
119. The method of claim 118, wherein said liver cell is a hepatocyte.
120. The method of any one of claims 106-119, wherein said polynucleotide is said polynucleotide of claim 85 or claim 86.
121. The method of any one of claims 106-120, wherein said polynucleotide is introduced into said eukaryotic cell by an mRNA or a recombinant virus.
122. The method of claim 121, wherein said polynucleotide is said mRNA of claim 86.
123. The method of claim 121 or claim 122, wherein said mRNA is introduced into said eukaryotic cell by contacting said eukaryotic cell with a lipid nanoparticle comprising said mRNA.
124. The method of claim 121, wherein said recombinant virus is said recombinant virus of any one of claims 94-98.
125. The method of claim 124, wherein said recombinant virus is a recombinant AAV.
126. A method for inactivating an HBsAg gene of an HBV genome or an HBV genome fragment in a target cell in a subject, said method comprising delivering to said target cell comprising said HBV genome or HBV genome fragment:(a) a polynucleotide comprising a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-84, wherein said engineered meganuclease is expressed in said target cell; or(b) said engineered meganuclease of any one of claims 1-84;wherein said engineered meganuclease produces a cleavage site at a recognition sequence comprising SEQ ID NO: 3 within said HBsAg gene, wherein said HBsAg gene is inactivated by235 Atty Docket No. P893392090WO (01344)introduction of an indel at said cleavage site, or wherein said HBsAg gene is inactivated by elimination of said HB V genome or said HBV genome fragment.
127. The method of claim 126, wherein said HBV genome or said HBV genome fragment is comprised by cccDNA.
128. The method of claim 127, wherein said cccDNA is eliminated following generation of said cleavage site.
129. The method of claim 127, wherein said HBsAg gene is inactivated in said cccDNA by introduction of said indel at said cleavage site.
130. The method of claim 129, wherein said indel is introduced by NHEJ.
131. The method of claim 129 or claim 130, wherein said inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
132. The method of claim 136, wherein said HBV genome or said HBV genome fragment is comprised in the genome of said target cell.
133. The method of claim 132, wherein said genome is the nuclear genome.
134. The method of claim 132, wherein said genome is the mitochondrial genome.
135. The method of any one of claims 132-134, wherein said indel is introduced by NHEJ.
136. The method of any one of claims 132-135, wherein said inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
137. The method of any one of claims 126-136, wherein the serum concentration of HBsAg is reduced in said subject.
138. The method of any one of claims 126-137, wherein said target cell is a liver cell.236 Atty Docket No. P893392090WO (01344)139. The method of claim 138, wherein said liver cell is a hepatocyte.
140. The method of any one of claims 126-139, wherein said polynucleotide is said polynucleotide of claim 85 or claim 86.
141. The method of any one of claims 126-140, wherein said polynucleotide is an mRNA or is comprised in the genome of a recombinant virus.
142. The method of claim 141, wherein said polynucleotide is said mRNA of claim 86.
143. The method of claim 141 or claim 142, wherein said mRNA is delivered to said target cell using a lipid nanoparticle comprising said mRNA.
144. The method of claim 140 or claim 141, wherein said polynucleotide is delivered to said target cell using a recombinant virus comprising said polynucleotide in its genome.
145. The method of claim 141, wherein said recombinant virus is said recombinant virus of any one of claims 94-98.
146. The method of claim 145, wherein said recombinant virus is a recombinant AAV.
147. A method for treating a disease associated with hepatitis B virus infection, said method comprising delivering to a target cell in said subject:(a) a therapeutically effective amount of a polynucleotide comprising a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-84, wherein said engineered meganuclease is expressed in said target cell; or(b) a therapeutically effective amount of said engineered meganuclease of any one of claims 1-84;wherein said target cell comprises an HBV genome or HBV genome fragment comprising an HBsAg gene, wherein said engineered meganuclease produces a cleavage site at a recognition sequence comprising SEQ ID NO: 3 within said HBsAg gene, wherein said HBsAg gene is inactivated by introduction of an indel at said cleavage site, or wherein said HBsAg gene is inactivated by elimination of said HBV genome or said HBV genome fragment.237 Atty Docket No. P893392090WO (01344)148. The method of claim 147, wherein said disease is chronic hepatitis B, hepatocellular carcinoma, and / or cirrhosis.
149. The method of claim 147 or claim 148, wherein said HBV genome or said HBV genome fragment is comprised by cccDNA.
150. The method of claim 149, wherein said cccDNA is eliminated following generation of said cleavage site.
151. The method of claim 149, wherein said HBsAg gene is inactivated in said cccDNA by introduction of said indel at said cleavage site.
152. The method of claim 151, wherein said indel is introduced by NHEJ.
153. The method of claim 151 or claim 152, wherein said inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
154. The method of claim 147 or claim 148, wherein said HBV genome or said HBV genome fragment is comprised in the genome of said target cell.
155. The method of claim 154, wherein said genome is the nuclear genome.
156. The method of claim 154, wherein said genome is the mitochondrial genome.
157. The method of any one of claims 154-156, wherein said indel is introduced by NHEJ.
158. The method of any one of claims 154-157, wherein said inactivated HBsAg gene does not encode an active and / or full-length HBsAg protein.
159. The method of any one of claims 147-158, wherein the serum concentration of HBsAg is reduced in said subject.
160. The method of any one of claims 147-159, wherein said target cell is a liver cell.238 Atty Docket No. P893392090WO (01344)161. The method of claim 160, wherein said liver cell is a hepatocyte.
162. The method of any one of claims 147-161, wherein said polynucleotide is said polynucleotide of claim 82 or claim 83.
163. The method of any one of claims 147-162, wherein said polynucleotide is an mRNA or is comprised in the genome of a recombinant virus.
164. The method of claim 163, wherein said polynucleotide is said mRNA of claim 83.
165. The method of claim 163 or claim 164, wherein said mRNA is delivered to said target cell using a lipid nanoparticle comprising said mRNA.
166. The method of claim 162 or claim 163, wherein said polynucleotide is delivered to said target cell using a recombinant virus comprising said polynucleotide in its genome.
167. The method of claim 163, wherein said recombinant virus is said recombinant virus of any one of claims 94-98.
168. The method of claim 167, wherein said recombinant virus is a recombinant AAV.
169. The method of any one of claims 147-168, wherein said subject is also administered one, two, three, four or more additional therapeutic agents selected from HBV combination drugs, HBV vaccines, HBV DNA polymerase inhibitors, immunomodulators, toll-like receptor (TLR) modulators, interferon alpha receptor ligands, hyaluronidase inhibitors, HBV antigen inhibitors (e.g., HBV core antigen (HBcAg) inhibitors, HBV surface antigen (HBsAg) inhibitors, HBx inhibitors, HBV E antigen inhibitors), anti-HBV antigen antibodies, inhibitory nucleic acids targeting HBV (e.g., antisense oligonucleotide, short interfering RNA (siRNA), DNA-directed RNA interference (ddRNAi)), HBsAg secretion or assembly inhibitors, HBV viral entry inhibitors, immune checkpoint inhibitor, cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitors, cyclophilin inhibitors, endonuclease modulators, ribonucleotide reductase inhibitors, covalently closed circular DNA (cccDNA) inhibitors, farnesoid X receptor (FXR) agonists, STING agonists, anti-HBV antibodies, CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein modulators, retinoic acid-inducible gene 1 stimulators, N0D2 stimulators, phosphatidylinositol 3-239 Atty Docket No. P893392090WO (01344)kinase (PI3K) inhibitors, indoleamine-2, 3 -dioxygenase (IDO) pathway inhibitors, PD-1 inhibitors, PD-L1 inhibitors, recombinant thymosin alpha- 1, Bruton’s tyrosine kinase (BTK) inhibitors, KDM inhibitors, HBV replication inhibitors, arginase inhibitors, gene therapy and cell therapy, gene editors, cellular therapy, and TCR-T cell therapy.
170. The method of any one of claims 147-169, wherein said subject is also administered one, two, three, four or more additional therapeutic agents selected from 3 -dioxygenase (IDO) inhibitors, apolipoprotein Al modulator, arginase inhibitors, B- and T-lymphocyte attenuator inhibitors, Bruton’s tyrosine kinase (BTK) inhibitors, CCR2 chemokine antagonist, CD137 inhibitors, CD160 inhibitors, CD305 inhibitors, CD4 agonist and modulator, compounds targeting hepatitis B core antigen (HBcAg), core protein allosteric modulators, covalently closed circular DNA (cccDNA) inhibitors, cyclophilin inhibitors, cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitors, DNA polymerase inhibitor, endonuclease modulators, epigenetic modifiers, famesoid X receptor (FXR) agonists, HBV DNA polymerase inhibitors, HBV replication inhibitors, HBV RNAse inhibitors, HBV viral entry inhibitors, HBx inhibitors, Hepatitis B large envelope protein modulator, Hepatitis B large envelope protein stimulator, Hepatitis B structural protein modulator, hepatitis B surface antigen (HBsAg) inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, hepatitis B virus E antigen inhibitors, hepatitis B virus replication inhibitors, Hepatitis virus structural protein inhibitor, HIV-1 reverse transcriptase inhibitor, Hyaluronidase inhibitor, inhibitor of apoptosis proteins family proteins (IAPS) inhibitors, IL-2 agonist, IL-7 agonist, immunomodulators, indoleamine-2 inhibitors, inhibitors of ribonucleotide reductase, Interleukin-2 ligand, ipi4 inhibitors, lysine demethylase inhibitors, histone demethylase inhibitors, KDM1 inhibitors, KDM5 inhibitors, killer cell lectin-like receptor subfamily G member 1 inhibitors, lymphocyte-activation gene 3 inhibitors, lymphotoxin beta receptor activators, modulators of Axl, modulators of B7-H3, modulators of B7-H4, modulators of CD 160, modulators of CD161, modulators of CD27, modulators of CD47, modulators of CD70, modulators of GITR, modulators of HEVEM, modulators of ICOS, modulators of Mer, modulators of NKG2A, modulators of NKG2D, modulators of 0X40, modulators of SIRPalpha, modulators of TIGIT, modulators of Tim-4, modulators of Tyro, Na+-taurocholate cotransporting polypeptide (NTCP) inhibitors, natural killer cell receptor 2B4 inhibitors, N0D2 gene stimulator, Nucleoprotein inhibitor, nucleoprotein modulators, OX-40 receptor agonist, PD-1 inhibitors, PD-L1 inhibitors, peptidylprolyl isomerase inhibitor, phosphatidylinositol-3 kinase (PI3K) inhibitors, Retinoic acidinducible gene 1 stimulator, Reverse transcriptase inhibitor, Ribonuclease inhibitor, RNA DNA polymerase inhibitor, SLC10A1 gene inhibitor, SMAC mimetics, Src tyrosine kinase inhibitor,240 Atty Docket No. P893392090WO (01344)stimulator of interferon gene (STING) agonists, stimulators of NODI, T cell surface glycoprotein CD28 inhibitor, T-cell surface glycoprotein CD8 modulator, Thymosin agonist, Thymosin alpha 1 ligand, Tim-3 inhibitors, TLR-3 agonists, TLR-7 agonists, TLR-9 agonists, TLR9 gene stimulator, toll-like receptor (TLR) modulators, and viral ribonucleotide reductase inhibitor.
171. The method of any one of claims 147-170, wherein said subject is administered an antiviral or an immune modulator.
172. The method of any one of claims 147-171, wherein said subject is administered one or more pharmaceuticals selected from tenofovir disoproxil, tenofovir alafenamide, entecavir, bulevirtide, telbivudine, adefovir dipivoxil, lamivudine, pegylated interferon, and interferon alpha.
173. A method for inactivating an HBsAg gene of an HBV genome or an HBV genome fragment in a target cell in a subject, said method comprising delivering to said target cell in said subject:(a) a first polynucleotide comprising a nucleic acid sequence encoding a first engineered meganuclease, wherein said first engineered meganuclease is expressed in said target cell, or said first engineered meganuclease, wherein said first engineered meganuclease is said meganuclease of any one of claims 1-84; and(b) a second polynucleotide comprising a nucleic acid sequence encoding a second engineered meganuclease, wherein said second engineered meganuclease is expressed in the eukaryotic cell, or a second engineered meganuclease;wherein said target cell comprises an HBV genome or HBV genome fragment comprising said HBsAg gene,wherein said first engineered meganuclease produces a first cleavage site at a first recognition sequence comprising SEQ ID NO: 3 within said HBsAg gene, and wherein said second engineered meganuclease produces a second cleavage site at a second recognition sequence that differs from SEQ ID NO: 3 in said HBV genome or HBV genome fragment,wherein said HBsAg gene is inactivated by introduction of an indel at said first cleavage site, wherein said HBsAg gene is inactivated by elimination of said HBV genome or said HBV genome fragment, or wherein said HBsAg gene is inactivated by excision of the intervening DNA between said first cleavage site and said second cleavage site.
174. The method of claim 173, wherein said first polynucleotide is a first mRNA.241 Atty Docket No. P893392090WO (01344)175. The method of claim 173 or claim 174, wherein said second polynucleotide is a second mRNA.
176. The method of claim 174 or claim 175, wherein said first mRNA is comprised by a first lipid nanoparticle that is contacted with said target cell.
177. The method of any one of claims 174-176, wherein said second mRNA is comprises by a second lipid nanoparticle that is contacted with said target cell.
178. The method of any one of claims 174-176, wherein said first mRNA and said second mRNA are each comprised by a lipid nanoparticle that is contacted with said target cell.
179. The method of claim 173, wherein said first polynucleotide is comprised by a first recombinant AAV that is contacted with said target cell.
180. The method of claim 173 or claim 179, wherein said second polynucleotide is comprised by a second recombinant AAV that is contacted with said target cell.
181. The method of claim 173, wherein said first polynucleotide and said second polynucleotide are comprised by a recombinant AAV that is contacted with said target cell.
182. The method of any one of claims 173-181, wherein said second recognition sequence is within said HBsAg gene.
183. The method of any one of claims 173-181, wherein said second recognition sequence is not within said HBsAg gene.
184. The method of any one of claims 173-181, wherein said second recognition sequence is within an HBV polymerase (pol) gene.
185. The method of claim 184, wherein said second recognition sequence comprises the nucleic acid sequence of SEQ ID NO: 57.242 Atty Docket No. P893392090WO (01344)186. The method of claim 185, wherein said second engineered meganuclease comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 78.
187. The method of claim 185 or claim 186, wherein said second engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 78.
188. The method of claim 185 or claim 186, wherein said second engineered meganuclease comprises an amino acid sequence comprising residues 2-343 of SEQ ID NO: 78.243 Atty Docket No. P893392090WO (01344)
